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A BRIEF HISTORY OF TRANSPLANTATION
Organ transplantation has long captured humans’ minds, reflected by the fact that 
archaeological finds dating as far back as to the ancient Egypt, China and India already showed 
evidence of experimental transplantation (1). However, substantial progress has only been 
made in the past decades, not in the least due to religious constrictions that left the field 
untouched for centuries.
The first official reports on transplantation date back to the Renaissance in the 16th Century, 
when the famous Italian surgeon Gasparo Tagliacozzi reconstructed noses and ears using 
skin grafts of the upper arm. Initially, both patient-derived (autologous) and donor-derived 
(allogeneic) grafts were used, but it soon appeared that the latter was rather unsuccessful. 
Tagliacozzi was one of the first to become aware that individual differences could severely 
hamper allogeneic transplantation: in his treatise De Curtorum Chirurgia per Insitionem (“On 
the Surgery of Mutilation by Grafting”) dated to 1597 he mentioned that “... the singular character 
of the individual entirely dissuades us from attempting this work on another person. For such is the 
force and power of individuality, that if anyone should believe that he could achieve even the least 
part of the operation, we consider him plainly superstitious and badly grounded in physical science”. 
This belief, in addition to heavy criticism by prominent writers, including in later times Voltaire, 
on the unethical donation procedure (that was devoid of donation consent and donors were 
often slaves), led to the abolishment of allogeneic transplantation.
It took a few centuries for allogeneic transplantation to gain appeal again, when slowly 
evidence started to accumulate that allograft transplantation could hold potential after all. 
One of the first memorable reports of a successful allogeneic skin transplantation involved the 
then 23-year-old Sir Winston Churchill, who at that time was a war correspondent during the 
Sudanese / Boer War in 1898. When a befriended officer got wounded, he donated a piece of his 
skin and documented the experience: “... he (i.e. the surgeon) then proceeded to cut a piece of skin 
and some flesh about the size of a shilling from the inside of my forearm. This precious fragment was 
then grafted onto my friend’s wound. It remains there to this day and did him lasting good in many 
ways. I for my part keep the scar as a souvenir”. Whether the graft was truly accepted long-term 
remains under debate (after all immunosuppressive drugs did not exist at that time), however 
it was a first sign that allogeneic transplantation could be successful after all (1).
Shortly thereafter, in 1905, the first successful allogeneic corneal transplantation was performed, 
and around that same time surgeons even started experimenting with transplanting animal 
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kidneys to patients with renal failure. The results were poor however, and patients did not 
survive beyond a few days. Similarly, the first properly documented human-to-human kidney 
transplantation performed in 1936 was rejected quickly and the recipient died shortly after 
transplantation. It was not until 1954 that the first successful human kidney transplantation 
took place, performed by Murray and Hartwell Harrison on identical twins. For his merits, 
Murray received the Nobel prize in 1990.
The field took a great leap forward during the Second World War. Many soldiers suffered from 
severe skin wounds and were in great need of allogeneic skin transplantation, and hence 
the British Medical Council asked the young Sir Peter Medawar to investigate allogeneic skin 
graft rejection. Fortunately so, for his research brought great new insights and he is now 
by many regarded as the Founding Father of transplantation immunology. Being one of the 
first to acknowledge the immune system in rejection, Medawar discovered that secondary 
transplantations were rejected much more quickly compared to primary transplantations 
– which he attributed to “actively acquired immune reactions”. In the 1950s, he and others 
revealed the importance of donor leukocytes in transplant immunity and rejection, by 
performing adoptive transfer experiments (although the exact mechanisms still remained 
elusive at that time). In 1960, he shared the Nobel Prize with Sir Frank Macfarlane Burnet for 
their work on “acquired immunological tolerance”, the “unresponsiveness” of the immune 
system to foreign (allogeneic) antigens. Their studies were seminal to understand the dichotomy 
between allograft rejection and acceptance.
Meanwhile, one started to understand that certain molecules expressed on the cell surface 
could be involved in anti-donor immune responses. These molecules were named “major 
histocompatibility antigens” (MHC), or more specifically “human leukocyte antigen” (HLA) 
molecules in humans. Together, the HLA antigens form a system called the HLA system, which 
is highly polymorphic between individuals. George Snell discovered the genes of the MHC 
system in mice.
The vital role of the HLA system in dictating human allograft acceptance versus rejection was 
demonstrated in the 1950s by Jean Dausset, Rose Payne and Jon van Rood. Jean Dausset found 
that sera from patients who had undergone blood transfusion could agglutinate white blood 
cells, and he identified the first leukocyte specificity (now known as HLA-A2). Rose Payne and 
Jon van Rood independently discovered that “agglutinating antibodies” were also present in 
women that had given birth to multiple children. The leukocyte agglutinating antibodies were 




computer programs. Based on these findings, correlations could be made between HLA and 
transplantation outcome, and quickly the vital importance of HLA matching became apparent. 
In 1967, Jon van Rood founded Eurotransplant (an international organization that matches 
patients and donors for solid organ transplantation), followed by Europdonor (the Dutch stem 
cell bank specialized in matching hematological patients with stem cell donors, now known 
as Matchis) in 1970, and Bone Marrow Donors Worldwide (the worldwide database with > 30 
million HLA-typed stem cell donors and cord blood samples) in 1988. These organizations have 
saved millions of lives by optimal matching of donors and recipients. For the discovery of the 
HLA system George Snell, Baruj Benacerraf and Jean Dausset won the Nobel Prize in 1980, 
although many still wonder why Jon van Rood was not among them.
For a long time, it was assumed that only humoral (antibody-mediated) immunity was involved 
in allograft rejection. However, during the 1960s, one started to realize that lymphocytes could 
also exert direct cytotoxicity towards allogeneic donor cells: revealing the important role for 
cellular (cell-mediated) immunity. This led to the development of the classical cell-mediated 
lympholysis (CML) assay by Brunner and Cerrottini: an assay that, until this day, has been widely 
used to investigate the effector function of cytotoxic immune cells. In addition, the mixed 
lymphocyte culture (MLC) assay developed by Bain, Vas and Lowenstein, enabled the detection 
of proliferation of alloreactive cells and was implemented to determine donor-recipient 
compatibility in bone marrow transplantation for years. In 1964, Bach and Hirschhorn refined 
the assay by specifically detecting the proliferative response of patient lymphocytes, while 
donor lymphocytes were chemically treated to prevent proliferation. Nowadays, except CML for 
anti-donor cytotoxicity testing for bone marrow and hematopoietic stem cell transplantation, 
these assays are no longer standard protocol.
Although standardization of HLA matching between donor and recipient and preclinical testing 
led to a vivid increase in transplantation success, it was not until the third milestone, the 
discovery of immunosuppressive drugs, that success rates really took off. Immunosuppressive 
drugs enabled the suppression of anti-donor immune responses (alloresponses) and thus 
remarkably expanded the possibilities and implications of allogeneic transplantation. Transplant 
recipients showed significantly less allograft rejection and much prolonged allograft survival. In 
particular the discovery of cyclosporine in the 1970s defined a turning point, for it generated a 
great boost to transplantation success from the 1980s onwards. Today, success rates are higher 
than ever, but unfortunately this comes with a price: broad-spectrum immunosuppression 
often leads to severe side effects, such as increased susceptibility to infections and cancer. 
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Attenuating dose-intake and identification of more refined immunosuppressive drugs are 
therefore key topics in current research (2).
GENERAL IMMUNOLOGY
The recipient’s immune system is key to allograft acceptance and rejection, as it is trained to 
distinguish between “self” and “non-self”. When immune cells mount a response against the 
donor, they are called “alloreactive” (in contrast to “autoreactive”, meaning they recognize 
“self”). When immune cells are not responsive towards a donor, they are called “tolerant”. 
Tolerance is the Holy Grail of transplantation, as it would obviate the use of potentially harmful 
immunosuppression.
Innate and adaptive immunity
When a pathogen tries to invade the body, it is subjected to several host-defence mechanisms. 
After anatomical barriers, the first line of defence it encounters is the innate immune system, 
one of the oldest defence mechanisms conserved throughout evolution. In fact, in addition 
to humans and other vertebrates, it can also be found in insects, plants and fungi. Innate 
immunity generates immediate defence and thereby quick and efficient protection. However, 
cells of the innate immune system cannot generate long-lasting protective immunity and their 
reactivity is not antigen-specific. Phagocytes for example, recognize pathogens by general 
pathogen-specific markers and natural killer (NK) cells elicit a response against any cell that 
does not express self-HLA.
In the far majority of cases, these aspecific defence mechanisms are sufficient to control and 
clear pathogens. However, when the innate immune system is unable to control the infection, a 
second immune strategy is summoned: the adaptive immune system. Unlike innate immunity, 
adaptive immunity provides long-lasting protection. Immunological memory ensures that 
upon repeated exposure to the same pathogen, the immune response is quick and efficient 
and progression to disease is prevented. It is therefore not surprising that the acquisition of 
immunological memory forms the basis for active vaccination strategies. Another contrast 
to innate immunity is that adaptive immunity is specific: adaptive immune cells (white blood 
cells called “lymphocytes”) are trained to specifically recognize only certain pathogens. B 
lymphocytes (or simply “B cells”) provide humoral immunity by producing antibodies, while T 
lymphocytes (or simply “T cells”) provide direct cell-mediated immunity. T cells can further be 
divided into CD4-expressing (CD4+) and CD8-expressing (CD8+) subsets: of which CD4+ T cells 




Furthermore, subsets of both B and T cells have the capacity to regulate the immune response 
(“Bregs” and “Tregs”), and thereby keep immune responses in check.
Both B and T cells express highly specialized receptors that recognize so-called “antigens”, which 
are usually parts of proteins (or sometimes polysaccharides). Such antigens can originate from 
the host itself (“self-antigens”) or from foreign sources (“non-self-antigens”). Non-self-antigens 
can be derived from bacteria, viruses and other pathogens, but also from food, and in light 
of transplantation, from organ donors. The main role of the immune system is to distinct self 
from non-self, and while self-antigens usually do not trigger immune responses, non-self-
antigens often do.
B cells recognize antigens by membrane-bound antibodies called B-cell receptors (BCRs), and 
T cells by T-cell receptors (TCRs). The part of the antigen that binds to the BCR or TCR is called 
the “epitope”. BCRs can recognize epitopes on an antigen directly, whereas TCRs recognize an 
epitope as a peptide presented within a major histocompatibility complex (MHC) molecule 
(FIGURE 1).
Figure 1. Recognition by B-cell receptors and T-cell receptors. B cells recognize antigens by membrane-
bound antibodies called B-cell receptors (BCRs), and T cells by T-cell receptors (TCRs). The part of the antigen 
that binds to the BCR or TCR is called the “epitope”. BCRs can recognize epitopes on an antigen directly, 
whereas TCRs recognize an epitope as a peptide presented within a major histocompatibility complex 
(MHC) molecule.
Since B and T cells generally only express receptors with a single specificity per cell (although 
exceptions do exist – see section “T-cell development”, p.20) and epitope recognition is highly 
stringent, a vast number of cells is needed to provide protection against all pathogens. On 
average, the human body contains around 2 x 1012 lymphocytes of which 2% is found in the 
peripheral blood circulation - the remainder reside within tissues and lymph.
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MHC molecules
The MHC complex is vital for immunological defence. It encodes MHC class I and MHC class II 
molecules, that are specialized in the presentation of peptides derived from intracellular and 
extracellular pathogens to immune cells respectively. All nucleated cells express MHC class I 
on their cell surface, whereas MHC class II is only expressed on antigen-presenting cells (APCs; 
typically dendritic cells, macrophages and B cells; atypically endothelial, epithelial and stromal 
cells) and activated T cells. Of note, amid the MHC class I and II genes reside the MHC class III 
genes, which encode for immune proteins such as components of the complement cascade 
(e.g. C2, C4, factor B), cytokines (e.g. TNF-α and -β) and heat shock proteins (e.g. HSP70). Since 
these proteins are not involved in antigen presentation itself, this section will focus on MHC 
class I and II.
MHC class I molecules present endogenous peptides to CD8+ T cells; whereas MHC class II 
molecules present exogenous peptides to CD4+ T cells (FIGURE 2). Although exceptions can 
occur, peptides presented in MHC class I molecules are generally restricted in size by the 
binding cleft (8-10 amino acids), while peptides presented in MHC class II molecules are not 
(15-24 amino acids). Teleologically, endogenous peptides are derived from proteins produced 
within the cell - and are therefore usually self-proteins involved in normal physiology. These 
should not trigger a defensive immune response for this would result in autoimmunity. On the 
other hand, MHC class I also presents endogenous peptides derived from intracellular viruses 
and bacteria, and such peptide:MHC-I complexes should trigger an immune response to kill 
the infected cells. Exogenous peptides are derived from proteins outside of the cell. APCs can 
take up foreign antigens, process them intracellularly into peptides and present those in the 
MHC class II molecules to CD4+ T cells. When CD4+ T cells recognize a specific peptide:MHC-II 
complex, they become activated and produce cytokines, which are small molecules that induce 




Figure 2. CD8+ and CD4+ T cells recognize HLA class I and class II presenting endogenous and exogenous 
peptides respectively. Exogenous antigens are taken up by the host cell (either by endocytosis, phagocytosis 
or pinocytosis) and degraded into peptides in so-called endosomes. The latter fuse with specialized vesicles 
that contain HLA class II molecules (initially loaded with a CLIP peptide to prevent binding of endogenous/
self-peptides). Subsequently, the exogenous peptides are loaded onto the HLA class II molecules, and the 
resulting peptide:HLA complexes are transported to the cell surface. Endogenous antigens are degraded 
into peptides by the intracellular proteasome, whereupon they enter the endoplasmatic reticulum (ER) via 
the TAP transporter. In the ER, the endogenous peptides are loaded onto HLA class I molecules and the 
peptide:HLA complexes are subsequently transported to the cell surface.
In humans, the MHC system is known as the human leukocyte antigen (HLA) system. At the 
genomic level, the HLA system consists of over 200 genes, which are located closely together 
on chromosome 6. The most important HLA class I genes are HLA-A, -B, -C, while HLA class 
II is divided into 3 major HLA class II genes HLA-DR, -DQ, and -DP (FIGURE 3). Each individual 
expresses 12 HLA-isoforms: HLA-A, -B, -C, -DR, -DP and -DQ on two haplotypes; one inherited 
from the mother and the other from the father. To date, 12,893 HLA class I and 4,802 HLA 
class II alleles have been identified (3), and this number is still growing. Years of intensive 
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international collaboration were needed to unravel the alleles – and even today new HLA alleles 
are described on a regular basis. Not surprisingly, the HLA system is the most polymorphic 
region of the entire human genome.
Figure 3. The different HLA class I and II genes and their position on chromosome 6. The HLA class I 
genes encode for the classical HLA-A, -B, and -C, and the non-classical HLA-E, -F, and -G antigens. The HLA 
class II genes encode for the classical HLA-DR, -DQ, and -DP, and the non-classical HLA-DM, and -DO antigens.
From an evolutionary point of view, great diversity in HLA molecules throughout a population 
is beneficial to the survival of the species, for it increases the chance of survival from infectious 
diseases: different HLA molecules can present different pathogen-derived peptides, increasing 
the chance that a TCR will recognize the complex. However, in transplantation it has been 
an eyesore for decades. The great variety in HLA molecules makes complete HLA matching 
between an unrelated donor and a recipient extremely difficult (if not impossible) and 
mismatched HLA molecules can be highly immunogenic. Anti-donor-HLA responses could lead 
to severe complications and even graft loss in the transplanted patient.
T-CELL IMMUNITY
T cells recognize their epitopes, peptide:MHC complexes (pMHC), by interaction with their TCR. 
This interaction determines whether the intracellular signalling pathways downstream of the 
TCR are triggered and the T cell becomes activated. In addition, TCRs provide the fundamental 
basis for T-cell selection to become part of the T-cell repertoire. It is needless to say that T-cell 
immunity relies heavily on the TCR, but other factors should not be neglected. These topics 





The TCR is a heterodimer and consists of two chains: either an α and a β chain (αβ T cells), or 
a γ and a δ chain (γδ T cells). The genes for these receptors are located on chromosomes 7 
(β/γ chain) and 14 (α/δ chain). The vast majority of T cells express αβTCRs, whereas only a small 
subset (approximately 5%) express a γδTCR. Although structurally similar, it is apparent that 
αβ T cells and γδ T cells are functionally different. Whereas αβ T cells are widely expressed, 
γδ T cells mainly reside in the gut mucosa. But more importantly, γδ T cells are not MHC-
restricted, and rather recognize lipid structures, (phosphorylated) non-peptidic antigens or 
stress-related antigens. Due to this non-pathogen-specific character, they are proposed to 
reside at the border of the innate and adaptive immune system, although their exact function 
is still under investigation. This thesis addresses αβ T cells, and from here onwards “TCR” refers 
to the αβTCR. Both the α and β TCR chains consist of two extracellular domains, the constant 
(C) and variable (V) domains. The constant domain shows little variability; its main purpose 
is to anchor the TCR in the membrane and to bind the two TCR chains together via disulphide 
bonds. The variable domain instead shows great diversity, for this is the part of the TCR that 
interacts with the peptide:MHC complex and is the main determinant of T-cell specificity. The 
variable domains are characterized by three complementarity determining regions (CDRs), 
which form loops that interact with the peptide:MHC complex.
At the genetic level, the TCR Vα chain is generated by V-J recombination, and the TCR Vβ chain 
by V-D-J recombination (FIGURE 4). CDR1 and CDR2 loops are encoded within the V region, 
whereas the CDR3 loop is encoded at the junctions between the segments. The nucleotide 
composition at these junctions is arbitrary and orchestrated by palindromic (P) and random 
non-templated nucleotide (N) insertions and/or nucleotide deletions. Consequently, the CDR3 
loops show extensive variation, resulting in a vast number of different TCR clonotypes.
So just like the massive variation in HLA molecules, there is enormous diversity in TCR usage. 
In theory, it has been estimated that an individual could generate over a quintillion (short scale: 
1018) unique TCRs, which leaves 1016 unique TCRs after they have been through a thorough 
selection to enter the periphery (thymic selection, the thorough selection process of TCRs 
that are allowed to enter the periphery; discussed in the next paragraph) (4). In practice, this 
number appears to be lower but is still estimated to be around 108 (5).
Given this enormous variation, the chance that two or more unrelated individuals at random 
generate an identical TCR is almost zero. Yet defying the odds, T cells that express (nearly) 
identical TCR usage have been identified in multiple unrelated individuals.
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Figure 4. TCR rearrangement of the Vα and Vβ chain. The genetic landscape encoding the TCRα- and 
β-chains is divided into V, (D), J and C regions. The mRNA for the TCRα chain is generated by rearrangement 
of a Vα gene segment with a Jα gene segment, and subsequent transcription and splicing to the Cα gene 
segment. Translation of the mRNA results in the TCRα-chain protein. The TCRβ chain is generated similarly, 
but contains an additional segment (D) that makes up the variable domain. After translation into protein, 
the TCRα and TCRβ chains pair and form the TCR heterodimer.
Such TCRs are called “public” TCRs, in contrast to “private” TCRs that are uniquely expressed 
within individuals. Whereas it is assumed that most TCRs are private, an increasing amount 
of evidence suggests that public TCRs may be more common than anticipated. Provided that 
individuals share the HLA allele presenting the viral peptide, public TCRs have been described 
for several viruses including cytomegalovirus (CMV) (6), Epstein-Barr virus (EBV) (7), human 
immunodeficiency virus (HIV) (8), and influenza (FLU) (9).
Public TCR usage can (partly) be explained by immunodominance. Pathogens are sufficiently 
large to form hundreds to thousands of antigenic peptides that can be presented by all HLA 
alleles, so in theory, the T-cell response can be extremely broad. In practice however, T-cell 
responses are often dominated by T cells directed against only a few viral peptides presented 
in specific HLA alleles, so-called “immunodominant epitopes”. This skewing of the T-cell 




individuals, but they can also be the same (“common immunodominant epitopes”). In the latter 
case, it is hypothesized that the viral peptides are critical for the survival of the pathogen and 
therefore cannot be eliminated or altered for viral escape. Although the mechanisms behind 
immunodominance are not well understood, TCRs that have a strong interaction with the 
peptide:HLA complex (“TCR affinity”) are more prone to be immunodominant: plausibly the 
associated enhanced T-cell survival and proliferation enable them to “outgrow” the other T-cell 
responses. Immunodominance thus creates a bias for public TCR usage, and for some viral 
specificities, public TCRs are present in almost 100% of individuals who express the relevant 
HLA and have encountered the virus of interest (11, 12).
T-cell development
Both T and B cells are generated from hematopoietic stem cells in the bone marrow. B cells 
subsequently migrate to the spleen for maturation, while T-cell progenitors migrate to the 
thymus. Here, they undergo strict positive and negative selection largely (though not solely) 
based on TCR affinity for the self-peptide:HLA complexes (13). Positive selection ensures 
that TCR affinity is sufficient to recognize self-HLA, whereas negative selection ensures that 
it is not too strong to avoid T-cell activation upon recognition of a self-peptide. To ensure 
optimal expression of self-peptides present throughout the body and not just the thymus, the 
thymic stroma has the ability to express tissue-specific peptides through an enzyme called 
autoimmune regulator (AIRE). The result of positive and negative selection is that merely 3% 
of T cells survive thymic selection and enter the periphery, generally expressing TCRs with low 
affinity for self-HLA. Furthermore, the majority of T cells express TCRs of a single TCR specificity, 
although T cells with two different TCRs can emerge during thymic selection (BOX 1).
When the T cells that survived thymic selection leave the thymus, they are in a so-called “naïve” 
state; meaning they have not encountered their specific antigen yet. They circulate through 
the body in the peripheral blood and lymph, and when they enter the lymph nodes and meet 
a professional antigen-presenting cell (APC; most often referring to the dendritic cell) that 
presents their specific antigen, they become activated and start to proliferate. Only those T 
cells that efficiently recognize the peptide:HLA complex will undergo proliferation, resulting 
in a large population of T cells expressing the same unique TCR (a “T-cell clone”). This process 
is called clonal expansion.
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Box 1.
From here on, the T cells are no longer naïve but turn into effector T cells, dedicated to 
directly eliminate pathogens, and memory T cells, the facilitators of long-lived immunological 
memory. When effector T cells have completed their job, they undergo apoptosis to maintain 
homeostasis in the T-cell compartment (14). Memory T cells survive, and because they have less 
activation requirements compared to their naïve counterparts, are able to quickly differentiate 
into effector T cells upon re-infection.
T-cell subsets
Functionally, T cells come in different flavours. As briefly mentioned in paragraph 2.1 “Innate 
and adaptive immunity”, the main subsets of αβ T cells are divided based on their co-receptor 




CD4+ T cells recognize MHC class II molecules and are therefore specialized in the recognition of 
exogenous pathogens. They are so-called “helper T cells” and orchestrate the immune response 
mainly by the production of cytokines. Well-known examples of helper T cells are T helper 1 
(Th1) and T helper 2 (Th2) cells, of which Th1 cells stimulate antibody production by B cells, 
and Th2 cells aid the clearance of parasites by eosinophils and facilitate isotype switching of 
B cells. An additional important subset of CD4+ T cells on the contrary regulate the immune 
response, and these cells are hence named regulatory T cells. They hamper immune responses 
to prevent their “overshooting” and associated damage to the host.
CD8+ T cells recognize MHC class I molecules and are therefore specialized in the recognition 
of endogenous pathogens, primarily viruses. CD8+ T cells are most often cytotoxic T cells 
(CTLs), which induce cell death of pathogen-infected host cells by producing cytokines and 
cytotoxins. Perforin and granulysin generate pores in the plasma membrane of the infected 
cell, whereupon granzymes (and granulysin) can enter the cell to induce apoptosis.
T-cell activation
In order to perform effector functions, the T cell needs to be activated. The first step of T-cell 
activation is binding of the TCR to its ligand: the peptide:MHC complex. Generally, a TCR docks 
onto a peptide:MHC complex in a conserved diagonal and orthogonal orientation, wherein the 
CDR1 and CDR2 loops bind to the MHC and the CDR3 loop to the peptide (although exceptions 
do exist; for example CDR1α can interact with the N-terminus and CDR1β with the C-terminus 
of the peptide) (FIGURE 5).
Figure 5. Docking mode of a TCR onto a peptide:MHC complex. A TCR docks in a conserved diagonal 
and orthogonal orientation, wherein the CDR1 and CDR2 loops bind to the MHC and the CDR3 loop to the 
peptide (although exceptions do exist; for example CDR1α can interact with the N-terminus and CDR1β 
with the C-terminus of the peptide).
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To support signalling from the TCR to within the cell, the TCR forms a complex with CD3 
molecules, of which CD3δ/ε and CD3γ/ε protrude extracellularly and CD3ζ projects 
intracellularly. The transmembrane parts of these CD3 subunits express residues that contain 
tyrosines, which are key to the phosphorylation cascade that enables downstream gene 
transcription for T-cell activation.
In addition, binding of the co-receptors CD4 (to the β2 chain of MHC class II) and CD8 (to the α3 
chain of MHC class I) to the MHC stabilizes the TCR:pMHC interaction (FIGURE 6). Stabilization is 
needed, since TCR affinity for peptide:self-HLA is generally low as a result of thymic selection. 
CD4 and CD8 co-receptors increase cell-cell interactions, which allows for prolonged T-cell 
signalling, and facilitate CD3 signal transduction within the cell. Thereby T-cell sensitivity is 
increased and the threshold for T-cell activation is lowered.
Figure 6. Structural overview of the TCR complex. The TCR forms a complex with CD3 molecules, of 
which CD3δ/ε and CD3γ/ε protrude extracellularly, and CD3ζ projects intracellularly. CD8 binds to the δ/ε 
domain of the HLA-I molecule.
In addition, binding of the costimulatory molecule CD28 on the T-cell surface to the membrane 
protein B7 (subtypes CD80 and CD86) on the surface of APCs is required for priming of naïve T 
cells. In fact, when naïve T cells solely undergo TCR:pMHC interactions without co-stimulation, 
they may even become anergic: a state of unresponsiveness that acts as a safety precaution 
to prevent autoimmunity. Memory T cells on the other hand, are known to be largely co-




why immunosuppressive drugs that tackle co-stimulatory molecules are effective against naïve, 
but not memory T cells. Finally, the formation of microclusters of TCRs on the T-cell surface 
and cell adhesion molecules such as ICAM-1 leads to the generation of a signalling unit called 
the “immunological synapse” that furthermore facilitates T-cell activation.
The cumulative binding strength of all non-covalent binding interactions (TCR affinity, co-
receptor binding, cell adhesion molecules, costimulatory molecules) is called TCR avidity. 
Especially when TCR affinity is very low, TCR avidity can compensate for the weak signal strength 
to induce T-cell activation.
When the sum of all interactions reaches the activation threshold, T-cell activation is induced 
by intracellular signalling downstream of the TCR. Phosphorylation of downstream proteins 
generates a cascade of events by enzymes, co-receptors, adaptor molecules that facilitate 
protein-protein interactions, and ultimately transcription factors that affect gene transcription 
in the nucleus (signal transduction). The main transcription factors that are activated upon T-cell 
recognition and are needed for T-cell activation are “activator protein 1” (AP-1; downstream the 
MAPK pathway, involved in apoptosis, survival and vital for IL-2 production), “nuclear factor 
kappa-light-chain-enhancer of activated B cells” (NF-κB; essential for T-cell activation and the 
induction of inflammatory responses), and “nuclear factor of activated T cell” (NFAT; activated 
by the protein phosphatase calcineurin and again vital for IL-2 production) (FIGURE 7). The 
process of T-cell activation is tightly regulated and, particularly in the case of priming, depends 
on the mode and strength of the TCR:ligand interaction (signal 1), co-stimulation (signal 2) and 
environmental cytokines (signal 3).
T-CELL IMMUNITY IN TRANSPLANTATION
Alloreactive T cells can play an important role in both solid organ transplantation and allogeneic 
hematopoietic stem cell transplantation (HSCT) rejection.
In allogeneic HSCT, T-cell alloreactivity is directed against recipient cells and can lead to 
graft-versus-host disease (GVHD). GVHD inflicts severe damage to mucosa, connective 
tissues and exocrine glands, and primarily involves the skin (dermatitis), liver (hepatitis), and 
gastrointestinal tract (enteritis) - although at chronic stages it can involve almost any organ. 
Around 35-50% of allogeneic HSCT recipients will develop a form of GVHD, and depending 
on its grade and responsiveness to immunosuppression, symptoms range from mild to life-
threatening. Interestingly however, T-cell alloreactivity may also benefit allogeneic HSCT: 
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Figure 7. Simplified schematic overview of intracellular signaling downstream of the TCR leading 
to T-cell activation. When the threshold for T-cell activation is reached, a cascade of biochemical events 
take place. First, the protein tyrosine phosphatase CD45 activates Src family kinases (e.g. Lck or Fyn) that 
were recruited by CD8 (or CD4) co-receptors. They subsequently phosphorylate tyrosines on so-called 
immunoreceptor tyrosine-based activation motifs (ITAMs) present on the intracellular parts of CD3 and the 
ζ-chains. Thereupon, ZAP-70, a cytoplasmic Syk kinase, binds the phosphorylated ITAMs and phosphorylates 
tyrosines on the adaptor protein linker for activation of T-cells (LAT). Consequently, LAT recruits the enzyme 
PLC-γ that triggers the MAPK, NF-κB and NFAT pathways: important regulators of gene transcription involved 
in T-cell activation.
when HSCT is implemented as therapy for leukemia treatment, alloreactive T cells can mount a 
response against residual leukemic cells and thereby reduce the risk of leukemia relapse. This is 
known as the “graft-versus-leukemia” (GVL) effect. Mild T-cell alloreactivity is therefore desired 
when allogeneic HSCT is applied for leukemia treatment. However, finding the delicate balance 
between risk of GVHD versus retaining the benefits of GVL can be difficult (15).
In solid organ transplantation, T-cell alloreactivity is involved in acute and chronic allograft 
rejection (as further discussed in paragraph 4.1). Roughly 10% of all (first) kidney transplant 
recipients encounter an episode of T-cell mediated rejection. Fortunately, most of these 
episodes can be resolved by immunosuppression, but when immunosuppression fails, the 
damage inflicted by alloreactive T cells can result in chronic allograft nephropathy (also known 




Of note, when addressing allogeneic HSCT and solid organ transplantation, the allo-versus-
self orientation is reversed: in allogeneic HSCT immune cells are donor-derived and the 
recipient is considered allogeneic, whereas in solid organ transplantation immune cells are 
recipient-derived and donor cells are allogeneic. For clarity, this thesis primarily addresses 
T-cell alloreactivity in light of solid organ transplantation; with a special focus on kidney (renal) 
transplantation.
Acute versus chronic T-cell-mediated rejection
Roughly, there are three different types of solid organ transplant rejection: hyperacute, acute 
and chronic.
Hyperacute rejection occurs, as the name implies, quickly upon transplantation. Within 
minutes, pre-existing anti-HLA donor-specific antibodies (DSA) of the recipient bind to the 
donor graft and initiate humoral rejection by activation of the complement system. The 
resulting inflammation and irreversible graft damage quickly lead to graft loss. Being driven by 
antibodies, this type of rejection is a form of “antibody-mediated rejection” (ABMR). Hyperacute 
rejection could easily result in systemic inflammation, and therefore intervention consists of 
graft removal. Fortunately, cross-matching and HLA compatibility screening has drastically 
reduced the incidence of hyperacute rejection over the years, and nowadays it is practically 
eliminated.
Acute rejection usually occurs in the first few months and within 12 months after transplantation. 
It can be antibody-mediated (acute ABMR) or T-cell mediated (acute TCMR, also known as 
acute cellular rejection). Acute ABMR and TCMR can occur separately but also simultaneously, 
although especially acute TCMR occurs frequently and when untreated, has poor clinical 
outcome. In renal transplantation, acute rejection manifests itself by organ dysfunction 
(decreased urine production and proteinuria) and microvascular pathology.
Finally, chronic rejection is often a combination of antibody-mediated (chronic ABMR) and 
T-cell mediated (chronic TCMR) rejection. Chronic rejection is initiated by alloreactive B and T 
cells but is furthermore facilitated by injury and repair mechanisms; leading to damage of the 
graft vessels (chronic allograft vasculopathy, CAV) and ischemic injury. In renal transplantation, 
chronic rejection manifests itself by the fibrosis of blood vessels, gradually leading to a loss of 
kidney function and overall graft loss.
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However, the diagnosis of acute and chronic rejection can be complex and requires the 
continuous adjustment of diagnostic criteria. For renal transplantation, these criteria are set 
at the Banff Conference for Allograft Pathology (17).
Direct versus indirect allorecognition
Alloreactive T cells can recognize alloantigen in a direct, indirect or semi-direct way.
Direct allorecognition occurs when recipient T cells directly recognize donor MHC antigens 
expressed on donor-derived APCs. These donor-derived APCs are typically carried along with 
the allograft as “passenger cells”. Allorecognition via the direct pathway is often robust, and is, 
aided by the large precursor frequency of alloreactive T cells (18), considered to be the instigator 
of acute T-cell mediated rejection (19). Donor-derived dendritic cells will however disappear 
within a few weeks after transplantation, and therefore direct allorecognition (in particular of 
HLA class II) is considered to be mainly involved in acute rejection.
When T cells recognize alloantigen via the indirect pathway, allo-derived peptides are presented 
by self-MHC molecules on the cell surface of recipient APCs. CD4+ T cells are notorious for 
exerting alloreactivity via the indirect pathway, and their involvement in chronic rejection of 
heart, kidney, liver and skin transplants has long been described (20-23).
Finally, the semi-direct pathway is a combination between the direct and indirect pathways: in 
this pathway recipient APCs take up donor-derived exosomes and thereupon express donor 
MHC on their cell surface, thereby enabling direct recognition of donor MHC by recipient 
alloreactive T cells.
Of note, these pathways are by no means exclusive, and rejection is inevitably the result of a 
complex interplay between the different forms of allorecognition.
Heterologous immunity
Old scholar textbooks state that a TCR only recognizes one specific peptide:MHC complex, and 
thus has a single TCR specificity. Although TCRs are considered highly specific, it is now known 
that T cells are able to recognize multiple antigens through cross-reactivity of their TCR. In 
fact, it is estimated that in theory, a single TCR could recognize over a million peptides (24, 25). 




Figure 8. Different docking modes by which TCRs can cross-react. A) Allo-HLA cross-reactivity of virus-
specific T cells. B) Proposed mechanisms of TCR cross-reactivity: TCR adaptation by induced fit, differential 
docking of the TCR onto the pMHC, structural degeneracy, molecular mimicry and antigen-dependent tuning 
of pMHC flexibility (54). Molecular mimicry is the most well-described example of an underlying mechanism 
for TCR cross-reactivity and is a form of TCR degeneracy: flexibility in TCR antigen recognition whereby a 
TCR can recognize multiple ligands. Especially the CDR loops are extremely flexible, and TCR cross-reactivity 
is mainly determined by conformational changes in the CDR3 loops (55, 56).
From an evolutionary point of view, TCR cross-reactivity is advantageous: in theory it would not 
be possible to generate a specific TCR for all pathogen-derived peptides, for the body cannot 
possibly accommodate such a large number of unique T-cell clonotypes. Besides, cross-reactive 
T cells with a memory phenotype can quickly respond towards a range of pathogenic antigens 
and thereby provide protection against different pathogens - even without previous encounter.
Immunity for a pathogen that is developed by exposure to another pathogen is called 
“heterologous immunity”. Several examples are known of T cells that, by means of TCR cross-
reactivity, provide protection against a different virus from the one they were initially primed 
for. (The term “virus-specific” is therefore misleading – yet this terminology is still most 
commonly used to refer to virus-induced T cells). For example, cross-reactive virus-specific 
CD8+ T cells have been described that recognize both the influenza virus and hepatitis C virus 
(26), or both the influenza virus and Epstein-Barr virus (EBV) (27). Also, FLU-specific A2/GIL 
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CD8+ T cells can cross-react with an HIV peptide (SLYNTVATL) (28). Although T-cell responses 
against this immunodominant HIV epitope cannot prevent HIV infection, they are associated 
with control of viremia and slower disease progression (29, 30). It should be noted, however, 
that the extent of heterologous immunity between viruses in humans is still a matter of debate, 
and recent research was unable to detect any cross-reactivity of EBV memory T cells against 
CMV or Influenza A viral epitopes (31).
In addition, T-cell cross-reactivity can occur between pathogen-derived peptides and self-
peptides, which could lead or contribute to autoimmune disorders. In fact, the estimation that 
a single TCR can recognize more than a million peptides has been verified by a diabetes type 
I autoimmune TCR (25). If self-peptides and pathogen-derived peptides appear structurally 
similar (“molecular mimicry”), recognition of self-peptides could elicit an immune response, 
which is suggested to play a role in multiple sclerosis (32, 33).
Moreover, virus-specific T-cell receptors do not only have the ability to cross-react with multiple 
peptides, but also with allogeneic HLA (allo-HLA). Especially cross-reactive virus-specific T 
cells with a memory phenotype could pose a threat to transplantation: since they have fewer 
activation requirements, immunosuppression with co-stimulatory inhibitors is only marginally, 
if at all, effective. Besides, their activation is much more rapid, and their effector function is 
greatly enhanced compared to naïve cells (34). Indeed, the potential threat of memory cells is 
illustrated by the first transplantation studies in mice, which surprisingly barely showed any 
rejection episodes in contrast to humans and non-human primates. This remarkable finding 
is explained by the sterile environment in which laboratory mice grow up: as a result of the 
lack of pathogen encounter, their memory T cell counts remain low. Upon adoptive transfer of 
virus-specific memory T cells, transplantation success dropped drastically (35).
Virus-specific memory T cells with cross-reactivity against MHC could thus hamper successful 
transplantation, and several in vivo mouse studies have shown that they can indeed result 
in allograft rejection (35-37). In humans, only a few studies have addressed the impact of 
allo-HLA cross-reactivity of virus-specific T cells on transplantation outcome so far (38-41). 
However, it is clear that also human virus-specific T cells are able to cross-react to allo-HLA (39, 
42, 43). The most prominent example is the cross-reactivity of EBV B8/FLR-specific CD8+ T cells 
against allo-HLA-B*44:02, which can be explained by molecular mimicry (despite large structural 
differences between HLA-B*08:01 and HLA-B*44:02) (11, 44). This cross-reactivity is of special 
interest as it is mediated by a public TCR and therefore shared by multiple individuals. If such 




predicted for specified patient-donor combinations. The clinical relevance of the EBV B8/FLR 
public cross-reactivity is however still under investigation (40). Moreover, the identification of 
novel public allo-HLA cross-reactive virus-specific T cells could further broaden the potential 
for making donor-patient risk estimations. More research is therefore needed to determine 
whether a) additional public allo-HLA cross-reactivities of virus-specific T cells can be identified 
that b) could affect transplantation outcome.
Immunosuppression
While evaluating the potential impact of cross-reactive virus-specific T cells on transplantation 
outcome, a quintessential factor to keep in mind is the impact of immunosuppression. 
Without immunosuppression allografts are easily rejected, so as a consequence, solid organ 
transplantation recipients are subjected to life-long intake of immunosuppressive drugs. Today, 
standard maintenance immunosuppression consists of induction therapy by CD25-blocking 
antibodies followed by a triad of calcineurin inhibitors (CNI; usually low-dose tacrolimus), 
mycophenolate mofetil (MMF) and corticosteroids (45). Although CNIs are very effective in 
hampering memory T-cell responses and are unmistakably associated with improved allograft 
survival, they are also associated with severe side effects such as nephrotoxicity, neurotoxicity, 
diabetes, metabolic syndrome and increased risk of viral infections (46-50). Therefore, attempts 
are being made to identify immunosuppressive drugs that specifically hamper alloresponses but 
maintain anti-viral immunity, and as an example, co-stimulation blockade is often suggested. 
Co-stimulation is required for full activation of naïve T cells, yet it is no longer (or significantly 
less) needed for activation of memory T cells. It thereby prevents priming of donor-specific 
naïve T cells but does not (or only to a minor extent) affect virus-specific memory T cells. Yet, 
an immunosuppressive regimen that fully replaces CNI by co-stimulation blockade does not 
hamper virus-specific memory T cells with cross-reactivity towards allo-HLA and may therefore 
prevent successful transplantation (51-53).
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AIM OF THIS THESIS
In vivo mouse models have clearly shown the negative impact of cross-reactive virus-specific 
memory T cells on transplantation outcome. However, the human situation is much more 
complex, and the exact role of cross-reactive virus-specific T cells on allograft survival remains 
elusive. The aim of this thesis is to gain more insight into the role of allo-HLA cross-reactive 
virus-specific (or perhaps rather virus-induced) memory CD8+ T cells in transplantation. 
Questions that will be addressed are: what is our current understanding of T-cell alloreactivity in 
transplantation (Chapter 2)? What is the potency and what are the flaws of current experimental 
techniques for the detection of allo-HLA cross-reactive virus-specific T cells in vitro (Chapter 
3)? What is the impact of a single viral infection on the allo-HLA cross-reactive T-cell repertoire 
(Chapter 4)? Is it possible to stimulate allo-HLA cross-reactive virus-specific T cells ex vivo 
to boost anti-virus immunity (Chapter 5)? What is the likelihood that virus-specific T cells of 
unrelated individuals express identical allo-HLA cross-reactive TCRs (Chapter 6)? And is the 
interaction of cross-reactive virus-specific TCRs with allogeneic ligands just as efficient as with 
viral ligands (Chapter 7)? Finally, the results, pitfalls and suggestions for future research are 
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ABSTRACT
Purpose of the review
Despite the association between alloreactive T cells and poor graft survival, the mechanisms 
behind T-cell-mediated rejection are still under investigation. In this review, we will discuss 
the latest insights into the impact of T-cell alloreactivity on solid organ transplantation and 
hematopoietic stem cell transplantation (HSCT), with special emphasis on the potential impact 
of heterologous immunity.
Recent findings
A large part of the memory T-cell repertoire is induced upon viral infections, and evidence for a 
role of T-cell receptor cross-reactivity of virus-induced memory T cells against allogeneic human 
leukocyte antigen (HLA) is accumulating in experimental and clinical solid organ transplantation 
studies. In HSCT, strong alloreactive potential of naïve T cells causes concerns for graft-versus-
host disease while additional HLA-DP matching is suggested to prevent CD4+ alloreactivity. 
Furthermore, virus-induced memory T cells hamper mixed chimerism induction, pointing once 
more towards a role for heterologous immunity.
Summary
Both memory and naïve T cells contribute to the alloimmune response after transplantation. 
Monitoring for T-cell phenotypes could help predict rejection episodes and/or graft-versus-
host disease, allowing timely intervention. Tailoring donor lymphocyte infusions and additional 
HLA matching could prevent strong alloreactivity in HSCT. Furthermore, the potential role of 
heterologous immunity in T-cell alloreactivity and transplantation is gaining interest.
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INTRODUCTION
T-cell-mediated alloreactivity is often involved in clinical complications after solid organ 
transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Whereas in SOT 
alloreactivity by T cells other than regulatory T cells (Tregs) is considered detrimental, the 
outlook on HSCT is more delicate. HSCT is frequently applied to cure hematological cancers, 
and a certain extent of T-cell alloreactivity is desired in order to attack residual malignant cells. 
This is known as the graft-versus-leukemia (GVL) effect. However, vigorous T-cell alloreactivity 
poses a risk for developing graft-versus-host disease (GVHD).
Both naïve and memory T cells have alloreactive potential. In HSCT, both are indispensable for 
proper functioning of the donor-derived immune system, although alloreactivity mediated by 
either subset can contribute to GVHD (57). In SOT, patients are treated with immunosuppressive 
drugs. Standard maintenance immunosuppressive therapy in SOT consists of a triad of 
calcineurin inhibitors (CNI; most commonly low-dose tacrolimus), mycophenolate mofetil 
(MMF) and corticosteroids. Together with induction therapy by CD25-blocking antibodies, 
this regimen is most potent compared to other current immunosuppressive regimens (45). 
Although effective in terms of patient survival and allograft rejection, treatment with CNI is 
associated with severe side effects such as nephrotoxicity (46), neurotoxicity (47), new-onset 
diabetes (48), metabolic syndrome (49) and increased susceptibility to viral infections (50, 58), 
which necessitate the identification of novel immunosuppressive drugs that specifically target 
alloreactive cells without hampering anti-viral responses. Hereto, costimulation blockade is 
suggested to be a promising strategy, and several studies have investigated the therapeutic 
potential of belatacept (a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-specific fusion 
protein blocking CD28-B7 costimulation) as an alternative to CNI (59). Immunosuppression 
by costimulation blockade has the advantage of selectively targeting naïve T cells, leaving 
memory T cells largely unaffected as they are less dependent on costimulation to exert 
effector functions. Virus-specific memory T cells are therefore only minimally hampered by 
costimulation blockade, however, the same applies to alloreactive memory T cells. Furthermore, 
memory T cells have the capacity to exert more vigorous immune responses upon antigen 
recognition compared to naïve T cells, and therefore alloreactive memory T cells are considered 
more prone to impact SOT outcome compared to naïve T cells (60).
Interestingly, alloreactive memory T-cell responses can be mounted without prior encounter 
of alloantigen. This is explained by heterologous immunity of virus-induced memory T cells, in 
which cross-reactivity of the T-cell receptor (TCR) enables the recognition of allogeneic human 
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leukocyte antigen (HLA) (Figure 1). The cross-reacting TCR has never been trained to recognize 
allogeneic HLA by positive and negative selection in the thymus, which suggests that cross-
reactive T cells simply mistake unknown allogeneic cells for virus-infected autologous cells. As 
cross-reactivity is an intrinsic feature of TCRs (24), one could envision that a substantial part 
of virus-induced memory T cells are cross-reactive. Indeed, 80% of all virus-induced T-cell 
lines and 45% of all virus-induced T-cell clones are reported to exert cross-reactivity against 
allogeneic HLA (43). Given the myriad of viral infections that are encountered throughout life, 
it is therefore likely to assume that all individuals harbor a large repertoire of virus-induced 
memory T cells with cross-reactive potential to allogeneic antigens. In vivo animal models have 
shown that virus-induced cross-reactive memory T cells hamper successful transplantation 
(35, 36, 61), but their impact on clinical transplantation remains elusive.
In this review, we will discuss the latest insights into T-cell alloreactivity and its impact on solid 
organ and HSCT outcome. Special emphasis will be given to the role of heterologous immunity 
of virus-induced T cells.
Figure 1. Virus-induced memory T cells can recognize allogeneic HLA + peptide by means of 
heterologous immunity. Through TCR cross-reactivity, a single TCR can recognize multiple antigens. In 
this schematic overview, virus-induced memory T cells recognize both self-HLA + viral peptide and allo-HLA 
+ peptide using the same TCR. HLA, human leukocyte antigen; TCR, T-cell receptor.
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SOLID ORGAN TRANSPLANTATION
Transplantation is the most desired treatment for end-stage organ failure. Despite drastically 
improved graft outcomes over time, rejection remains a major threat to successful 
transplantation. Alloreactive T cells play a pivotal role in SOT rejection, although their mode of 
action is not always fully understood. However, recent experimental and human studies have 
generated new and relevant data on this topic.
Solid organ transplantation: experimental studies
CD4+ T cells play a prominent role in both humoral and cellular alloreactivity, by providing 
help to alloreactive B cells and CD8+ cytotoxic T cells respectively. The latter requires that 
alloantigens are recognized by both CD4+ and CD8+ T cells: both as processed peptides in self-
HLA as well as intact allogeneic HLA class I molecules. Accordingly, Sivaganesh et al. (62) showed 
that unprimed alloreactive CD8+ T cells directly recognized intact allogeneic HLA class I antigens 
taken up and presented by recipient dendritic cells, provided that alloantigen peptides were 
also presented in self-HLA-class II. The authors therefore hypothesized that direct pathway 
CD8+ alloreactive T cells depend on indirect pathway CD4+ alloreactive T-helper cells for their 
activation (62). According to this model, matching for HLA class I alone would be sufficient to 
prevent CD8+ T-cell activation. Yet, a recent study by Ishii et al. (63) suggested that CD8+ T-cell 
responses could also be elicited upon sole HLA class II mismatching. In a kidney transplant 
model, CD8+ T cells recognized peptides from mismatched MHC class II molecules presented 
by matched MHC class I, which led to allograft rejection (63). Thus, MHC class II peptides may 
serve as minor histocompatibility antigens (mHAg) that could trigger CD8+ T-cell alloreactivity. 
This implies that matching for HLA class II may not only prevent CD4+, but also CD8+ T-cell 
allorecognition.
As an induction therapy prior to transplantation, T cells can be depleted by lymphocyte-
depleting antibodies, such as antithymocyte globulin (ATG) or alemtuzumab. However, 
lymphocyte depletion can provoke a disturbed balance in T-cell subsets as a result of 
homeostatic proliferation in favor of memory T cells. To prevent this, Mai et al. (64) studied 
interleukin (IL)-7 receptor blockade following lymphodepletion. IL-7 is a central regulator of both 
CD4+ and CD8+ T-cell survival and homeostasis, and IL-7 receptor blockade indeed prevented 
memory T-cell proliferation and promoted allograft survival in both pancreatic island and skin 
transplantation mouse models (64). Alternatively, selective depletion of CD2hiCD8+ effector 
memory T cells by targeting CD2 has been shown to promote immunosuppression-free renal 
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allograft survival in nonhuman primates who were tolerized by a donor bone marrow transplant 
(65).
Apart from traditionally primed memory T cells (either by viral infection or alloantigen 
exposure), naturally occurring memory T cells with unknown priming history also exist. 
These may be primed by endogenous signals or even emerge spontaneously from naïve T 
cells without passing the effector phase (66, 67). Several studies on unprimed mice housed 
in pathogen-free conditions have indicated that these endogenous memory T cells could be 
alloreactive (57, 68). Recently, Su et al. (69) demonstrated that endogenous memory T cells 
could mediate cardiac allograft rejection. Graft infiltration, activation and enhanced effector 
function of these endogenous memory CD8+ T cells were directly linked to prolonged cold 
ischemia times, suggesting that these cells may respond to danger signals, which has been 
suggested previously (70, 71).
Yet, not all memory T cells are detrimental, and distinctive memory T-cell phenotypes may 
in fact have antagonistic effects on transplantation outcome. Whereas effector memory 
CD8+ T cells are mainly described to have a detrimental impact on transplant outcome, it 
appears that central memory CD8+ T cells may instead promote allograft acceptance. Indeed, 
Krupnick et al. (72) showed that central memory CD8+ T cells infiltrating into lung allografts 
were crucial for their acceptance. These cells had potent immunoregulatory properties, and 
were able to down-regulate CD4+ and CD8+ T-cell alloresponses (72). The observed regulation 
was attributable to nitric oxygen (NO) production by graft-infiltrating central memory CD8+ T 
cells that were abundantly present in accepted lung allografts. In contradiction to this study, 
central memory T cells have also been described to mediate graft rejection in experimental 
skin transplantation (35). This discrepancy may be explained by the unique physiology of the 
lungs to limit pulmonary inflammation (73), or because nonvascularized skin allografts are 
less susceptible to tolerogenesis (74). The impact of central memory T cells on transplantation 
outcome may therefore vary depending on the transplanted organ.
A common feature of memory T-cell differentiation is the gradual loss of CD28, which can 
have direct implications for transplantation, since (alloreactive) memory T cells that have lost 
CD28 expression are less dependent on costimulatory signals for their activation. In addition, 
CD28 loss renders them insusceptible to costimulation blockade by belatacept (53). Therefore, 
costimulation blockade alone may be insufficient to suppress the activity of progressively 
matured alloreactive CD28null T cells. Indeed, a large phase III clinical trial (Belatacept Evaluation 
of Nephroprotection and Efficacy as First-line Immunosuppression Trial; BENEFIT) investigating 
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immunosuppression by belatacept as an alternative to cyclosporine, showed that allograft 
rejection was significantly higher in the belatacept versus the cyclosporine group (17-22% vs 7% 
respectively) (75). Surprisingly, a recent nonhuman primate renal transplantation model with 
belatacept in combination with the mammalian target of rapamycin (mTOR) inhibitor sirolimus, 
found no necessity for memory T-cell depletion to ensure allograft survival (76). A subsequent 
human study conducted by the same group supported these data (77), indicating that the 
combination of costimulation and mTOR inhibition could be sufficient to hamper memory T 
cell responses. The findings remain to be confirmed in larger human studies.
In addition to belatacept resistance, Demmers et al. (78) demonstrated that terminally 
differentiated CD4+CD28null effector memory T cells can also be unresponsive to tacrolimus and 
everolimus. In addition, the authors showed that these terminally differentiated CD4+CD28null 
effector memory T cells were able to proliferate in response to allogeneic renal tubular 
epithelial cells (TECs). Although terminally differentiated CD4+CD28null effector memory cells 
are uncommon in healthy individuals, they are found during end-stage renal disease and are 
associated with cytomegalovirus (CMV) infection (79, 80).
Interestingly, the humoral arm of the immune system may also affect T-cell mediated 
alloimmunity, as was recently described by Jane-Wit et al. (81). They showed that alloantibody 
and complement deposition on the cell surface of allogeneic endothelial cells upregulated the 
transcription of pro-inflammatory genes, leading to recruitment and activation of alloreactive 
CD4+ T cells and resulting in cardiac allograft vasculopathy in mice (81). Additionally, the group of 
Heeger described a direct interaction of complement and T cells. Naïve CD4+ T cells were shown 
to express complement receptors C3aR and C5aR, which upon activation induced type 1 helper 
T cell (Th1) maturation (82). Recently, they found that blockade of the complement receptors 
also significantly enhanced the stability of alloantigen-induced Tregs (83). These findings create 
a therapeutic potential for C3aR and C5aR antagonists, as they could simultaneously hamper 
alloreactive T cells and promote alloantigen-induced Treg stability.
Solid organ transplantation: clinical studies
Cytomegalovirus (CMV) infection is negatively associated with graft outcome, and recent 
clinical studies highlight the potential role of the anti-CMV response. Donckier et al. (84) found 
that strong effector memory CD8+ T-cell expansion induced by lymphodepletion impeded 
early immunosuppression withdrawal in cadaver liver transplant recipients. The expansion 
mainly involved CMV- and Epstein-Barr virus (EBV)-directed T cells, and correlated with the 
occurrence of acute rejection. The authors therefore suggested a model in which virus-
induced effector memory CD8+ T cells homeostatically proliferated upon lymphodepletion, and 
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subsequently cross-reacted to the donor tissue: creating a causal link between graft rejection 
and heterologous immunity. Likewise, a role for heterologous immunity in graft rejection was 
suggested by Roux et al. (85), who performed a longitudinal study on lung transplant recipients. 
It was shown that memory CD8+ T-cell responses directed against CMV comprised a large 
proportion of the intra-graft immune infiltrate and could therefore be involved in transplant 
rejection (85). Moreover, Nguyen et al. (86) found cross-reactive CMV-directed memory CD8+ T 
cells in a lung-transplant recipient. Interestingly, despite increased numbers of highly activated 
cross-reactive CD8+ T-cells prior to and during CMV reactivation, there was no negative 
correlation with long-term transplantation outcome. This finding is in concordance with their 
previous findings on cross-reactive EBV-induced CD8+ T cells, which were also detected in 
human lung allografts without exerting a negative effect on transplant outcome (40). The latter 
two studies may therefore seem to argue against a role for cross-reactive virus-induced T cells 
in transplant outcome. However, one should keep in mind that the donor used in the CMV 
study did not express the cross-reacting HLA-B27 subtype, which could explain for the lack 
of detrimental effect on transplantation outcome. Furthermore, the cross-reactive response 
described in the EBV study is shown to be highly peptide-dependent and as a consequence is 
tissue-specific (87). The cross-reactive T cells specifically recognize a peptide derived from the 
ATP-binding cassette sub-family D member 3 (ABCD3) protein, and although lung tissue cells 
can express ABCD3, this study also showed that ABCD3 expression does not, as per definition, 
lead to surface presentation of the appropriate cross-reacting peptide (87). This cross-reactive 
response should therefore ideally also be investigated in other human transplantation types.
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hematopoietic stem cell transplantation (HSCT) can be employed for both malignant and 
nonmalignant hematological diseases. Whereas HSCT for malignant diseases aims at inducing 
GVL by moderate alloreactivity, HSCT for nonmalignant hematological diseases aims at full 
donor-specific tolerance. The latter can be achieved by inducing a state of mixed hematopoietic 
chimerism, in which there is a stable balance between immune cells of the donor and the 
recipient (88).
Hematopoietic stem cell transplantation: experimental studies
Recent experimental studies on T-cell alloreactivity in HSCT mainly focus on alloreactivity 
directed against malignant cells. Although entering the field of tumor immunology is beyond 
the scope of this review, lessons can be learned regarding the alloreactive potential of donor-
derived T cells. For instance, Binsfeld et al. (89) developed a murine model to investigate 
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the curative properties of allogeneic SCT in multiple myeloma, and revealed that especially 
alloreactive CD8+ T cells are potent mediators of the graft-versus-myeloma (GVM) effect.
Westerhuis et al. (90) recently studied the effect of heterologous immunity on the induction of 
mixed chimerism. In an experimental mouse model, the persistence of mixed hematopoietic 
chimerism was hampered by recipient CD8+ T cells induced upon vaccination with the vaccinia 
virus (90). The authors therefore hypothesize that heterologous immunity of vaccinia-induced 
CD8+ T cells directed against allogeneic antigens interfered with the mixed chimerism induction. 
This study is one of the first describing heterologous immunity in HSCT. Since patients 
undergoing HSCT are highly immunocompromized, infections are a regular complication (91), 
potentially interfering with mixed chimerism induction or contributing to GVHD.
Hematopoietic stem cell transplantation: clinical studies
In essence, replacing the recipient’s immune system by that of a donor results in the presence 
of donor-derived naïve T cells in the recipient. Unfortunately, naïve CD4+ T cells can be highly 
alloreactive and may predispose for developing acute GVHD, which was recently confirmed 
by Chérel et al. (92). Analyzing HSCT in HLA-identical twins of different sex, they found that 
naïve CD4+ T cells exerted vigorous alloreactivity towards the H-Y minor antigen (92). Selective 
depletion of naïve CD4+ T cells from HSCT allografts may therefore prevent GVHD. This is in 
line with data by Distler et al., who showed that CD45RA-negative T cells exert only limited 
alloreactivity (93), and therefore assessed the functional properties of CD45RA-depleted donor 
leukapheresis products. When naïve CD4+ and CD8+ T cells were depleted from leukapheresis 
products by using CD45RA, they indeed observed reduced alloreactive CD8+ T cell numbers, 
without effecting responses against pathogens. Unexpectedly, alloreactive CD4+ T-cell numbers 
were not reduced (94). The authors ascribe this to the completely HLA-mismatched setting 
and emphasize this is not representative for clinical HSCT. In addition, CD45RA targeting may 
deplete late-differentiated memory T cells and naïve Tregs. Depletion of late-differentiated 
memory T cells may hamper anti-virus responses, but could also be beneficial, given their high 
alloreactive potential as previously discussed (78). The depletion of Tregs, on the contrary, 
does raise concerns as they are potent tolerogenic cells and are even employed for tolerance 
induction (95). Inevitably, the forthcoming multicenter pilot trial using CD45RA-depleted donor 
lymphocyte infusions (DLI) will give more insights into the overall effects of CD45RA depletion.
Currently, HLA matching for HSCT does not include HLA-DP, and mismatching of HLA-DP has 
previously been suggested to selectively induce GVL (and not GVHD) in T-cell-depleted allo-
HSCT patients (96). However, the immunogenicity of HLA-DP is still under investigation, and 
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recent studies call for awareness of CD4+ reactivity against HLA-DP. For instance, Stevanovic 
et al. (97) described two patients who underwent severe acute GVHD after prophylactic CD4+ 
DLI, induced by alloreactive CD4+ T cells directed against mismatched HLA-DP on epithelial 
cells. Interestingly, both patients suffered from CMV reactivation shortly after HSCT. A likely 
explanation is therefore that anti-viral inflammatory responses induced HLA class II expression 
on colonic epithelial cells, enabling the recognition of HLA-DP by alloreactive CD4+ donor T cells 
and the establishment of severe acute colonic GVHD. Whereas prophylactic CD4+ T-cell DLI is 
an effective treatment of residual malignant hematopoietic cells, this study calls for caution of 
performing this procedure in the presence of concurrent viral infections. Interestingly, a great 
effort is put into the understanding of the molecular mechanisms behind anti-HLA-DP cross-
reactivity (98, 99), which recently resulted in the development of a prediction algorithm (100, 
101). The algorithm accurately predicted known and unknown allo-HLA-DP CD4+ T-cell cross-
reactivity in vitro (100), and thereby creates a valuable tool for risk prediction in unrelated HSCT.
Combining these data, it appears that there is an association between virus infection, T-cell 
cross-reactivity against allogeneic HLA and GVHD. Plausibly, the majority of these alloreactive 
cells are primed by direct alloantigen recognition, and inflammation induced by viral infection 
simply upregulates allogeneic HLA on the donor cells. Yet, as suggested by the experimental 
study by Westerhuis et al., virus-induced T cells may also affect HSCT outcome. Research into 
heterologous immune responses in HSCT is of special interest at present, as progress is being 
made into the employment of adoptive transfer of virus-induced T cells to treat viral infections 
in HSCT patients (102).
CONCLUSION
Recent literature describes the alloreactive potential of both naïve and memory T-cells. 
Research on HSCT revealed that especially naïve CD4+ T cells have high alloreactive potential. 
Tailoring donor-lymphocyte infusions by partial selection of naïve alloreactive T cells and 
additional HLA-DP matching to prevent strong CD4+ alloreactive responses are therefore 
promising therapeutic strategies. Whereas in SOT, naïve T cells are efficiently hampered by 
immunosuppression, memory T cells could escape suppression and provide a barrier to 
successful transplantation. A large part of the memory T-cell compartment is induced by 
viral infection, and heterologous immunity of virus-induced memory T cells directed against 
donor-HLA demands attention in both solid organ transplantation and HSCT. However, much 
is still unknown with regard to their impact on clinical transplantation outcome, and additional 
research is strongly urged.
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ABSTRACT
Background
Virus-specific T cells have the intrinsic capacity to cross-react against allogeneic HLA antigens, a 
phenomenon known as heterologous immunity. In transplantation, these cells may contribute 
to the alloimmune response and negatively impact graft outcome. This study describes the 
various techniques that can be used to detect heterologous immune responses of virus-specific 
CD8+ T cells against allogeneic HLA antigens. The strengths and weaknesses of the different 
approaches are discussed and illustrated by experimental data.
Methods
Mixed lymphocyte reactions (MLRs) were performed to detect allo-HLA cross-reactivity of 
virus-specific CD8+ T cells in total peripheral blood mononuclear cells. T-cell lines and clones 
were generated to confirm allo-HLA cross-reactivity by IFNγ production and cytotoxicity. In 
addition, the conventional MLR protocol was adjusted by introducing a 3-day resting phase and 
subsequent short restimulation with alloantigen or viral peptide, whereupon the expression 
of IFNγ, interleukin-2 (IL-2), CD107a and CD137 was determined.
Results
The accuracy of conventional MLR is challenged by potential bystander activation. T-cell lines 
and clones can circumvent this issue, yet their generation is laborious and time-consuming. 
Using the adjusted MLR and restimulation protocol, we found that only truly cross-reactive T 
cells responded to re-encounter of alloantigen and viral peptide, while bystander-activated 
cells did not.
Conclusions
The introduction of a restimulation phase improved the accuracy of the MLR as a screening 
tool for the detection of allo-HLA cross-reactivity by virus-specific CD8+ T cells at bulk level. 
For detailed characterization of cross-reactive cells, T-cell lines and clones remain the golden 
standard.
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INTRODUCTION
Viral infections are a common complication after transplantation and are associated with 
rejection and decreased graft survival (103). Viruses may cause transplant injury directly by 
infecting cells of the graft, or indirectly by activating innate and adaptive immune responses. 
Local viral infections, for instance initiated by BK virus in kidney transplantation or by airborne 
viruses in lung transplantation, may harm the graft by lytic viral replication within epithelial cells 
and immune cell-mediated (bystander) injury (104, 105). In addition, viral infections can alter the 
cytokine milieu inside the graft or even systemically, affecting the differentiation and function 
of lymphocytes including alloreactive T cells. For example, cytomegalovirus (CMV) infection 
induces a systemic immune activation characterized by increased levels of Th1-associated 
cytokines in both healthy individuals and kidney transplant recipients (106).
The role of viruses in alloimmune responses is illustrated by experimental murine studies. 
Whereas transplantation tolerance is easily achieved in pathogen-free mice, it is far more 
difficult to achieve in humans and nonhuman primates. As humans and nonhuman primates 
are continuously exposed to bacteria and viruses, this suggests that pathogens and acquired 
immunological memory may affect alloresponses. Indeed, studies using pathogen-free versus 
pathogen-experienced mice showed that the latter were significantly less susceptible to the 
induction of tolerance (35). Interestingly, viral infections may affect transplant outcome even 
if viremia has been resolved long before transplantation, and virus-specific CD8+ T cells may 
directly contribute to graft rejection (37), suggesting a role for memory T cells induced by viral 
exposure (35, 107).
A significant part of virus-specific memory CD8+ T cells can recognize allogeneic human 
leukocyte antigens (allo-HLA) (108). This is due to cross-reactivity of their T-cell receptor (TCR), 
enabling the recognition of different epitopes by the same TCR. This phenomenon is known 
as heterologous immunity. Heterologous immunity often occurs in a physiological setting and 
creates an evolutionary benefit by enhancing the protection against (un)related pathogens. 
Cross-reactivity is essential for organisms that encompass only a restricted number of T cells 
and is an intrinsic feature of all TCRs (24). Therefore, it is not surprising that the vast majority 
of virus-specific CD8+ T cells in healthy individuals can cross-react to 1 or multiple allo-HLA 
antigens in vitro (43).
Compared to naïve T cells, memory T cells tend to be less sensitive to immunosuppressive drugs 
(109, 110). Therefore, memory T cells that cross-react to donor alloantigens may play a role in T 
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cell-mediated allograft rejection (111-114). Several studies in heart, kidney, and liver transplant 
recipients demonstrate a distinct correlation between the frequency of donor-reactive memory 
T cells before and the incidence and severity of rejection episodes after transplantation (115, 
116). Indeed, cross-reactive virus-specific memory T cells have been found in allografts of lung 
transplant recipients (39, 40, 86).
Clinical studies on cross-reactive virus-specific memory T cells in transplantation are 
limited, and additional studies are required. A potential obstacle facing these studies is the 
complex detection of truly cross-reactive responses. Here, we have described the strengths 
and weaknesses of various approaches that can be used to detect and functionally analyze 
virus-specific CD8+ T cells with cross-reactivity to allo-HLA antigens. We compared current 
experimental methods, divided into bulk culture and clonal analyses, for their accuracy, 
potential applications and limitations. Furthermore, we suggest an altered protocol to more 
accurately distinguish true cross-reactivity from bystander-activation at bulk level.
MATERIALS AND METHODS
Collection of responder and target cells
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy individuals and 
anonymous donors (Buffy coats, Sanquin Blood Supply, The Netherlands) after informed 
consent in accordance with the Declaration of Helsinki. PBMCs were isolated by standard density 
gradient centrifugation and cryopreserved. Epstein-Barr Virus transformed lymphoblastoid cell 
lines (EBV-LCLs) were generated by incubating PBMCs with supernatant of the EBV-producing 
marmoset cell line B95.8 for 1.5 hours at 37°C, and additional culture in RPMI 1640 Medium 
(Gibco) supplemented with penicillin/streptomycin, glutamine and 10% fetal calf serum (FCS). 
Single-antigen-expressing cell lines (SALs) were generated as described previously (117). HLA 
typing was performed by sequence-specific oligonucleotide (SSO) or sequence-specific primer 
(SSP) genotyping at the Tissue-typing laboratory (Leiden University Medical Center (LUMC), 
Leiden, The Netherlands).
Generation of virus-specific CD8+ T-cell lines and clones
CD8+ memory T-cell lines and clones were generated from individuals 1 and 2 by fluorescence-
activated cell sorting (FACS Aria; BD), as previously described (118). PBMC were stained with 
phycoerythrin (PE)-labeled viral tetramers CMV pp65(417-426) HLA-B*07:02/TPRVTGGGAM 
(CMV B7/TPR), EBV EBNA-3A(379-387) HLA-B*07:02/RPPIFIRRL (EBV B7/RPP), and EBV EBNA-
3A(458-466) B*35:01/YPLHEQHGM (EBV B35/YPL) (Protein facility, LUMC) and fluorescein 
isothiocyanate (FITC)-labeled monoclonal antibodies (mAb) against CD4, CD19, CD45-RA, 
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CD14, CD40, CD16 and CD56. The FITC channel (FL1) served as a dump channel, as concurrent 
CD8 mAb and major histocompatibility complex (MHC)-tetramer staining may trigger TCR 
internalization. T-cell receptor (TCR) usage was determined by DNA sequencing using TCR-
specific polymerase chain reaction (PCR) primers (119).
Mixed lymphocyte reaction
Responder PBMC (5x105 cells) were labeled with carboxyfluorescein succinimidyl ester (CFSE, 
Molecular Probes, 5mM), and co-cultured for 6 days with irradiated stimulator PBMC (3000 
Rad, responder:stimulator ratio 1:1) in a 24-well flat bottom plate at a slant. Culture medium 
consisted of either RPMI 1640 Medium (Gibco) supplemented with penicillin/streptomycin, 
glutamine and 15% human serum (HS) or Iscove’s Modified Dulbecco’s Medium (IMDM, Lonza) 
supplemented with 10% HS, penicillin/streptomycin and 0.00036(v/v)% β-mercaptoethanol. For 
culture beyond 6 days, medium was supplemented with IL-2 (10 U/mL) to ensure T-cell survival. 
Cells were stained with fluorescence-labeled CD8 and CD3 antibodies, a viability dye (fixable 
viability dye eFluor 506, eBioscience) and viral tetramer conjugated with PE or allophycocyanin 
(APC) (Protein facility, LUMC, or Sanquin, Amsterdam, The Netherlands). Flow cytometric 
analyses were performed on FACS Calibur and FACS CANTO (BD Biosciences).
Proliferation assay with correction for bystander activation: Mixed lymphocyte 
reaction followed by restimulation
After 6 days of MLR with unmanipulated responders and allogeneic stimulators (see above), 
medium was replaced with culture medium containing 10 U/ml IL-2, and cells were cultured for 
additional 3 days to allow downregulation of activation markers. Importantly, addition of viral 
peptide during the first MLR is discouraged because this will lead to preferential expansion 
of T-cell clones with a high affinity for the viral peptide. Next, the cells were taken up in 
stimulation medium (IMDM + 10% HS + βME + P/S + a-CD28 (2 µg/ml) + a-CD29 mAb (1 µg/ml)) 
and restimulated with: PMA (10 ng/ml, Sigma-Aldrich) and ionomycin (1 µg/ml, Sigma-Aldrich) 
(TCR-independent positive control), the original allogeneic stimulators (2x106), autologous cells 
(5x105) loaded with 10-100 ng viral peptide (TCR-dependent positive control), or co-stimulation 
alone (negative control) in a non-tissue-culture-treated round-bottom 96-wells plate. Stimulator 
cells were labeled with Celltracker Violet BMQC (Invitrogen) to allow discrimination between 
responders and stimulators. Costimulation through anti-CD28 and anti-CD29 antibody binding 
was provided to ensure optimal responses (120). The kinetics of the functional markers were 
previously analyzed: cytokine production and CD107a exposure peaked after 6 hours of 
restimulation, while the induction of CD137 and other activation markers was most prominent 
after 24 hours (data not shown). a-CD107a-PE antibody (BD Pharmingen) was added during 
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the 6-hour restimulation and after 1 hour monensin (0.7 µg/ml; GolgiStop, BD Pharmingen) 
and brefeldin A (10 µg/ml; Invitrogen) were administered to inhibit protein secretion. Next, the 
cells were harvested and stained intracellularly for IL-2 (IL-2-PE-Cy7, BioLegend) and IFNγ (IFNγ-
allophycocyanin (APC)-eFluor 780, eBioscience). CD137 was measured by cell-surface staining 
(CD137-PE, BD Pharmingen) at 24 hours after restimulation (without addition of monensin and 
brefeldin A). All parameters were analyzed by flow cytometry (FACS CANTO; BD Biosciences).
Cytokine production assay
IFNγ levels were measured in a standard enzyme-linked immunosorbent assay (ELISA), 
performed according to the manufacturer’s protocol (U-CyTech ELISA kit; U-CyTech, the 
Netherlands). CD8+ T-cell lines and clones were stimulated by a panel of 11 EBV-LCLs or 6 SALs. 
5x103 CD8+ T cells were incubated with 5x104 EBV-LCLs or SALs in triplicate wells for 24 hours 
at 37°C in IMDM supplemented with penicillin/streptomycin, glutamine, 5% FCS, 5% HS, and 
IL-2 (10 U/mL), after which supernatants were collected.
Cytotoxicity assay
For optimal culture conditions, CD8+ T-cell lines and clones were cultured with irradiated PBMCs 
(4000 Rad) from anonymous buffy coats 8 days prior to cytotoxicity testing. Cytotoxic capacity 
was assessed by 51Chromium-release (51Cr) assay (121). Serial dilutions (responder/stimulator 
ratio 30:1; 10:1; 1:1; 0.1:1) of responder CD8+ T-cell lines and clones were stimulated with 51Cr-
labeled EBV-LCLs and/or phytohaemagglutinin (PHA) blasts in round-bottom 96-wells plates 
for 4 hours at 37°C, in IMDM, penicillin/streptomycin, glutamine, 5% FCS, 5% HS, and IL-2 (10 
U/mL). PHA blasts were generated by incubation of 1x106 cells PBMCs with PHA (0.8mg/mL; 
Murex Biotec Limited). Supernatants were collected for analysis on a γ-counter (PerkinElmer 
2470 Wizard2), and specific lysis was determined by the following calculation: (Experimental 51Cr 
release -Spontaneous 51Cr release)/(Maximum 51Cr release - Spontaneous 51Cr release) x100. Maximum 
51Cr release of the target cells was determined in PBS 1% Triton X-100, and spontaneous 51Cr 
release in medium. Values for specific 51Cr lysis represent the mean ± standard deviation of 
triplicate wells.
RESULTS
Techniques to assess virus-specific T cells with cross-reactivity to alloantigen 
in bulk cultures
Cross-reactivity of virus-specific T cells can be assessed in bulk cultures using PBMCs. PBMCs 
are easily obtained from blood samples, do not need pre-culturing, and are considered to be 
a fair representation of the immune repertoire.
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Mixed lymphocyte reaction: a tool to screen for cross-reactivity and determine precursor 
frequencies of cross-reactive T cells
A widely used method to determine alloreactive lymphocytes in vitro at bulk level is the mixed 
lymphocyte reaction (MLR). Responder PBMCs are cultured with irradiated allogeneic stimulator 
PBMCs, whereupon proliferation and expression of activation markers can be assessed. Figure 
1 shows how MLR can be used to determine proliferation of cross-reactive CD8+ T cells that 
recognize both viral and alloantigen epitopes.
Figure 1. Identification of virus- and alloantigen cross-reactive CD8+ T cells by combining MLR with 
viral tetramer staining. A) Flow chart of the experimental setup for a standard MLR. B) Flow-cytometric 
analysis of CD8+ T cells after a 6-day MLR. Plotting viral tetramer against CFSE can distinguish between 
virus-specific cells (CFSE+tetramer+CD8+CD3+ T cells, green), cross-reactive cells (CFSEdimtetramer+CD8+CD3+ 
T cells, orange), and alloreactive cells (CFSEdimtetramer-CD8+CD3+ T cells, red). Schematic overview of allo-, 
virus- and cross-reactive T cells (right panel) C) Overview of different FACS plots after a 6-day MLR showing 
from left to right: a proliferative response of tetramer-positive and tetramer-negative cells upon allogeneic 
stimulation; no proliferative response of tetramer-positive and tetramer-negative cells upon autologous 
stimulation; a proliferative response of tetramer-positive and tetramer-negative cells upon viral peptide + 
IL-2 stimulation; a proliferative response of tetramer-negative cells but no proliferative response of tetramer-
positive cells upon IL-2 stimulation alone.
We composed a panel of 16 different HLA-typed stimulator PBMCs, which covered the most 
common HLA class I molecules in the Western European population (>5%) (Table S1, SDC, 
http://links.lww.com/TXD/A15). The PBMCs of two HLA-typed healthy individuals were screened 
against this panel in MLR. In both individuals, CD8+ T cells directed against different viral 
epitopes proliferated upon encounter with 1 or more stimulator targets (Table S2, SDC, http://
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links.lww.com/TXD/A15). CMV B7/TPR and EBV B7/RPP T-cell responses of individual 1, as well 
as EBV B35/YPL T-cell responses of individual 2, revealed potential cross-reactivities to allo-HLA 
antigen (Figure 2A). Additional MLRs were performed, which confirmed allo-HLA cross-reactivity 
(Figure 2B). CMV B7/TPR T cells proliferated strongly in response to stimulators expressing HLA-
A29, whereas EBV B7/RPP T cells responded toward HLA-B40-expressing stimulators. EBV B35/
YPL T cells appeared to recognize the HLA class II molecule HLA-DRB1*03:01.
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Proliferating alloreactive T cells produce IL-2 and additional cytokines that can promote T-cell 
activation and proliferation in an antigen-independent manner. Consequently, it is difficult to 
determine which responses are truly cross-reactive. IL-2-mediated bystander proliferation is 
illustrated by CMV B7/TPR T cells of individual 3 in Figure 3B. To get an impression of potential 
bystander activation, the extent to which virus-specific T cells proliferate in response to IL-2 can 
be assessed (Figure 1). However, unresponsiveness to IL-2 alone does not exclude bystander 
activation and proliferation in response to IL-2 alone does not exclude true cross-reactivity 
toward alloantigen. The probability of bystander activation can be assessed by performing 
additional MLRs with various HLA-typed stimulators. Overall, these findings demonstrate that 
performing MLRs against a broad panel of HLA-typed targets can aid in identifying HLA class I 
and II antigens recognized by cross-reactive virus-specific CD8+ T cells, yet one should be aware 
of bystander activation.
Figure 3. Potential cross-reactivity of virus-specific CD8+ T cells can be misinterpreted due to 
bystander activation in a mixed lymphocyte reaction. A) Flow chart of a 6-day MLR. B) FACS plots 
depicting the extent of proliferation and tetramer-reactivity of CD8+ T cells after 6-day culture with (from 
left to right): allogeneic stimulators, autologous stimulators (negative control), viral peptide and IL-2 (positive 
control) or IL-2 alone (cytokine-mediated bystander activation).
Responder HLA typing:
R3 (FLU A2/GIL): A1, A2, B8, B44(12), Cw5, Cw7, DR1, DR4
R4 (CMV B7/TPR): A2, B7, remainder unknown
Allogeneic stimulator HLA typing:
FLU A2/GIL: A2, A19, B7, B16, DR2, DR6
CMV B7/TPR: A1, A31(19), B8, B51(5), DR13(6), DR3
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MLR with restimulation: identification of cross-reactive T cells in total PBMC, an optimized 
protocol to detect true cross-reactivity at bulk level
Performing multiple MLRs is time-consuming, and it would thus be beneficial to rule out 
bystander activation in a single experiment. This could be achieved by combining a primary MLR 
with a subsequent short restimulation with the same allogeneic responder (122). This approach 
ensures a more accurate and sensitive detection of alloreactivity due to clonal expansion and 
diminished activation requirements of prestimulated alloreactive cells. Cross-reactive cells 
responding during the primary MLR will respond quickly against the original stimulator cells, 
yet only modestly to other allogeneic stimulator cells (123).
We introduced a 3-day resting period and restimulation phase following the conventional MLR 
to identify truly cross-reactive T cells and simultaneously elucidate their function by assessment 
of cytokine production, exposure of the degranulation marker CD107a, and expression of 
the activation marker CD137 (124, 125). The FLU A2/GIL and CMV B7/TPR responses of the 
responder-stimulator combinations that were previously investigated in conventional MLR 
(Figure 3B) were now investigated in MLR with restimulation. Proliferating FLU A2/GIL T cells 
expressed comparable levels of interferon γ (IFNγ), IL-2, CD107a and CD137 upon restimulation 
with either TCR-independent stimulus (PMA-ionomycin), autologous cells pulsed with viral 
peptide, or allogeneic stimulator cells. This indicated true cross-reactivity (Figure 4B). In 
contrast, CMV B7/TPR cells showed no IFNγ, IL-2, CD107a and negligible CD137 expression 
levels upon allogeneic restimulation compared to TCR-independent stimulus and autologous 
cells with viral peptide, suggesting that the CMV B7/TPR T cells indeed proliferated in an 
alloantigen-independent manner (as indicated by IL-2-mediated proliferation; Figure 3B) and 
thus were not truly cross-reactive. When cross-reactive or bystander-activated cells were not 
restimulated, they expressed no or very little functional and activation markers. These findings 
were reproduced in independent experiments with the same responder-stimulator pairs. The 
examples depicted in Figure 4 are representative for n = 15 responses of T cells specific for 
epitopes of CMV, EBV and FLU. The altered MLR with restimulation protocol is thus a suitable 
tool to identify true cross-reactivity at bulk level.
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Figure 4. Restimulation after an MLR can help to discriminate true cross-reactivity from bystander 
activation. A) Flow chart of the 9-day MLR followed by 6-24 hr restimulation. B) Expression of IFNγ, IL-2, 
CD107a and CD137 in FLU A2/GIL+ T cells that cross-react to alloantigen, and CMV B7/TPR+ T cells that have 
proliferated independent of alloantigen. Responder and stimulator cells correspond to the ones used in 
Figure 3B. The examples of true cross-reactivity and bystander activation are representative for n = 15 
responses for epitopes of CMV, EBV and FLU.
Responder HLA typing:
R3 (FLU A2/GIL): A1, A2, B8, B44(12), Cw5, Cw7, DR1, DR4
R4 (CMV B7/TPR): A2, B7, remainder unknown
Stimulator HLA typing:
FLU A2/GIL: A2, A19, B7, B16, DR2, DR6
CMV B7/TPR: A1, A31(19), B8, B51(5), DR13(6), DR3
Techniques to assess virus-specific T-cells with cross-reactivity toward 
alloantigen using T-cell lines and clones
To determine in-depth characteristics and cytotoxicity of cross-reactive CD8+ T cells, CD8+ T-cell 
lines and clones are recommended. In addition, they can be used to support MLR findings.
T-cell lines and clones: accurate detection and in-depth characterization of TCR cross-
reactivity at clonal level
To confirm allo-HLA cross-reactivity of CMV- and EBV-specific T cells, we generated CD8+ T-cell 
lines and clones of the following viral specificities: CMV B7/TPR, EBV B7/RPP, and EBV B35/YPL. 
Homogeneity of the lines and clones was confirmed by TCR usage (Table S3, SDC, http://links.
lww.com/TXD/A15). The T-cell lines and clones were first stimulated with a panel of HLA-typed 
immortalized EBV-LCLs, whereupon IFNγ production was determined by ELISA (Figure 5A, 5B). 
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Significant amounts of IFNγ were produced by EBV B35/YPL T-cell line 2A6 upon recognition 
of HLA-DRB1*03:01+ EBV-LCLs and by CMV B7/TPR T-cell line 5A1 upon recognition of HLA-
A29+ EBV-LCLs. The EBV B7/RPP T-cell clones 9G6 and 10D8 produced moderate levels of IFNγ 
upon recognition of HLA-B40+ EBV-LCLs. T-cell lines and clones with similar viral specificity 
but different TCR usage did not produce IFNγ in response to the same allo-HLA molecules, 
demonstrating that cross-reactivity is mediated by a subpopulation of virus-specific T cells with 
defined TCR usage. In contrast to EBV-LCLs, SALs did not induce significant IFNγ production, 
suggesting that the recognized endogenous peptide might not be expressed by these cells 
(Figure 5C). This highlights the importance of testing cross-reactivity with different cell types.
Figure 5. Generation of virus-specific T-cell lines and clones followed by analysis of cross-reactivity 
based on IFNγ secretion. A) Flow chart of the procedure to generate CD8+ T-cell clones and subsequent 
measurement of IFNγ production upon stimulation with allogeneic cells by ELISA. B) IFNγ production by 
CD8+ T-cell lines 2A6 (EBV B35/YPL; R2) and 5A1 (CMV B7/TPR; R1) and CD8+ T-cell clones 9G6 and 10D8 (both 
EBV B7/RPP; R1) upon stimulation with HLA-typed EBV-LCLs. EBV B35/YPL T-cell line 2A6 responded to EBV-
LCL 9 (HLA-DR3), CMV B7/TPR T-cell line 5A1 to EBV-LCL 3 and 9 (both HLA-A*29:02), and EBV B7/RPP T-cell 
clones 9G6 and 10D8 responded to EBV-LCL 3 (HLA-B60), 8 (HLA-B*40:01), 21 (HLA-B61). Positive control: 
EBV-LCL sharing the autologous HLA antigen (B35/B7) loaded with viral peptide. C) IFNγ production of EBV 
B7/RPP T-cell clones 9G6 and 10D8 upon stimulation with SALs expressing depicted HLA molecules. All bars 
represent the mean of duplicates.
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Responder HLA typing:
R1: A*02; A*03; B*07; B*35; C*04; C*07; DRB1*01; DRB1*08; DQB1*04:02; DQB1*05:01
R2: A*02; A*03; B*07; B*35
Stimulator HLA typing:
EBV-LCL 2: A*24:02; A*33:01:01; B*14:02:01; C*02:02/02:32; C*08:02/08:29; DR1; DQ*05:01; DP1; DP4
EBV-LCL 3: A*03:01/03:22; A*29:02/29:09; B*07:02/07:61/07:114; B*44:03/44:105; C*07:02:01; C*16:01:01; DR2
EBV-LCL 6: A*01:01:01:01; A*26:01:01; B*08:01:01; B*49:01:01; C*07:01:01; DR01; DR*03:04; DQ*03:04; DQ*05:04
EBV-LCL 8: A*02:03:01; A*24:02; B*38:02:01; B*40:01:02; C*03:04:01; C*07:02:01; DR2; DR5
EBV-LCL 9: A*29:02:01; A*31:01:02; B*18:01/18:17N; B*58:01:01; C*05:01; C*07:18/07:01; DR3; DR8; DQ2
EBV-LCL 10: A*24:03:01; B*51:01:01; C*15:02:01; DR*11:04; DQ*03:01; DP*04:02
EBV-LCL 12: A*24:02:01; A*30:01:01; B*51:01:01; B*58:01:01; C*01:02:01; C*03:02:02; DR1; DR7; DQ1; DQ2
EBV-LCL 15: A*24:02; A*31:01:02; B*39:01; B*55:01:01; C*03:03:01; C*12:03:01; DR13; DQ1; DP2; DP4
EBV-LCL 16: A*30:01:01; A*68:02:01; B*42:01:01; C*17:01:01; DR*03:02; DQ*04:02; DP*01:01; DP*04:02
EBV-LCL 20: A31; A*24:02; B7; Cw4; Cw7; DR12; DR15
EBV-LCL 21: A*02:10; A30; B13; B61; Cw6; DR7; DR9
Figure 6. Cytotoxic potential of cross-reactive T-cell lines and clones. A) Flow chart of the generation 
of CD8+ T-cell clones and subsequent measurement of cytotoxicity toward allogeneic cells in a 51Chromium-
release assay. B) Percentage specific lysis of 51Chromium-labeled target cells by CD8+ T-cell lines 2A6 (EBV 
B35/YPL; R2) and 5A1 (CMV B7/TPR; R1) and CD8+ T-cell clones 9G6 and 10D8 (both EBV B7/RPP; R1). Negative 
control: autologous PHA blasts without peptide (TA-). Positive control: autologous PHA blasts loaded with 
viral peptide (TA + YPL, TA + TPR, TA + RPP). All bars represent triplicate wells with standard deviation.
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Responder HLA typing:
R1: A*02; A*03; B*07; B*35; C*04; C*07; DRB1*01; DRB1*08; DQB1*04:02; DQB1*05:01
R2: A*02; A*03; B*07; B*35
Stimulator HLA typing:
T1: EBV-LCL 9: A*29:02:01; A*31:01:02; B*18:01/18:17N; B*58:01:01; C*05:01; C*07:18/07:01; DR3; DR8; DQ2
T2: PHA-blast S1.2 Figure 2B: A*02:01; A*32:01; B*35; Cw*04:01; DRB1*03:01; DRB1*11; DQB1*02; DQB1*03:01
T3: PHA blast SB.2 Figure 2B: A1; A2; B8; B44(12); Cw5; Cw7; DRB1*03:01; DRB3*01:01; DQB1*02; 
DQA1*05:01/05:03; DPB1*01:01; DPB1*04:02
T4: PHA blast SC.2 Figure 2B: A*01:01; A*03:01; B*08:01; B*35:01; C*04:01; C*07:01; DRB1*03:01; DRB1*11:01
T5: PHA blast SE.2 Figure 2B: A*30:02; B*18:01; C*05:01; DRB1*03:01; DRB1*07; DQB1*03
T6: EBV-LCL 3: A*03:01/03:22; A*29:02/29:09; B*07:02/07:61/07:114; B*44:03/44:105; C*07:02:01; C*16:01:01; 
DR2
T7: PHA blast S2 Figure 2B: A24(9); A29(19); B7; B60(40); Cw7; DR13(6); DR8; DQ6(1); DQ4
T8: PHA blast S13 Figure 2B: A*24:02; A*2901; B*39:06; B*44:03; Cw*07:02; Cw*16:01; DRB1*07; DRB1*08:01; 
DQB1*02:02; DQB1*04:02
T9: PHA blast SE: A2; A29(19); B57(17); B55(22); Cw3; Cw6; DR14(6); DR7; DQ5(1); DQ9(3)
T10: PHA blast SF Figure 2B: A*29:02; A*69:01; B*45:01; B*15:17; C*06:02; C*07:01; DRB1*15:01; DRB1*11:01; 
DQB1*06:02; DQB1*03:01
T12: EBV-LCL 8: A*02:03:01; A*24:02; B*38:02:01; B*40:01:02; C*03:04:01; C*07:02:01; DR2; DR5
T13: PHA blast SG: A*01:01; A*02:01; B*08:01; B*40:01; C*03:04; C*07:01; DRB1*03:01; DRB1*13:02; DQB1*06:04; 
DQB1*02:01
T14: EBV-LCL 21: A*02:10; A30; B13; B61; Cw6; DR7; DR9
T15: PHA blast S16 Figure 2B: A*03:01; A*31:01; B*15:01; B*40:02; Cw*02:02; Cw*03:03; DRB1*04:01; DRB1*13:01; 
DQB1*03:02; DQB1*06:03
T16: PHA blast SI Figure 2B: A1; B8; B61(40); Cw7; DR3; DR13(6); DQ1; DQ2
T17: PHA blast SJ Figure 2B: A2; B35; B61(40); Cw4; DR1; DR4; DQ5(1); DQ7(3)
Furthermore, the cytotoxic capacity of the T-cell lines and clones was determined in a 
51Chromium-release assay, which is the golden standard for measuring cytotoxicity of cross-
reactive T cells (126). CMV B7/TPR T-cell line 5A1 efficiently lysed HLA-A*29:01+ EBV-LCLs, 
whereas EBV B35/YPL T-cell line 2A6 and EBV B7/RPP T-cell clones 9G6 and 10D8 were not 
cytotoxic toward the EBV-LCLs that induced IFNγ production (Figure 6). This is in concordance 
with previous data, demonstrating a similar discrepancy of cross-reactive CD8+ T cells that 
produce IFNγ, but lack cytotoxic capacity in response to alloantigen (127).
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DISCUSSION
This article summarizes the advantages, limitations and applications of commonly used 
experimental methods for the detection of virus-specific CD8+ T cells with cross-reactivity to 
allogeneic HLA antigen (see overview in Table S4, SDC, http://links.lww.com/TXD/A15).
We conclude that MLR can be a useful tool to screen for cross-reactivity of virus-specific T cells 
against alloantigen at bulk level. By using determined responder-stimulator combinations, 
donor-specific cross-reactivity can be identified and characterized. Furthermore, precursor 
frequencies of cross-reactive T cells can be calculated and unknown allo-HLA cross-reactivity 
can be identified by using a broad array of HLA-typed targets. Accordingly, we were able 
to identify allo-HLA specificity in conventional MLR: CMV B7/TPR CD8+ T cells proliferated 
in response to HLA-A29+, EBV B7/RPP T cells to HLA-B40+ and EBV B35/YPL CD8+ T cells 
proliferated in response to HLA-DRB1*03:01 stimulators. Interestingly, the latter alloresponse 
was mediated by CD8+ T cells cross-reacting toward HLA class II alloantigen. Recognition of 
an HLA-DRB1*03:01-derived peptide within an HLA class I molecule was unlikely as not all 
stimulators shared HLA class I molecules. Although cross-reactivity of virus-specific CD8+ T 
cells toward HLA class II molecules is rare, it has been reported previously for CMV-reactive 
T cells (43, 128). Therefore, when evaluating MLR results, one ought to keep in mind that TCR 
cross-reactivity is not restricted by the rules of cognate pMHC recognition.
Although MLR provides a suitable tool for cross-reactivity screening, it has limitations. First, a 
vast amount of both responder and stimulator cells is needed. Second, due to the usage of bulk 
PBMC cultures, high-affinity alloresponses may dominantly overgrow low-affinity alloresponses, 
leading to an underestimation of the latter. Third, cross-reactive cells with a low precursor 
frequency may not, or only incidentally, be detectable at bulk level depending on the number of 
analyzed responder cells. Fourth, the composition of cell types within the PBMC compartment 
may differ between stimulators, which could lead to further overestimation or underestimation 
of alloantigen recognition. MLRs are thus insufficient in detecting the full spectrum of cross-
reactivity, resulting in only a moderate sensitivity of the assay.
In addition, one should keep in mind that allo-HLA cross-reactivity is directed against the 
combination of allogeneic HLA and endogenous peptide (129). Because cells derived from 
different individuals may differ in HLA expression levels and/or the ability to present cross-
reactive peptides, the strength of an alloresponse could vary between individuals (Figure 2A). 
Moreover, tissue-specific expression of endogenous peptides could influence alloreactivity 
61
Heterologous immunity in organ transplantation
(130, 131), and thereby affect transplantation outcome of different organs. Indeed, tissue-
specific cross-reactivity of virus-specific T cells has been described: cross-reactive EBV-induced 
CD8+ T cells showed decreased cytotoxic capacity toward epithelial and endothelial target cells 
compared to PBMCs due to poor presentation of the cross-reactive peptide in these cell types 
(87). Because MLR uses PBMCs as targets, potential recognition of tissue-specific peptides 
remains unnoticed. The latter could be overcome by modifying the protocol using different 
stimulator cell types such as epithelial and endothelial cells.
Finally, one of the major issues affecting the accuracy of MLR is bystander activation. In our 
experience, a vigorous proliferative response against allogeneic stimulator cells by virus-specific 
T cells in MLR gives a fair indication for cross-reactivity. On the contrary, less pronounced 
responses are more difficult to interpret. These responses could represent truly cross-
reactive responses with low TCR affinity and/or low precursor frequencies, but they may also 
be the result of cytokine-mediated bystander activation. Hereto, a resting period and short 
restimulation phase was introduced in the conventional MLR protocol. We have shown that this 
experimental approach accurately identifies truly cross-reactive T cells based on proliferative 
capacity, cytokine production, degranulation and activation state upon encounter of alloantigen 
or viral peptide.
Cross-reactive T cells may respond differently to restimulation with alloantigen, depending on 
the TCR affinity and the levels of allo-HLA and peptide presented on the stimulator cells. The 
extent of the response may be less reproducible when studying cross-reactive responses with 
a very low precursor frequency. The number of cross-reactive T cells at the start of each MLR 
could differ by chance, and this difference is enlarged during the 9-day culture period. This 
protocol should therefore not be used for determining the strength of an alloresponse, but 
rather as a quick tool to discriminate cross-reactivity from bystander activation.
Compared to bulk level protocols, T-cell lines and clones can provide more detailed 
characterization and do not suffer from bystander activation and dominant overgrowth of 
TCR cross-reactivity. T-cell lines and clones can be screened against large panels of different cell 
types that express a wide array of HLA antigens (87, 117, 121, 132), and because they constitute 
a homogeneous population, the cross-reactive HLA antigen and peptide can be identified (44). 
Also, the mechanism underlying TCR cross-reactivity can be investigated. Molecular mimicry 
and alternate TCR docking modes have been identified as mechanisms for TCR cross-reactivity 
(44, 133-135). Moreover, T-cell lines and clones can be used to determine cytotoxicity of cross-
reactive T cells, which is important because differences in effector function can influence the 
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impact on transplantation outcome. Our data show that cross-reactive T cells producing IFNγ 
upon alloantigen encounter are not always cytotoxic toward the same targets and highlight 
the importance of performing multiple functional assays for proper characterization of the 
cross-reactive response.
Despite these advantages, T-cell lines and clones have limitations as well. First, their generation 
is labor-intensive and time-consuming and they only represent part of the total T-cell repertoire 
generated against a specific viral epitope. Moreover, the precursor frequency, which has 
prognostic value for the impact of alloreactive T-cell responses on transplantation outcome 
(136), cannot be determined.
A major limitation of all techniques is the availability of viral peptide-HLA tetramer complexes. 
Although available tetramers are believed to cover the most dominant epitopes in individuals 
with the corresponding HLA type, it is not possible to address the total impact of all virus-
specific CD8+ T cells. Unfortunately, it is thereby impossible to uncover all cross-reactivities of 
virus-specific T cells. Moreover, limited availability of HLA class II tetramers impairs the analysis 
of the cross-reactive potential of virus-specific CD4+ T cells, leaving their role in heterologous 
immune responses underexposed. Finally, current methods studying cross-reactive responses 
are labor-intensive and costly, which might hamper large scale screening of transplant recipients 
required to address the impact of cross-reactive T-cell responses on transplant function and 
outcome.
In conclusion, the cross-reactive potential of virus-specific T cells against allogeneic HLA antigen 
can be studied by using the techniques discussed, provided that one should be aware of their 
limitations. Depending on the research question and the availability of cells and resources, 
one can apply bulk MLR cultures for fast broad-spectrum screening, or T-cell lines and clones 
for in-depth characterization of heterologous immune responses.
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SUPPLEMENTARY MATERIAL





















Table S2. Virus-specific CD8+ T cells in two healthy individuals show proliferation upon encounter with one 








1 Two healthy individuals (R1 and R2) selected on the presence of CD8+ T cells directed against CMV, EBV 
and/or FLU were tested in mixed lymphocyte reactions against a panel of HLA-typed stimulators and 
analysed by flow cytometry.
2 The viral epitopes that showed cross-reactivity to 1 or more allogeneic stimulators, defined as cells that 
bound indicated viral tetramers and proliferated in the MLR, are depicted.
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ABSTRACT
Virus-specific T cells have been shown to cross-react with allogeneic HLA (allo-HLA) at a clonal 
level. However, the impact of a single virus on the allorepertoire has never been investigated 
at the polyclonal level. We made an inventory of the incidence and specificity of allo-HLA-
cross-reactive-virus-specific CD8+ T cells in 24 healthy individuals. T cells were stained for 25 
virus-specific tetramers, and mixed lymphocyte reactions were performed against a panel 
of HLA-typed allostimulators. Allospecificity was confirmed by IFNγ-ELISA using T-cell clones 
against a panel of HLA-typed cell-lines. The polyclonal immune repertoire directed against CMV 
alone was associated with a memory response against six allo-HLA molecules. Besides, a single 
allostimulator activated memory T-cell responses with multiple viral specificities. Concluding, 
a single virus can substantially broaden the allo-HLA memory T-cell repertoire. This study 
only looked at CMV- and EBV-specific T cells, whereas the immune repertoire consists of T 
cells directed against many different viruses. Hence, transplant patients receiving an HLA-
mismatched graft may already express a polyclonal repertoire of anti-donor-memory T cells 
before transplantation.
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INTRODUCTION
As a result of the inherent capacity of T-cell receptors (TCRs) to cross-react to multiple antigens, 
T cells can express memory phenotypes even for antigens they have never been exposed to. 
Virus-specific TCRs have been shown to commonly cross-react to allogeneic HLA (allo-HLA), 
and as a result, an alloreactive memory T-cell pool may exist without prior interaction with 
allogeneic HLA. This is of particular interest to the field of transplantation, where memory T-cell 
responses directed against donor cells pose a threat to transplant tolerance (60). Compared to 
naïve cells, memory T cells have a stronger effector potential, improved survival capacities and 
upregulated cell adhesion molecules that enable binding to and entering of inflammation sites. 
In addition, they have lower activation requirements as they do not rely on co-stimulation for 
their activation. Co-stimulation blockade is an important factor in routine immunosuppressive 
regimens and is very effective in preventing the activation of naïve T cells, but not of memory 
T cells. Calcineurin inhibitors (CNI) effectively suppress the activity of both phenotypes 
(137), but as they are extremely potent and non-specific, they come at the price of increased 
susceptibility to opportunistic infections (138). In addition, they have severe toxic side effects 
such as chronic nephrotoxicity and neuropathy (46, 47). In the quest for finding alternative 
immunosuppressive agents, a major focus lies on co-stimulation blockade, thereby leaving the 
memory compartment largely unaffected (59, 75-77). A recent report of a randomized clinical 
trial comparing the CNI tacrolimus to the CD28-CD80/86 co-stimulation inhibitor belatacept 
in kidney transplant recipients however shows that the acute rejection rate was significantly 
higher and more severe in the belatacept-treated versus the tacrolimus-treated group (139). 
Potentially, virus-specific memory T cells with cross-reactivity to donor HLA may have played 
a role in these rejections.
Several research groups have examined the potential cross-reactivity of virus-specific memory 
T cells toward allo-HLA. However, so far, studies primarily focused on the identification and 
characterization of individual allo-HLA-reactive virus-specific memory CD8+ T-cell clones, 
whereas a viral infection generally induces a polyclonal immune response. The latter is 
comprised of T cells expressing a broad range of TCRs with different epitope specificities and 
large variation in TCR affinity and avidity for their epitopes. As TCR cross-reactivity of virus-
specific T cells occurs in 45% of virus-specific T-cell clones and 80% of virus-specific T-cell lines 
(43), polyclonal immune responses that are generated in response to just a single virus are 
likely to induce many memory T cells that are able to cross-react to different allogeneic HLA 
molecules. The impact of such a broad polyclonal virus-induced immune response on the 
allorepertoire within an individual has not yet been determined. In this report, we made an 
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inventory of polyclonal anti-virus immune responses and their impact on the allorepertoire 
in healthy individuals.
MATERIALS AND METHODS
Collection of responder and target cells
Peripheral blood mononuclear cells (PBMCs) were derived from healthy individuals of both 
male and female origin with informed consent conform the Declaration of Helsinki. Standard 
density gradient centrifugation (Ficoll-Isopaque separation) was performed to isolate PBMCs 
from whole blood. PBMCs were cryopreserved prior to usage.
Epstein-Barr Virus transformed lymphoblastoid cell lines (EBV-LCLs) were generated from 
PBMCs by incubation with supernatant of the EBV-producing marmoset cell line B95.8 for 
1.5 hours at 37°C. Culturing was done in Iscove’s Modified Dulbecco’s Medium (IMDM; Lonza, 
Basel, Switzerland) supplemented with penicillin/streptomycin (Gibco), glutamine and 10% 
fetal calf serum (FCS).
Generation of virus-specific CD8+ T-cell clones and lines
CD8+ memory T-cell clones and lines were generated by fluorescence-activated cell sorting 
(FACS Aria; BD) (118). PBMCs were stained with phycoerythrin (PE)-labeled viral tetramers (Table 
1) (Leiden University Medical Center Protein facility, Department of Immunohematology and 
Blood Transfusion, the Netherlands) and fluorescein isothiocyanate (FITC)-labeled monoclonal 
antibodies (mAb) for CD4, CD19, CD45-RA, CD14, CD40, CD16 and CD56 (BD Pharmingen). FL1 
was used as a dump channel to avoid TCR internalization as a result of simultaneous CD8 mAb 
and major histocompatibility complex (MHC)-tetramer staining. CD8+ memory T-cell clones were 
generated by sorting 1 cell per well96 and CD8+ memory T-cell lines by sorting 10 cells per well96. 
TCR usage was assessed by antibody staining against the TCR Vb (IO Test Vbeta TCR repertoire 
kit, Beckman Coulter, USA). CD8+ memory T-cell clones and lines were cultured in the presence 
of irradiated allogeneic PBMCs (4000 Rad) from anonymous buffy coats (Sanquin, Leiden, the 
Netherlands) for 8 days prior to experimental testing to achieve optimal conditioning.
HLA typing of responder and target cells
HLA typing was achieved by sequence-specific oligonucleotide (SSO) and sequence-specific 
primer (SSP) genotyping, at the European Federation of Immunogenetics (EFI)-accredited 
national reference laboratory for histocompatibility testing at the Leiden University Medical 
Center, Department of Immunohematology and Blood Transfusion, the Netherlands.
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Mixed lymphocyte reactions
To assess proliferation of cross-reactive viral tetramer-positive CD8+ T cells in response to the 
most commonly occurring HLA class I alleles in the Western population (>5%), PBMCs of healthy 
donors positive for multiple CMV and/or EBV tetramers were labeled with carboxyfluorescein 
succinimidyl ester (CFSE) and stimulated with irradiated allogeneic PBMCs (3000 Gy) in 
mixed lymphocyte reactions (MLRs) against a panel of 16 HLA-typed stimulators. MLRs were 
performed in Roswell Park Memorial Institute medium (RPMI) supplemented with penicillin/
streptomycin (Gibco), glutamine, 15% human serum (HS) and 10 CU/ml IL-2. Upon 8 days, 
proliferation of tetramer-positive cells was measured by flow cytometry as identified by the 
tetramer+CFSElowCD8+ subset. MLRs were first performed against stimulator pools (4x4), and 
subsequently against individual stimulators of the pool(s) of interest.
Cytokine production assays
Virus-specific CD8+ T-cell clones and lines were stimulated with a panel of allogeneic EBV-LCLs 
(E:T 1:10; triplicate wells) for 24 hours at 37°C in IMDM (Lonza) supplemented with penicillin/
streptomycin, glutamine, 5% fetal calf serum (FCS; Lonza), 5% human serum (HS), and IL-2 
(10 CU/mL). The panel was designed to cover the most commonly occurring HLA class I alleles in 
the Western population (>5%). Interferon γ (IFNγ) production was measured by enzyme-linked 
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RESULTS
For an overview of the experimental procedure, a flowchart is added in the supplementary 
material (Supplemental Figure 1).
The polyclonal CD8+ T-cell response directed against a single virus has the 
potential to recognize multiple allogeneic stimulators
First, an inventory was made of the incidence and specificity of allo-HLA cross-reactive virus-
specific CD8+ T cells in a cohort of 30 healthy individuals. PBMCs were stained with a panel of 
CMV (n = 13) and EBV (n = 12) tetramers (Table 1).
Healthy donors that stained positive for multiple tetramers directed against the same virus 
(n = 24) were screened for alloreactivity in mixed lymphocyte reactions (MLRs), which were 
performed against a panel of allogeneic cells (n = 16) designed to express the most common 
HLA class I antigens (>5%) in the Western population (Table 2).
Table 1. Panel of 25 CMV- and EBV-specific tetramers directed against public viral epitopesa
CMV EBV
HLA Peptide Origin HLA Peptide Origin
A1 VTEHDTLLY pp65 A2 GLCTLVAML BMLF1 
A1 YSEHPTFTSQY pp65 A3 RLRAEAQVK EBNA3A 
A2 NLVPMVATV pp65 A3 RVRAYTYSK BRLF1
A2 VLEETSVML IE-1 A3 KHSRVRAYTYSK BRLF1
A3 TVYPPSSTAK pp150 B7 RPPIFIRRL EBNA3A
A11 GPISGHVLK pp65 B8 FLRGRAYGL EBNA3A
A24 QYDPVAALF pp65 B8 RAKFKQLL BZLF1
B7 RPHERNGFTVL pp65 B35 EPLPQGQLTAY BZLF1
B7 TPRVTGGGAM pp65 B35 HPVGEADYFEY EBNA-1
B8 ELRRKMMYM IE-1 B35 MGSLEVMPM LMP2A
B8 ELKRKMIYM IE-1 B35 YPLHEQHGM EBNA3A
B8 QIKVRVDMV IE-1 B35 AVLLHEESM EBNA3B
B35 IPSINVHHY pp65
aAll tetramers are phycoerythrin (PE)-labelled
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Figure 1. Multiple virus-specific CD8+ T cells of the same individual proliferate in response to 
allostimulation. A) Example of individual HD2 showing alloreactivity of the polyclonal immune response 
against EBV. Plots show: EBV B8/FLR x Pool 1 (stimulator 1-4); EBV B8/RAK x Pool 4 (stimulator 13-16); EBV 
B35/EPL x Pool 3 (stimulator 9-12); EBV B35/HPV x Pool 1 (stimulator 1-4). B) Example of individual HD4 
showing alloreactivity of the polyclonal immune response against CMV. Plots show: CMV A2/NLV x Pool 1 
(stimulator 1-4); CMV B7/RPH x Pool 4 (stimulator 13-16); CMV B7/TPR x Pool 3 (stimulator 9-12). All plots 
are gated on CD8+ lymphocytes.
Within polyclonal anti-viral immune responses, T cells with different viral epitope specificities 
were able to proliferate in response to allogeneic stimulation. This was observed for EBV 
and CMV responses, and also for both viruses within the same individual (Figure 1, Table 3). 
Interestingly, single allogeneic stimulators were able to induce multiple different virus-specific 
CD8+ T-cell responses in the same responder (Figure 2).
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Alloreactivity of polyclonal anti-viral immune responses
Figure 2. Single allogeneic stimulators induced multiple virus-specific CD8+ T-cell responses in MLR 
in the same responder (HD1). Although the EBV B8/FLR response should be interpreted with caution due 
to its proliferation background in media (% proliferated Tm-positive cells of total Tm-positive cells: 4.3%), 
its alloresponses were much more pronounced (% proliferated Tm-positive cells of total Tm-positive cells: 
respectively 35.8% (S9); 45.9% (S10); 22.7% (S12); and 25% (S7)). Plots are gated on CD8+ T cells. X-axis: CFSE. 
Y-axis: virus-specific tetramer.
The polyclonal CD8+ T-cell response directed against a virus contains multiple 
allo-HLA specificities
Virus-specific T cells with different viral specificities exerted different patterns of alloreactivity 
against the stimulator panel in MLR, indicating that they had different allo-HLA specificities as 
well. To confirm, virus-specific CD8+ memory T-cell clones were generated as a proof of principle 
to determine their allospecificity in IFNγ ELISA against a panel of EBV-immortalized B-cell lines 
(EBV-LCLs) (Supplemental Table 1). For example, responder HD23 showed cross-reactivity of 
CMV A2/NLV- and CMV B35/IPS-specific T cells. The CMV B35/IPS response was directed against 
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HLA-B*51:01 and HLA-B*58:01/B*57:01, a public cross-reactivity that was recently identified by 
our group (140). The CMV A2/NLV alloresponse showed cross-reactivity in response to multiple 
allo-HLA molecules: a CMV A2/NLV T-cell line (1A2) showed cross-reactivity against HLA-B*39:01, 
and a CMV A2/NLV T-cell clone (#1) against the combination of HLA-A2 and HLA-B50 (Table 4, 
Supplemental Figure 2). TCR Vb usage analysis confirmed that the CMV A2/NLV T-cell line and 
clone expressed multiple TCR clonotypes, whereas the CMV B35/IPS T-cell lines and clones 
expressed a public TCR (140). Findings were confirmed in additional MLRs (data not shown). 
Infection with CMV in this individual therefore enabled alloreactivity towards (a minimum of) 
six different allogeneic HLA molecules.










TCR Vβ usage Allo-HLA cross-
reactivity
CMV B35/IPS HD23 Clone 7C8 7, 9, 10, 12 TRBV28 HLA-B*51:01
HLA-B*57:01
HLA-B*58:01
HD23 Clone 8C1 9, 12b n.d.* HLA-B*58:01b




HD23 Cell line 6A8 7, 9, 12 TRBV28 + TRBV20-1 HLA-B*57:01
HLA-B*58:01
CMV A2/NLV HD23 Clone 1 23c TRBV20-1 HLA-A*02
HLA-B*50:01
HD23 Cell line 1A2 15 TRBV3-1 + TRBV18 + 
TRBV6 + TRBV20-1
HLA-B*39:01
aReactivity against EBV-LCLs expressing syngeneic HLA-B*35:01 and HLA-A*02:01 was disregarded for 
analyses of CMV B35/IPS and CMV A2/NLV responses respectively, as it potentially reflects reactivity 
towards the cognate epitope
bPotential minor reactivity towards EBV-LCL 7 (HLA-B*57:01), however the response was too small to 
include in analysis
cAll T-cell lines and clones were tested against EBV-LCL panel 1, except CMV A2/NLV Clone 1 (EBV-LCL 
panel 2)
*n.d. = not determined
4
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DISCUSSION
As humans are exposed to a myriad of viruses throughout their life-time and TCR cross-
reactivity is a common feature of T cells, it is not surprising that the majority of virus-specific 
T cells are able to cross-react to allo-HLA. Although our understanding of this cross-reactivity 
increases and even mechanisms underlying this cross-reactivity have been proposed (135, 
141), the possible clinical relevance of these cross-reactive T cells remains under investigation 
(39-41, 142).
In this study, we aimed to determine the footprint of a single virus on the allorepertoire. We 
observed broad alloreactivity of virus-specific T cells on multiple levels: T cells with different 
viral epitope specificities, T cells with the same viral epitope specificities, and even T cells 
of the same clonotype were able to recognize multiple allogeneic HLA molecules. Polyclonal 
alloimmune responses of EBV and CMV T cells were identified in several individuals. This is 
particularly interesting given the fact that the experiments were restricted to known (dominant) 
viral epitopes for tetramer-staining. In total, 13 CMV- and 12 EBV-specific tetramers were 
available. It is thus remarkable that polyclonal alloresponses were found for both EBV and 
CMV, as the limited number of available tetramers inevitably leads to underestimation of the 
scope of the polyclonal alloresponse. Accordingly, a large population of tetramer-negative 
CD8+ T cells responded to allostimulation (Figure 1, 2), possibly containing additional cross-
reactive virus-specific T cells directed against unknown viral epitopes. In addition, alloreactivity 
screening was restricted to HLA-I alleles present in >5% of the Western population, and the 
allospecificity of polyclonal anti-virus responses will most likely be broader when taking into 
account less common HLA class I molecules as well.
Finally, we previously published that functional virus-specific T-cell responses can be induced 
by stimulation with allogeneic cells (143). We again observed that allostimulation was able to 
induce proliferation of virus-specific T cells, and in addition that a single allogeneic stimulator 
was able to stimulate T cells of multiple viral specificities (belonging to the same individual): 
further illustrating the impact of virus-specific immune responses on the allorepertoire.
In conclusion, infection with a single virus can generate a diverse allorepertoire. Cross-reactive 
memory T-cells in the polyclonal anti-viral immune response can have broad alloreactive 
potential, as not only T cells with different viral epitope specificities, but also T cells sharing 
viral specificity and T cells of the same clonotype can be cross-reactive with multiple allo-
HLA molecules. Thereby, the many viruses encountered throughout life could induce a 
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broad repertoire of (donor-specific) alloreactive memory T cells in transplant recipients 
already in place at the time of transplantation. This message is important to keep in mind, 
especially when seeking alternative immunosuppression strategies. Current standard-of-care 
immunosuppression covers suppression of the memory compartment, and it is still unclear 
what will happen to the alloresponse when the naïve compartment is selectively targeted 
instead. For example, based on the high prevalence of pre-existing allo-HLA cross-reactivity, 
one could argue that clinical rejection rates should be higher than is currently the case; 
potent immunosuppression is likely to play an important role here. In addition, the functional 
characteristics of the allo-HLA cross-reactive virus-specific T cells may not be sufficient to mount 
potent immune responses: for example due to low TCR avidity for the alloepitope (144). Yet, 
also low-avidity cross-reactive clonotypes could gain momentum when triggered upon viral 
infection or reactivation; and current standard-of-care anti-viral prophylaxis may also play an 
indirect role in preventing alloresponses (145, 146). Finally, continuous allostimulation, as is the 
case in a transplantation setting, may induce mechanisms of regulation or T-cell exhaustion 
(147). Answering these questions will make an invaluable contribution to unravel the clinical 
relevance of allo-HLA cross-reactive virus-specific memory T cells in transplantation.
4
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SUPPLEMENTARY MATERIAL
Supplemental Figure 1. Flowchart of the experimental procedure to determine alloreactivity of polyclonal 
T-cell immune responses.
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Supplemental Figure 2. Allospecificity of CMV-specific CD8+ memory T-cell clones was determined in 
IFNγ ELISA against a panel of HLA-typed EBV-LCLs. All T-cell lines and clones were derived from HD23 and 
tested against EBV-LCL panel 1 or EBV-LCL panel 2 (CMV A2/NLV Clone 1) (Supplemental Table 1). Reactivity 
of CMV B35/IPS T-cell clones against EBV-LCLs expressing syngeneic HLA-B*35:01 (e.g. reactivity of CMV B35/
IPS T-cell clone 7C8 versus EBV-LCL 5) and reactivity of CMV A2/NLV T-cell clones against EBV-LCLs expressing 
syngeneic HLA-A*02:01 (e.g. reactivity of CMV A2/NLV T-cell clone 1 versus EBV-LCL 30) were disregarded 
for analysis, as these potentially reflect reactivity towards the cognate epitope. X-axis: EBV-LCLs. Y-axis: 
IFNγ production in pg/ml. Positive control: EBV-LCL expressing syngeneic HLA + viral peptide (1000ng/ml). 
Red = reactivity against these EBV-LCLs was confirmed.
4
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ABSTRACT
Viral infection is a major cause of morbidity and mortality, and there are few therapeutic 
options available to augment a virus-specific T-cell response. Although allo-HLA cross-
reactivity from virus-specific memory T cells is common, it is unclear whether priming with 
specific allogeneic cells could conversely elicit a viral peptide/self-HLA restricted cytotoxic T-cell 
response in humans. First, we used the previously described allo-HLA-B*44:02 cross-reactivity 
of EBV peptide/HLA-B8 restricted T cells, to determine whether allogeneic HLA stimulation can 
elicit a cytolytic immune response against EBV. HLA-B8+ HLA-B*44- EBV-seropositive PBMCs 
were stimulated with either HLA-B*44:02+ or HLA-B*44:03+ mismatched irradiated PBMCs in a 
7-10 d MLR. The allo-HLA stimulated responder cells were then evaluated for cytotoxicity using 
EBV peptide loaded autologous target cells and unloaded HLA-B8+ EBV LCL target cells. PBMCs 
from EBV-seropositive donors gained EBV-specific cytolytic effector function following specific 
allo-HLA stimulation. Finally, we also elicited cytolytic CMV-specific responses using specific 
allogeneic cell stimulation, to confirm that this technique can be used to elicit viral peptide/
self-HLA restricted responses even from nonpublic TCR responses. Allogeneic cell stimulation 
used as a cell therapy may be a potential tool to augment an antiviral T-cell response in patients 
with EBV or CMV infection.
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INTRODUCTION
Control of viral replication depends primarily on virus-specific memory T-lymphocyte activity 
(148, 149). In the normal course of viral infections, antiviral immunity and non-infectivity 
correlates with the development of virus-specific effector memory T cells. Absence of HIV-
specific CD8 T cells is associated with progression to AIDS in HIV-infected individuals (150), 
and the use of lymphocyte-targeted biologic therapies has recently been associated with 
viral reactivation that might not respond to antiviral antibiotics (151). For example, whereas 
allogeneic marrow depleted of T cells prevents acute and chronic forms of graft-versus-
host disease (GVHD) post-transplant, the risk of infections, particularly with EBV and CMV, is 
increased (152). Furthermore, viral infection can cause severe morbidity and mortality, even 
in healthy individuals without specific immune defects.
New therapies are therefore required to increase the number and/or effector function of virus-
specific T cells. Antiviral prophylaxis can be toxic and does not result in an increase in virus-
specific T cells, nor does it achieve long-term eradication. Adoptive transfer of third-party cell 
lines may be associated with GVHD or failure due to allogeneic rejection (153), and is technically 
difficult (154). Peptide stimulation does not induce a polyclonal T-cell response and can fail to 
induce cytotoxic CD8+ T-cell responses (155).
Furthermore, although Ag-specific T-cell responses are actively maintained, they are reversible 
and short lived in the absence of stimulating Ag (156-158). We have recently confirmed that 
alloreactivity from virus-specific T cells is common, and that the allo-HLA reactivity and virus 
specificity is mediated via the same TCR (43). Forty-five percent of virus-specific CD4 and CD8+ 
T cell clones were shown to be cross-reactive against allo-HLA molecules. For example, EBV 
infection in a HLA-B8+ individual always selects for a dominant “public” Vb6S2 TCR (7), which 
cross-reacts against allo-HLA-B*44:02 (11). We confirmed the previously described alloreactivity 
of this EBV EBNA3A–specific T cell (HLA-B8/FLRGRAYGL restricted) against allogeneic HLA-
B*44:02 (43, 121). Allo-HLA cross-reactivity was also shown for CMV, varicella-zoster virus (VZV) 
and influenza virus–specific T cells, which express nonpublic TCRs (43).
A high level of cross-reactivity against allo-HLA molecules is therefore an essential feature of 
the virus-specific memory TCR (7, 11, 24, 35, 43, 112, 121, 128, 159-161). This allo-HLA cross-
reactivity by virus-specific T cells can be reproducibly detected in vitro. However, it is currently 
unknown whether stimulation with allogeneic-HLA molecules could conversely and specifically 
augment an HLA-restricted virus-specific T-cell response. The purpose of this study was to 
5
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assess whether allogeneic HLA challenge could be a useful tool to augment an HLA-restricted 
antiviral CD8+ T-cell response, as determined by cytolytic functional assays. We used virus-
specific tetramers to confirm that in vitro allogeneic challenge of EBV- and CMV-seropositive 
individuals resulted in proliferation of human virus–specific CD8+ T cells. Furthermore, we 
confirmed that this proliferation was associated with increased cytolytic effector function from 
the allo-HLA primed cells against viral Ags. Our proof-of-principle results demonstrate that 
allo-HLA stimulation may be a potential tool to augment cytolytic antiviral CD8+ T cell effector 
responses in patients with viral infection. This approach should be investigated further.
MATERIALS AND METHODS
Preparation of responder, stimulator, and target cells
Responder and stimulator cells were both obtained using blood samples from healthy donors 
after informed consent. PBMCs were isolated from heparinized blood by standard density 
gradient centrifugation and were subsequently cryopreserved until use. EBV-transformed 
lymphoblastoid cell lines (EBV-LCLs) were generated using standard procedures and were 
cultured in RPMI 1640 (Cambrex) with 10% FCS. The HLA type of all cells used in our experiments 
was determined molecularly by sequence-specific oligonucleotide and sequence-specific primer 
genotyping at the Leiden University Medical Center, Department of Immunohematology and 
Blood Transfusion, The Netherlands.
Proliferation assays for EBV EBNA3A–specific T-cell responses
For the proliferation assays, 1 x 106 CFSE-labeled PBMCs from an HLA-B8+ HLA-B*44- EBV-
seropositive healthy donor were co-cultured with 1 x 106 HLA-B*44:02+ or HLA-B*44:03+ 
mismatched irradiated PBMCs (3000 rad) also from healthy donors, in a 24-well flat-bottom 
plate. Cells were incubated for 7-10 d in RPMI 1640 culture medium with 15% human serum 
and IL-2 (60 IU/ml). Next, fluorescence-activated cell sorter analysis was performed after 
staining the cells with CD8-APC (Becton Dickinson) and PE-labeled HLA-B8/FLR tetrameric 
complexes to detect cell division. In all experiments, HLA-A2/GLC and HLA-B8/RAK tetrameric 
complex staining served as negative controls. The proliferation assays for EBV EBNA3A-specific 
T-cell responses were repeated using 20 different HLA-B8+B44- responder - HLA-B8-B*44:02+ 
stimulator pairings, and eight different HLA-B8+B44- responder - HLA-B8-B*44:03+ stimulator 
pairings. The HLA typing of the selected responder-stimulator example is given below Figure 1A.
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Proliferation assays for CMV-specific T-cell responses
To determine whether allo-HLA stimulation could elicit an antiviral response against any virus or 
specificity, we had to first determine a new method whereby specific allogeneic cells stimulating 
the proliferation of virus-specific T cells from any given individual could be identified easily. 
CFSE-labeled PBMCs (1 x 106) from CMV-seropositive healthy donors were first co-cultured 
with a pool of 1 x 106 total mismatched irradiated PBMCs (3000 rad) from four different healthy 
donors (0.25 x 106 cells of each individual stimulator), in a 24-well flat-bottom plate. Each 
responder was screened against four different pools of four PBMCs. The 16 total different 
allogeneic stimulator cells were selected to cover the most common occurring HLA molecules. 
Cells were incubated for 7-10 d in RPMI 1640 culture medium with 15% human serum and IL-2 
(60 IU/ml).
Fluorescence-activated cell sorter analysis was performed after staining the cells with PE-
labeled CMV-specific tetrameric complexes to detect cell division. If proliferation of CMV-
specific cells was detected after stimulation with a screening pool of four different allogeneic 
PBMCs, then the same responder PBMCs were tested individually against the four stimulator 
PBMCs to determine which allogeneic cells elicited proliferation of the CMV-specific T cells. The 
proportion of CMV-specific tetramer-positive T cells within the total CD8+ T-cell population were 
also determined before and after allogeneic cell stimulation using routine FACS analyses. The 
CMV-seropositive responder cells were then stimulated with the individual relevant PBMCs (or 
control) in a new assay (without CFSE labeling), following which the allo-HLA–primed responder 
cells were harvested and used as effector cells in the cytotoxicity assays (see below). The HLA 
typing of the selected responder-stimulator examples is given below Figures 2B and 3.
Proliferation assay for combined stimulation of two virus specificities from 
one responder
T-cell alloresponses are polyclonal and polyclonal antiviral T-cell responses targeting different 
viral epitopes are required for effective antiviral immunity. To confirm that allo-HLA stimulation 
could induce a polyclonal antiviral T-cell response targeting different viral epitopes, we 
stimulated a single responder PBMC with a combination of two allogeneic PBMCs, expressing 
HLA molecules that were known to stimulate different CMV-specific T-cell responses, from 
within that individual responder. CFSE-labeled PBMCs (0.85 x 106) from a CMV-seropositive 
healthy donor responder were first co-cultured with a pool of 1 x 106 total mismatched 
irradiated PBMCs (3000 rad) from two different healthy donors S1 and S2 (0.5 x 106 cells of 
each individual stimulator), in a 24-well flat-bottom plate. S1 and S2 expressed allogeneic HLA 
molecules (HLA-A*02:05 and HLA-B*51:01, respectively) known to stimulate different CMV-
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specific T-cell responses (pp65/A2 and pp65/B35 respectively) from the responder. A single 
stimulator cell expressing both HLA-A*02:05 and HLA-B*51:01 was not available. Cells were 
incubated for 7-10 d in RPMI 1640 culture medium with 15% human serum and IL-2 (60 IU/ml). 
Fluorescence-activated cell sorter analysis was performed after staining the cells with PE-
labeled CMV pp65/A2 and CMV pp65/B35 specific tetrameric complexes to detect cell division.
Cytotoxicity assays
To confirm that allogeneic cell stimulation resulted in increased virus-specific cytolytic effector 
function from the stimulated PBMCs, and not just proliferation, we performed cytolytic assays 
using autologous cells loaded with the relevant viral peptide or unloaded EBV-LCLs as target 
cells. Responder PBMCs from EBV- or CMV-seropositive healthy donors were first specifically 
stimulated in a 7-10 d MLR with allogeneic irradiated cells to stimulate a virus-specific memory 
T cell of interest (see above). The stimulated PBMCs were then evaluated for cytotoxicity by 
incubating serial dilutions with 2000 viral-peptide-loaded autologous target cells or EBV-LCL 
target cells, in a 4h [51Cr] release assay. Cognate viral peptide or control viral peptide was 
directly added to the autologous target cells and incubated for 60 min, simultaneously with 
chromium incubation, and then washed three times. Supernatants were harvested for gamma 
counting: percent-specific lysis = (experimental release 2 spontaneous release) / (maximum 
release – spontaneous release) x 100%. Values for specific lysis are presented as the mean of 
triplicate wells with SD.
RESULTS
EBV-specific CD8+ T cells proliferate following specific allo-HLA stimulation
To determine whether an allogeneic HLA challenge could specifically stimulate a virus-specific 
CD8+ T-cell response within whole blood, a modification of the MLC assay was used. EBV 
EBNA3A-specific T cells proliferated only in response to stimulation with HLA-B*44:02+, and 
not HLA-B*44:03+, mismatched irradiated PBMCs, implying specific stimulation of cross-reactive 
virus-specific T cells by allogeneic HLA molecules (Figure 1). EBV EBNA3A-specific T cells did 
not proliferate in response to stimulation with allogeneic HLA-B8+HLA-B44- PBMCs, excluding 
the possibility that the cells could be responding to EBV peptides contained within the culture 
medium or presented via stimulator cells (data not shown). Proliferation was associated with 
a specific increase in the proportion of EBV EBNA3A-specific T cells within the CD8+ T-cell 
compartment (Supplemental Figure 1), and no proliferation of HLA-A2/GLC or HLA-B8/RAK 
restricted T cells was detected (data not shown), thereby excluding bystander proliferation 
and confirming the allo-HLA dependency of the stimulation. These results confirm that virus-
95
Heterologous immunity in organ transplantation
specific CTL can directly recognize and proliferate in response to allogeneic HLA to which they 
are cross-reactive and have never been exposed.
Figure 1. EBV-specific CD8+ memory T cells specifically proliferate after allogeneic cell stimulation. 
(A) EBV EBNA3A-specific T cells are specifically stimulated to proliferate after 7-10 d in vitro co-culture with 
HLA-B*44:02+, but not HLA-B*44:03+, mismatched irradiated PBMCs. Bystander activation was excluded. 
FACS plots gated on total HLA-B8/FLR-tetramer-complex-positive lymphocytes. Assay repeated multiple 
times with different responder-stimulator pairings, with similar results. A representative result is shown. 
Responder: HLA-A*02, A31; B*08, B39; DRB1*03, DR16. HLA-B*44:02+ stimulator: HLA-A*11, -; B*44:02, B51; 
DRB1*12, DR15. HLA-B*44:03+ stimulator: HLA-A*02, A68; B*44:03, B51; DRB1*08, DR13. (B) Proliferation of 
EBV EBNA3A-specific T cells is reproducible across different responder-stimulator pairings. Assay repeated 
with 20 different HLA-B8+B44- responder - HLA-B8-B*44:02+ stimulator pairings, and 8 different HLA-B8+B44- 
responder - HLA-B8-B*44:03+ stimulator pairings. Results are expressed as a relative proportion of EBV 
EBNA3A-specific T cells within the CD8+ T-cell compartment after HLA-B*44:02 or HLA-B*44:03 stimulation, as 
compared with the non-stimulated PBMCs. HLA-B*44:02 stimulation significantly increased the proportion 
of EBV EBNA3A-specific T cells, as compared with HLA-B*44:03 stimulation (p = 0.0002).
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CMV-specific CD8+ T cells proliferate following specific allo-HLA stimulation
To determine whether allo-HLA stimulation can elicit proliferation of CMV-specific T cells, 
we screened for responder CMV-specific T-cell proliferation using pools of PBMC stimulator 
cells from four different donors who were chosen to cover the most commonly occurring HLA 
molecules. Proliferation of CMV-specific CD8+ memory T cells was detectable using pools of 
four different PBMC stimulators together (Supplemental Table I). The individual PBMC giving 
the specific stimulation was then easily determined in a second assay. For example, CMV pp65-
specific T cells (HLA-A2/NLV restricted) from a healthy donor (responder 2) proliferated in 
response to a PBMC pool of four different PBMCs (pool 4; Figure 2A, Supplemental Table I). The 
same responder was then tested individually against the stimulators present in the screening 
pool to identify the specific stimulator (Figure 2B).
Proliferation was associated with a specific increase in the proportion of CMV pp65-specific 
T cells within the CD8+ T-cell compartment (Figure 3). Screening experiments were repeated 
multiple times with different responders and for different CMV CD8 T-cell specificities. Using 
this technique, proliferation of HLA-A2/NLV- and HLA-B35/IPS-restricted CD8+ T cells from 
different responders was elicited (Supplemental Table I). Furthermore, this stimulation is 
demonstrable without the need to generate virus-specific T-cell clones from the responder, 
even when the virus-specific T cell of interest does not express a public TCR, thereby suggesting 
that allogeneic cells stimulating viral-peptide/HLA-restricted T cells from any given responder 
are readily identifiable in the routine laboratory.
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Figure 2. Screening for allo-HLA cross-reactivity of virus-specific memory T cells. A representative 
example is shown. (A) CMV pp65-specific CD8+ memory T cells (A2/NLV restricted) from Responder 2 (R2) 
proliferate following stimulation with a pool of four PBMCs (pool 4 containing stimulators 13-16), but not 
other pools of four different stimulator PBMCs (pool 2 shown). (B) R2 was then tested individually against 
all four stimulators present in pool 4 (S13-16). R2 proliferated only when stimulated with S13 and not when 
stimulated with the other three stimulators present in pool 4 (S15 shown), thereby confirming that the CMV 
pp65-specific T cells from R2 were specifically stimulated by only S13 allogeneic cells.
HLA typing of responder 2: HLA-A*02, A11; B*35, B40; DRB1*11, DR15.
Stimulator 13: HLA-A*02:01, A*02:05; B*18, B50; DRB1*11, DR13.
Stimulator 15: HLA-A*23, A29; B*15, B53; DRB1*11, DR13.
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Figure 3. The proportion of CMV-specific CD8+ T cells is specifically increased following allogeneic 
cell stimulation. A representative example is shown. CMV pp65-specific CD8+ T cells accounted for 2.1% of 
total CD8+ T cells from responder 2 (R2), following 8 d co-culture with stimulator 13 (S13). The proportion 
of CMV pp65-specific CD8+ T cells was unaltered by co-culture with stimulator 15 (S15) or IL-2 containing 
medium alone. The primed responder cells shown here were then harvested and used as effector cells in 
the cytolytic assay shown in Figure 6.
HLA typing of responder 2: HLA-A*02, A11; B*35, B40; DRB1*11, DR15.
Stimulator 13: HLA-A*02:01, A*02:05; B*18, B50; DRB1*11, DR13.
Stimulator 15: HLA-A*23, A29; B*15, B53; DRB1*11, DR13. 
Allo-HLA stimulation is associated with an increase in the total number, not 
just proportion, of virus-specific memory T cells
To confirm that specific allo-HLA stimulation was associated with an increase in the total 
number of virus-specific T cells, not just an increased proportion of virus-specific T cells, we 
extrapolated the total number of CMV-specific T cells based on the total number of harvested 
lymphocytes and the proportion of tetramer-positive T cells before and after stimulation. In two 
separate experiments after stimulation with S13, the number of CMV-specific T cells increased 
from 320 to 35,200 and from 2280 to 33,110, respectively (Table I). These data are consistent 
with specific in vitro allo-HLA stimulation being associated with a 10- to 100-fold increase in 
the total number of virus-specific T cells, as compared with the number of virus-specific T cells 
after stimulation with an allogeneic control cell (Table 1).
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Table 1. Specific allo-HLA stimulation is associated with an increase in the total number, not just proportion, 
of virus-specific memory T cells





















in Total No. of 
CMV-Specific 





2 × 106 2.9 × 106 0.015 435 1.36
S13 1 × 106 3.2 × 106 1.1 35,200 110
S15 1 × 106 3.2 × 106 0.01 320 1
R2 Medium 
only
2 × 106 0.5 × 106 0.04 200 0.09
S13 3 × 106 7.7 × 106 0.43 33,110 14.5
S15 3 × 106 5.7 × 106 0.04 2280 1
aRelative to control stimulation with allogeneic S15
Allo-HLA stimulation may stimulate polyclonal antiviral T-cell responses
Polyclonal T-cell responses targeting different viral epitopes are required for effective antiviral 
immunity. We therefore stimulated a single responder PBMC with a combination of two 
allogeneic PBMCs, expressing HLA molecules that were already known to stimulate different 
CMV-specific T-cell responses, from within that one individual responder. CMV A2/pp65- and 
CMV B35/pp65-specific T cells from the same responder both proliferated in response to 
stimulation with two different HLA molecules, present on the surface of two different allogeneic 
PBMCs, within the same assay. Negative controls gave appropriate results, suggesting that 
allo-HLA stimulation may be capable of stimulating multiple different virus-specific T cells from 
within the one responder (Figure 4).
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Figure 4. Allo-HLA stimulation may stimulate polyclonal antiviral T-cell responses. (A) CMV A2/pp65- 
and (C) CMV B35/pp65-specific T cells from the same responder both proliferated in response to stimulation 
with two different HLA molecules, present on the surface of two different allogeneic stimulator PBMCs, 
in the same assay. Negative controls gave appropriate results (B, D). Thereby suggesting that allo-HLA 
stimulation may be capable of stimulating multiple different virus-specific T cells, targeting different viral 
epitopes, from within the one responder.
HLA typing responder PBMCs: HLA-A*02:01, A11; B*35, B40; DR*11, DR15.
Stimulator 1: HLA-A*02:01, A*02:05; B*18, B50; DRB1*11, DR13.
Stimulator 2: HLA-A*02, A36; B*51, B72; DRB1*03, DR10.
EBV- and CMV-specific CD8+ memory T cells gain viral peptide/self-HLA–
restricted cytolytic effector function following specific allo-HLA stimulation
For viral protection, it is essential that the proliferation of virus-specific T cells following 
allogeneic stimulation is associated with a gain of cytolytic effector function against the original 
viral peptide/self-HLA restricted target Ag. We therefore performed a cytolytic assay using 
responder HLA-B8+ EBV-seropositive healthy donor PBMCs following in vitro stimulation with 
either homozygote HLA-B*44:02 or HLA-B*44:03-mismatched irradiated PBMCs, and with viral-
peptide-loaded autologous cells and unloaded EBV-transformed B cells (EBV-LCLs) as target 
cells. Following 7-10 d of stimulation with HLA-B*44:02-mismatched irradiated PBMCs, primed 
responder cells from an HLA-B8+ EBV-seropositive healthy donor showed increased cytolytic 
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effector function against both HLA-B8+ EBV-LCLs and FLR-peptide-loaded autologous target 
cells, but not HLA-B8- EBV-LCLs nor RAK-peptide-loaded autologous target cells (Figure 5), as 
compared with the same PBMCs co-cultured with either HLA-B*44:03-mismatched PBMCs or 
cultured with IL-2 containing medium alone. This increased cytolytic effector function was 
associated with proliferation and an increase in the proportion of EBV EBNA3A-specific CD8+ 
T cells (Supplemental Figure 1). Likewise, specific stimulation of CMV-specific CD8+ T cells 
with allo-HLA resulted in increased cytolytic effector function against CMV-peptide-loaded 
autologous cells (Figure 6). Confirming that allogeneic HLA challenge can indeed increase the 
(in vitro) cytolytic effector function of human CMV- and EBV-specific CD8+ T cells against their 
original cognate viral Ag. We argue that these proof-of-principle results may have important 
implications for treatment of viral infections, if confirmed in vivo.
DISCUSSION
This study demonstrates that human virus-specific memory T cells gain cognate viral-Ag-specific 
cytolytic effector function following stimulation with allogeneic HLA molecules against which 
they are cross-reactive. Stimulation of peripheral blood from a non-sensitized HLA-B8+ EBV-
seropositive healthy donor with HLA-B*44:02-mismatched irradiated PBMCs increases (in vitro) 
cytolytic effector function against EBV. Furthermore, we show that this technique can be used to 
elicit cytolytic effector function against any potential viral Ag, as shown for CMV. These results 
provide proof-of-principle evidence that stimulation with specific allogeneic HLA molecules 
could be useful for treatment of viral infections.
The importance of our findings is reinforced by functional studies showing that the proliferation 
of EBV- and CMV-specific CD8+ memory T cells corresponded with a specific increase of cytolytic 
effector function against viral peptide-loaded autologous cells, which was not detectable 
without specific allo-HLA stimulation. Cytolysis of the EBV-LCLs by the HLA-B*44:02-primed 
effector cells suggests that virus-infected cells can spontaneously process and present viral 
peptides via HLA class I molecules in the course of normal infection, and that the amount of 
peptide present is sufficient to trigger killing from allo-HLA primed effector cells.
EBV infection in an HLA-B8+HLA-B44- individual selects for a public BV6S2 TCR, which cross-
reacts against allogeneic HLA-B*44:02 (7). Although not all virus-specific immune responses give 
rise to a public TCR, the allo-HLA cross-reactivity of virus-specific T cells from a given individual 
can be detected easily in vitro using techniques we have described here and elsewhere (43, 121). 
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Figure 5. EBV-specific cytolytic effector function of allo-HLA primed cells using EBV-LCL target cells 
and viral peptide-loaded autologous target cells. (A) PBMCs from a HLA-B8+ EBV-seropositive donor gain 
EBV-specific cytolytic effector function following allogeneic HLA-B*44:02+ cell stimulation. Unstimulated 
HLA-B8+ PBMCs and HLA-B*44:03-stimulated HLA-B8+ PBMCs do not demonstrate cytolytic effector function 
against HLA-B8+ EBV-LCLs. E:T ratio 50:1; targets 2000 and EBV EBNA3A-specific T cells accounted for 20.8% 
of effector cell population after HLA-B*44:02 stimulation. Positive control EBNA3A T-cell clone is described 
previously (121), and responder PBMCs used in this assay are also obtained from the same donor.
HLA typing of responder PBMCs and EBNA3A T-cell clone: HLA-A*01, A*02; B*08:01, -; DRB1*03, -.
HLA-B8+ EBV-LCL: HLA-A*01, -; B*08, -; DRB1*03, -.
HLA-B8- EBV-LCL: HLA-A*03, -; B*07, -; DRB1*15, -.
***p < 0.0001 versus HLA-B8- EBV-LCL.
(B) PBMCs from an HLA-B8+ EBV-seropositive donor gain HLA-B8/FLR-restricted cytolytic effector function 
following allogeneic HLA-B*44:02 stimulation. Unstimulated HLA-B8+ PBMCs and HLA-B*44:03-stimulated 
HLA-B8+ PBMCs do not demonstrate cytolytic effector function against FLR-peptide-loaded autologous 
cells. E:T ratio 50:1; targets 2000 and EBV EBNA3A-specific T cells accounted for 20.8% of effector cell 
population after HLA-B*44:02 stimulation. Positive control EBNA3A T-cell clone is described previously (15), 
and responder PBMCs used in this assay are also obtained from the same donor.
HLA typing of responder PBMCs, autologous target PBMCs, and EBNA3A T cell clone: HLA-A*01, A*02; B*08:01, 
-; DRB1*03, -.
***p = 0.0094 versus RAK-peptide-loaded autologous cells.
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Figure 6. CMV-specific cytolytic effector function of allo-HLA primed cells. PBMCs from a CMV-
seropositive HLA-A2+ donor (responder 2; R2) gain HLA-A2/NLV-restricted cytolytic effector function 
following heterozygote allogeneic cell stimulation with stimulator 13 cells (R2 x S13). S15-stimulated PBMCs 
do not demonstrate cytolytic effector function against NLV-peptide-loaded autologous cells (R2 x S15). A 
strong secondary response against stimulator 13 (S13) is demonstrated from R2 responder cells primed with 
S13 (positive control), but not S15. E:T ratio 100:1; targets 2000 and CMV A2/NLV-specific T cells accounted 
for 2.1% of effector cell population after stimulation with S13.
HLA typing of responder 2: HLA-A*02, A11; B*35, B40; DRB1*11, DR15.
Stimulator 13: HLA-A*02:01, A*02:05; B*18, B50; DRB1*11, DR13.
Stimulator 15: HLA-A*23, A29; B*15, B53; DRB1*11, DR13.
***p < 0.0001 versus IPS-loaded autologous cells.
Indeed, successful stimulation of cytolytic effector function against CMV Ag reveals that this 
technique could potentially be useful to elicit T-cell cytolytic effector function against any 
virus or specificity. Furthermore, stimulation of two different CMV-specific T-cell responses 
from one individual suggests that allo-HLA stimulation may also be capable of stimulating 
a polyclonal antiviral T-cell response targeting different viral epitopes, which does not occur 
with single peptide stimulation. Techniques described here should be reproducible in most 
routine laboratories.
We have confirmed that these effects are mediated by leukocytes present in the blood 
components and are related to the expression of HLA Ags. We used irradiated isolated PBMCs 
for stimulation of the virus-specific memory T cells, thereby excluding any contributions by 
plasma, platelets, or erythrocytes. Therefore, we suggest that allogeneic cell therapy should 
be investigated using only isolated leukocytes as stimulators.
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Immunologic memory is one of the hallmarks of the adaptive immune response. Functional 
virus-specific memory T cells are essential for proper host defense because, in the periphery, 
infected cells can be targeted for immediate killing, both during the initial infection and on 
subsequent reinfection or viral reactivation.
The results presented in this study suggest that specific allogeneic cell therapy could prime 
or maintain virus-specific memory. The proportion and total number of virus-specific T cells 
in the CD8+ compartment increased significantly following specific allo-HLA stimulation. CFSE 
dilution and counting experiments confirmed that the increase in the proportion of virus-
specific memory T cells was secondary to proliferation, and not just better survival of memory 
T cells in culture, with the number of virus-specific memory T cells increasing between 10- and 
100-fold. Data from preliminary clinical studies suggest that CMV-specific CD8+ T-cell levels 
greater than 1 x 107 / L of peripheral blood may correlate with protection (162); therefore, 
the total number of virus-specific T cells induced by proliferation following allogeneic cell 
stimulation may be important in isolation.
However, others have also shown that the memory T cell state-of-readiness is actively 
maintained and reversible, requiring ongoing specific TCR signaling (156, 158). Transfer 
of memory T cells to naive mice, in the presence or absence of priming Ag, reveals that 
maintenance of T-cell memory is short lived in the absence of TCR-mediated signaling (156). 
Furthermore, recently activated memory T cells can bypass the requirement for CD28/CD80/
CD86 costimulation, as compared with resting memory T cells that are still dependent on CD28 
triggering for their activation (163). Although at baseline in our EBV-specific cytolytic assay 1.5% 
of CD8+ T cells in the peripheral blood of the individual were EBV EBNA3A-specific T cells, no 
cytolysis of FLR-peptide-loaded autologous cells could be detected prior to allo-HLA-B*44:02 
stimulation, suggesting specific allogeneic cell priming was important to induce the observed 
cytolysis. Therefore, the allogeneic stimulation used in our assays may also have increased 
cytolytic effector function of the virus-specific T cells via triggering TCR signaling or abrogating 
costimulation requirements, regardless of the changes to the total number of cells.
To evade these cytolytic CD8+ T-cell responses, viruses have evolved many different strategies 
for immune evasion (164-166), most of which interfere with the various steps necessary for 
MHC class I restricted Ag presentation. For example, CMV evades MHC class I Ag presentation 
by reducing the stability of class I heavy chains (167) and also by dislocating MHC class I heavy 
chains from the endoplasmic reticulum (168). The coordinated function of murine CMV genes 
can completely inhibit CTL lysis (169). Among others, the EBV EBNA1 protein contains an element 
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that interferes with its proteasomal proteolysis, and the HSV ICP47 protein inhibits the TAP 
complex (170, 171). HIV is highly efficient at evading immune responses through mechanisms 
such as modulation of MHC class II presentation (172) and downregulation of MHC class I 
molecules (150, 172-174). Many other viral immune evasion strategies are also described (175-
179).
Allogeneic cell therapy may be capable of bypassing all these viral strategies of immune evasion 
as the virus-specific memory T cells are directly stimulated via molecular mimicry (44). The allo-
HLA molecule against which the virus-specific T cell is cross-reactive is constitutively expressed 
and occupied by the stimulating self-peptide. Theoretically, allogeneic cell therapy could even 
stimulate additional virus-specific responses other than the specificity of interest. Steffens et 
al. (180) demonstrated that preemptive CMV-specific CD8+ T-cell immunotherapy, guided by 
viral DNA load, prevented lethal disease and reduced the risk of virus recurrence. Similarly, 
allogeneic cell therapy may ensure a high proportion of pre-existing activated virus-specific 
memory T cells to prevent disease and accelerate the resolution of productive infection.
Finally, we acknowledge that further work is required before allogeneic cell therapy can be used 
in the clinical setting to treat viral infections. In these experiments, we have used healthy blood 
donors as responder PBMCs, not cells from immunosuppressed patients. Whereas infusion of 
irradiated leukocytes should not be associated with chimerism or engraftment, this possibility 
should be considered in an extremely immunodeficient recipient. Repeated allogeneic cell 
therapy may also cause sensitization of a recipient to future transplantations. It is also unclear 
whether such treatment would stimulate a de novo virus-specific response from naive T cells 
(181-183). Nonetheless, results demonstrated in this study suggest allo-HLA stimulation may 
have potential as an alternative to adoptive transfer or pharmacological therapy to treat viral 
infections.
The high frequency of allo-HLA cross-reactivity by virus-specific T cells is increasingly being 
recognized. We provide (in vitro) evidence that allogeneic cell therapy may be useful to 
conversely stimulate a beneficial antiviral cytolytic effector response for treatment of viral 
infection. This proof-of-principle technique could provide important future options for the 
treatment of viral infections. This approach should be investigated further.
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SUPPLEMENTARY MATERIAL











- - + - +
Responder 2
A2/NLV
- - - - +
Responder 3
A2/NLV
- - - - -
Responder 4
B35/IPS
- - - - +
Pools of 4 different allogeneic cells were first used to screen for allo-HLA cross-reactivity of CMV-specific 
CD8+ T cells within whole blood, using CFSE staining of proliferating responder cells. The specific allogeneic 
cell giving the stimulation was then easily identified in a second assay. Specific allogeneic stimulation was 
associated with not only proliferation but also increased cytolytic activity against the original cognate 
viral antigen. Specific allogeneic cells stimulating a virus-specific T-cell response were identifiable for most 
responders and specificities. + Specific proliferation detected. - No proliferation detected. PBMCs from 
responder 2 were used in the assays described in Figures 2, 3 and 6.
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Supplemental Figure 1. The proportion of EBV-specific CD8+ T cells is specifically increased following 
allogeneic cell stimulation. EBV EBNA3A-specific CD8+ T cells accounted for 20.8% of total CD8+ T cells, 
following 8-day co-culture with homozygote HLA-B*44:02 mismatched irradiated PBMCs. The proportion of 
EBV EBNA3A-specific CD8+ T cells was unaltered by co-culture with homozygote HLA-B*44:03+ PBMCs. FACS 
plots gated on total CD8+ T-cell population. The primed responder cells shown here were then harvested 
and used as effector cells in the cytolytic assays shown in Figure 5.
Responder: HLA-A*01, A*02; B*08, -; DRB1*03, -.
HLA-B*44:02+ stimulator: HLA-A*02, A68; B*44:02, -; DRB1*07, DR14.
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ABSTRACT
Virus-specific T cells can recognize allogeneic HLA (allo-HLA) through TCR cross-reactivity. The 
allospecificity often differs by individual (private cross-reactivity), but can also be shared by 
multiple individuals (public cross-reactivity); however, only a few examples of the latter have 
been described. Because these could facilitate alloreactivity prediction in transplantation, 
we aimed to identify novel public cross-reactivities of human virus-specific CD8+ T cells 
directed against allo-HLA by assessing their reactivity in mixed lymphocyte reactions. Further 
characterization was done by studying TCR usage with primer-based DNA sequencing, cytokine 
production with ELISA, and cytotoxicity with 51chromium-release assays. We identified three 
novel public allo-HLA cross-reactivities of human virus-specific CD8+ T cells. CMV B35/IPS CD8+ 
T cells cross-reacted with HLA-B51 and/or HLA-B58/B57 (23% of tetramer-positive individuals), 
FLU A2/GIL CD8+ T cells with HLA-B38 (90% of tetramer-positive individuals) and VZV A2/ALW 
CD8+ T cells with HLA-B55 (two unrelated individuals). Cross-reactivity was tested against 
different cell types including endothelial and epithelial cells. All cross-reactive T cells expressed 
a memory phenotype, emphasizing the importance for transplantation. We conclude that public 
allo-HLA cross-reactivity of virus-specific memory T cells is not uncommon and may create 
novel opportunities for alloreactivity prediction and risk estimation in transplantation.
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INTRODUCTION
Alloreactive T cells are a major cause of graft loss after solid organ transplantation and acute 
graft-versus-host disease (aGVHD) after hematopoietic stem cell transplantation (HSCT) (114, 
184). In particular alloreactive T cells expressing a memory phenotype are a potential threat, 
since their activation threshold is substantially lower compared with their naïve counterpart, 
while their effector function is enhanced (161, 185). Interestingly, alloreactive memory T cells are 
present in all individuals, even without prior exposure to alloantigen. This can be explained by 
heterologous immunity of virus-specific T cells: the inherent capacity of T-cell receptors (TCRs) 
to cross-react with multiple antigens. Heterologous immunity thereby arms virus-specific T cells 
with a TCR that can recognize a range of related and unrelated viral peptides, creating a survival 
benefit to the host. This scenario describes the recognition of different peptides presented by 
a self-HLA. TCR cross-reactivity, however, can also be directed against allogeneic HLA (allo-
HLA). As a consequence, memory T cells that are primed by viral infections may contribute to 
allograft rejection. Alarmingly, such TCR cross-reactivity of virus-specific memory T cells against 
allogeneic HLA is indeed common (43).
The TCR repertoire differs by individual due to both intrinsic (thymic selection) and extrinsic 
(allergens / viral infections) factors. Although most TCRs appear to be unique to individuals 
(private TCRs), dominant TCR sequences have also been found in multiple individuals (public 
TCRs). Public TCRs are selected for optimal recognition of immunodominant viral epitopes (186), 
and cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) in particular are known for inducing 
public TCR responses (6, 7, 187). Inherent to their structural differences, the allospecificity of 
cross-reactive private TCRs (even with the same viral specificity) is directed toward different 
alloepitopes (private cross-reactivity) (188), and alloreactivity by private TCR cross-reactivity 
is therefore impossible to predict. In contrast, cross-reactivity of public TCRs is directed 
against the same alloepitopes in multiple individuals and thus could facilitate the prediction 
of alloreactivity by memory T cells. A classic example of such public cross-reactivity is found in 
HLA-B8+ individuals: when infected with the EBV virus, they select a public TCR that, in addition 
to the viral epitope (HLA-B8/FLR), recognizes allogeneic HLA-B*44:02 (11). Such cross-reactive 
virus-specific T cells were also identified in HLA-B8+B44- lung-transplant recipients transplanted 
with an HLA-B*44:02 graft (39, 40).
To date, public cross-reactivity of virus-specific T cells is considered uncommon because it 
requires strict TCR preservation in unrelated individuals; however, reports of other TCR cross-
reactivities with similar allospecificity in unrelated individuals give reason to challenge this 
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conception (189-192). Furthermore, Nguyen et al. recently identified cross-reactivity of CMV A2/
NLV-specific T cells with nearly identical TCR usage against HLA-B27 in two unrelated individuals 
(86).
To the best of our knowledge, these indications of public cross-reactivity of virus-specific T 
cells are the only ones described so far. Identification of additional public cross-reactivities of 
virus-specific T cells and knowledge concerning their prevalence and functional characteristics 
could enable monitoring and facilitate risk estimation in a transplantation setting. Therefore, we 
aimed to identify novel public cross-reactivities of virus-specific CD8+ memory T cells directed 
against allogeneic HLA antigens.
MATERIALS AND METHODS
Collection of responder and target cells
Responder and target peripheral blood mononuclear cells (PBMCs) were derived from healthy 
donors with informed consent in accordance with the Declaration of Helsinki. PBMCs were 
isolated from whole blood by standard density gradient centrifugation (Ficoll-Isopaque 
separation) and cryopreserved until usage.
EBV-transformed lymphoblastoid cell lines (EBV-LCLs) were generated according to standard 
protocol. Supernatant of the EBV-producing marmoset cell line B95.8 was added to bulk 
PBMCs, incubated for 1.5 h at 37°C, and cultured in RPMI 1640 Medium (Gibco, Carlsbad, CA) 
supplemented with 10% fetal calf serum (FCS), penicillin/streptomycin and glutamine.
Phytohemagglutinin (PHA) blasts were generated from PBMCs by culturing in RPMI 1640 
medium (Gibco) supplemented with penicillin/streptomycin, glutamine, 15% human serum 
(HS), and PHA (4mg/mL; Murex Biotech Ltd).
Human umbilical vein endothelial cells (HUVECs) were cultured in M199 medium (Gibco) 
supplemented with 10% FCS, sodium pyruvate (Gibco), penicillin/streptomycin (Gibco) and 
0.01% β-mercaptoethanol (0.05M; Sigma Aldrich, St. Louis, MO). HUVECs were used at passages 
1-4.
Proximal tubular epithelial cells (PTECs) were cultured in DMEM ham F12 medium (Lonza) 
supplemented with 26μg/mL Hydrocortisone (Sigma Aldrich), 1% 1x insulin-transferrin-sodium 
selenite media supplement (ITS; Sigma Aldrich), 10μg/mL human Epidermal Growth Factor 
(hEGF; Sigma Aldrich), 0.08 pg/mL 3,3′,5-Triiodo-L-thyronine sodium salt (Sigma Aldrich), and 
penicillin/streptomycin (Gibco). PTECs were used at P1-P4.
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HLA typing was achieved by sequence-specific oligonucleotide (SSO) and sequence-specific 
primer (SSP) genotyping at the European Federation of Immunogenetics (EFI)- accredited 
national reference laboratory for histocompatibility testing at the Leiden University Medical 
Center, Department of Immunohematology and Blood Transfusion, the Netherlands.
Proliferation assays
Proliferation of virus-specific CD8+ T cells was determined at bulk level by mixed lymphocyte 
reactions (MLRs). Responder PBMCs were labeled with carboxyfluorescein succinimidyl ester 
(5mM; Molecular Probes) and incubated for 8 days with 1 x 106 irradiated stimulator PBMCs 
(3000 Rad, responder:stimulator (R:S) ratio 1:1) in RPMI 1640 Medium (Gibco) supplemented 
with penicillin/streptomycin, glutamine, 15% HS and IL-2 (10 U/mL). Analysis was done by flow 
cytometry (FACS Calibur; BD Biosciences) using viral tetramers conjugated with phycoerythrin 
(PE) and CD8 antibody conjugated with allophycocyanin (APC) (Protein facility of the Leiden 
University Medical Center, Department of Immunohematology and Blood Transfusion, the 
Netherlands).
In addition, proliferation of CD8+ T-cell clones was determined by thymidine (3H) incorporation. 
CD8+ T-cell clones (0.5 x 106 cells; responders) were stimulated with irradiated PBMCs and 
EBV-LCLs (0.5 x 106 cells; stimulators) and incorporated with 3H-thymidine (20 μCi) at day 4. After 
24 h, cells were harvested using a Tomtec cell harvester (Tomtec, Hamden, CT) and read by liquid 
scintillation spectrophotometry on a 1450 LSC MicroBeta TriLux microplate scintillation and 
luminescence counter (Perkin Elmer, Waltham, MA). The stimulation index (SI) was calculated 
as: mean counts per minute (CPM) of experimental wells / mean CPM unstimulated (medium-
only) wells.
Generation of virus-specific CD8+ T-cell clones
Virus-specific CD8+ memory T-cell clones were generated by fluorescence-activated cell sorting 
(FACS; FACSAria; BD Biosciences), as described previously (118). PBMCs of healthy donors 
were stained with PE-labeled viral tetramers CMV pp65(123-131) HLA-B*35:01/IPSINVHHY 
(CMV B35/IPS), influenza (FLU) IMP(58-66) HLA-A*02:01/GILGFVFTL (FLU A2/GIL), and varicella 
zoster virus (VZV) IE62(593-601) HLA-A*02:01/ALWALPHAA (VZV A2/ALW) (Protein facility of the 
Leiden University Medical Center) and fluorescein isothiocyanate (FITC)-labeled mAb against 
CD4, CD19, CD45-RA, CD14, CD40, CD16 and CD56 (BD Pharmingen, San Diego, CA). The FL1 
channel was used as a dump channel to avoid direct CD8 mAb staining, as simultaneous CD8/
MHC staining triggers TCR internalization. TCR usage was determined by primer-based DNA 
sequencing using primers against the Vβ and Vα alleles (119).
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For optimal conditioning, CD8+ T-cell clones were cultured with irradiated PBMCs (4000 rad) 
from anonymous buffy coats (Sanquin, Leiden, the Netherlands) 8 days prior to functional 
testing.
Cytokine production assays
Interferon γ (IFNγ) production of CD8+ T-cell clones was measured by ELISA according to the 
manufacturer’s protocol (U-CyTech ELISA kit; U-CyTech, Utrecht, the Netherlands). Overall, 
5 x 103 CD8+ T cells were stimulated with 5 x 104 EBV-LCLs for 24 h at 37°C in IMDM (Lonza) 
supplemented with penicillin/streptomycin, glutamine, 5% FCS (Lonza), 5% HS, and IL-2 
(10 U/mL) in triplicate wells.
Cytotoxicity assays
Cytotoxicity was determined by 51chromium (51Cr)-release assay, as previously described 
(118, 121). In short, CD8+ T-cell clones were stimulated with 51Cr-labeled PHA blasts, EBV-LCLs, 
PTECs and HUVECs for 4 h at 37°C in IMDM (Lonza) supplemented with penicillin/streptomycin, 
glutamine, 5% FCS (Lonza), 5% HS, and IL-2 (10 U/mL). 51Cr release was measured on a γ-counter 
(PerkinElmer 2470 Wizard2, PerkinElmer) and specific lysis was determined by the following 
calculation: (experimental 51Cr release - spontaneous 51Cr release) / (maximum 51Cr release - 
spontaneous 51Cr release) x 100. Spontaneous 51Cr release of the target cells was determined in 
medium alone, and maximum 51Cr release was determined by adding Triton. Values for specific 
51Cr lysis represent the mean ± standard deviation of triplicate wells.
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RESULTS
Virus-specific CD8+ T cells from different individuals proliferate in response to 
the same allo-HLA antigens
A cohort comprising 30 healthy individuals was screened for allo-HLA reactivity of virus-specific 
CD8+ T cells in MLRs against a panel of stimulators expressing the most frequent HLA class I 
antigens (>5%) in the Western population. In multiple responders, CD8+ T cells with the same 
viral specificity showed a similar proliferative pattern against the panel (Table 1), and additional 
MLRs with different stimulators confirmed corresponding allo-HLA specificity. First, CD8+ T 
cells directed against self-HLA-B35 presenting CMV-derived peptide IPSINVHHY (pp65 123-
131) proliferated in response to HLA-B51+ and HLA-B58+ allogeneic cells in 23% (3 of 13) of 
CMV B35/IPS tetramer-positive individuals. Second, CD8+ T cells directed against self-HLA-A2 
presenting FLU-derived peptide GILGFVFTL (MP 58-66), proliferated in response to HLA-B38+ 
allogeneic targets in 90% (18 of 20) of FLU A2/GIL tetramer-positive individuals. Third, CD8+ 
T cells directed against self-HLA-A2 presenting VZV-derived peptide ALWALPHAA (IE62 593-
601) proliferated in response to HLA-B55+ allogeneic targets in two unrelated individuals. The 
percentage of VZV A2/ALW tetramer-positive individuals showing this cross-reactivity could 
not be determined because the low precursor frequency of VZV A2/ALW-specific T cells in 
peripheral blood hampers their accurate detection by tetramer staining. Representative FACS 
plots are shown in Figure 1A, and heat maps of all MLRs are shown in Data S1.
Furthermore, CMV B35/IPS, FLU A2/GIL, and VZV A2/ALW CD8+ T cells from individuals that 
expressed the cross-reactive HLA antigen themselves did not proliferate in response to the 
latter, indicating self-tolerance. Interestingly, CMV B35/IPS CD8+ T cells from an HLA-B35+B51+ 
heterozygous individual did not proliferate against syngeneic HLA-B51 but did against allogeneic 
HLA-B58 (Figure 1B).




CMV B35/IPS 16 13 3
FLU A2/GIL 22 20 18
VZV A2/ALW 22 n.a. 11
CMV B35/IPS, cytomegalovirus pp65(123-131) HLA-B*35:01/IPSINVHHY; FLU A2/GIL, influenza IMP(58-66) 
HLA-A*02:01/GILGFVFTL; n.a. = not applicable
1This cross-reactivity has been identified in two additional individuals outside the cohort
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Figure 1. Proliferation of virus-specific CD8+ T cells directed at dominant viral epitopes in response 
to allogeneic HLA. (A) Proliferation of CMV B35/IPS, FLU A2/GIL, and VZV A2/ALW CD8+ T cells against 
respectively allogeneic HLA-B51 and -B58, HLA-B38 and HLA-B55 in mixed lymphocyte reaction. Shown 
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of 13 responders), FLU A2/GIL T-cell proliferation (18 of 20 responders) and VZV A2/ALW T-cell proliferation 
(2 of 2 responders). (B) Proliferation of CMV B35/IPS and FLU A2/GIL CD8+ T cells of individuals expressing 
the cross-reactive HLA antigen in response to allogeneic cells expressing the antigen. In total, 4 HLA-
B35+B51+, 1 HLA-B35+B58+ and 4 HLA-A2+B38+ responders were tested against 5 HLA-B51+, 5 HLA-B58+ and 
6 HLA-B38+ stimulators respectively. Representative examples are shown. All plots were gated on PBMCs 
and CD8+ antibody staining. Full HLA typing of the responders and stimulators is included in Data S2. 
CFSE, carboxyfluorescein succinimidyl ester; CMV B35/IPS, cytomegalovirus pp65(123-131) HLA-B*35:01/
IPSINVHHY; FLU A2/GIL, influenza IMP(58-66) HLA-A*02:01/GILGFVFTL; VZV A2/ALW, varicella zoster virus 
IE62(593-601) HLA-A*02:01/ALWALPHAA.
Shared allo-HLA cross-reactivity is assigned to public TCR usage of virus-specific 
CD8+ memory T cells
CMV B35/IPS-, FLU A2/GIL-, and VZV A2/ALW-specific CD8+ memory T-cell clones were generated 
from the individuals that showed proliferation in response to identical allo-HLA antigens, and 
highly conserved TCR Vα and Vβ usage was observed. Remarkably, the TCR usage of CMV B35/
IPS- and FLU A2/GIL-specific T-cell clones derived from individuals also expressing the cross-
reactive HLA antigen highly resembled the TCR usage of allo-HLA cross-reactive T-cell clones. 
Only minor amino acid differences within the CDR3α (FLU A2/GIL) and CDR3β (CMV B35/IPS) 
regions were able to abrogate the occurrence of cross-reactivity (Table 2, Data S2).
Stimulation with allogeneic PBMCs confirmed that T-cell clones expressing public TCRs were 
able to proliferate in response to the cross-reactive alloantigen. Allorecognition of HLA-B51, 
in contrast to HLA-B58, induced robust proliferation of cross-reactive CMV B35/IPS T cells, 
similar to stronger compared with cognate antigen (B35 + IPS). Allorecognition of HLA-B38 
also induced comparable proliferation of cross-reactive FLU A2/GIL T cells as cognate antigen 
(A2 + GIL), whereas HLA-B55 allorecognition induced less pronounced proliferation of VZV A2/
ALW T cells compared to cognate antigen (A2 + ALW). T-cell clones derived from individuals 
that also expressed the cross-reactive HLA antigen (CMV B35/IPS 8A2, FLU A2/GIL 4A2) did not 
proliferate in response to syngeneic cross-reactive HLA. Of interest, HLA-B38 allorecognition 
of FLU A2/GIL T cells was hampered by differences in Va usage (FLU A2/GIL 3F8), and even in 
CDR3a usage alone (FLU A2/GIL 4A2) (Figure 2).
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Figure 2. Allo-HLA cross-reactive cytomegalovirus-, influenza-, and varicella zoster virus-specific 
CD8+ memory T-cell clones are able to proliferate in response to allogeneic PBMCs. Clones derived 
from individuals expressing the cross-reactive HLA antigen (CMV B35/IPS 8A2, FLU A2/GIL 4A2) did not. 
SI = stimulation index. All experiments were performed in triplicate, and error bars represent the standard 
deviation. CMV B35/IPS, cytomegalovirus pp65(123-131) HLA-B*35:01/IPSINVHHY; FLU A2/GIL, influenza 
IMP(58-66) HLA-A*02:01/GILGFVFTL; SI, stimulation index; VZV A2/ALW, varicella zoster virus IE62(593-601) 
HLA-A*02:01/ALWALPHAA.
Virus-specific CD8+ memory T-cell clones with public cross-reactive TCRs produce 
IFNγ on stimulation with allogeneic targets
IFNγ production of the T-cell clones was determined by ELISA. CMV B35/IPS-, FLU A2/GIL-, and 
VZV A2/ALW-specific CD8+ memory T-cell clones bearing public TCRs produced IFNγ in response 
to EBV-LCLs expressing self-HLA and viral peptide and EBV-LCLs expressing cross-reactive allo-
HLA antigens. Interestingly, minor HLA-B57 cross-reactivity was observed for HLA-B58 cross-
reactive CMV B35/IPS T cells (Figure 3A and 3B), whereas no significant proliferation against 
HLA-B57 was observed in MLR at the bulk or clonal level (data not shown; Figure 2). Cross-
reactive FLU A2/GIL T-cell clones produced IFNγ mainly on HLA-B*38:01 allorecognition, whereas 
HLA-B*38:02 allorecognition resulted in only limited IFNγ production. FLU A2/GIL T-cell clones 
with the same Vb but different Va usage did not cross-react against HLA-B38. Cross-reactive 
VZV A2/ALW T-cell clone 1C12 produced IFNγ on HLA-B55+ allorecognition, comparable to VZV 
A2/ALW T-cell clone 12, as published previously (193). Furthermore, despite highly similar TCR 
usage, virus-specific T cells isolated from individuals carrying cross-reactive HLA antigens did 
not produce IFNγ when stimulated with syngeneic HLA. Interestingly, CMV B35/IPS T-cell clone 
8A2 (derived from the heterozygous HLA-B35+B51+ individual that showed minor proliferation 
in response to HLA-B58) produced high levels of IFNγ on recognition of HLA-B58+ EBV-LCLs, 
and limited levels on recognition of HLA-B57+ EBV-LCLs (Figure 3B). Heat maps of the IFNγ 
ELISAs are included in Data S1, and the allospecificity of all T-cell clones is indicated in Table 2.
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Figure 3. Allo-HLA cross-reactive virus-specific CD8+ memory T cells from different individuals 
produce IFNγ in response to allogeneic EBV-LCLs. (A) Cross-reactive CMV B35/IPS T-cell clones produced 
IFNγ upon HLA-B51 and HLA-B58 allorecognition. In addition, HLA-B58 cross-reactive CMV B35/IPS T cells 
consistently produced limited amounts of IFNγ upon HLA-B57 allorecognition. Cross-reactive FLU A2/GIL 
T-cell clones produced IFNγ upon HLA-B*38:01, and to a limited extent, HLA-B*38:02 allorecognition. Finally, 
HLA-B55 allorecognition induced IFNγ production of cross-reactive VZV A2/ALW T-cell clone 1C12. (B) Virus-
specific CD8+ memory T-cell clones derived from individuals expressing the cross-reactive HLA antigen do 
not produce IFNγ against EBV-LCLs expressing syngeneic HLA. All experiments were performed in triplicate 
at E:T ratio 1:10, and error bars represent the standard deviation. CMV B35/IPS, cytomegalovirus pp65(123-
131) HLA-B*35:01/IPSINVHHY; EBV-LCL, Epstein–Barr virus transformed lymphoblastoid cell line; FLU A2/
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Public allo-HLA cross-reactive CMV B35/IPS-, FLU A2/GIL-specific CD8+ memory 
T cells are cytotoxic, unlike public allo-HLA cross-reactive VZV A2/ALW-specific 
CD8+ memory T cells
51Cr-release assays showed efficient lysis of HLA-B51+ EBV-LCLs and PHA blasts by HLA-B51 
cross-reactive CMV B35/IPS T cells, whereas HLA-B58/B57 cross-reactive CMV B35/IPS T cells 
(including T-cell clone 8A2 derived from the heterozygous HLA-B35+B51+ individual) were unable 
to lyse HLA-B58+ and HLA-B57+ EBV-LCLs and PHA blasts. Interestingly, the same applied for 
T cells that recognized all three allo-HLA antigens. Furthermore, FLU A2/GIL T-cell clones 
efficiently lysed HLA-B*38:01+ EBV-LCLs and PHA blasts, whereas HLA-B*38:02+ EBV-LCL lysis 
was considerably lower. None of the FLU A2/GIL T-cell clones derived from the HLA-A2+B38+ 
individual were cytotoxic toward HLA-B38 targets. VZV A2/ALW T-cell clones showed only minor 
cytotoxicity towards HLA-B55+ EBV-LCLs and PHA blasts, below the generally applied cut-off 
level of 10% (194) (Figure 4A).
Finally, additional 51Cr-release assays were performed with PTECs and HUVECs as targets to 
determine possible tissue specificity of the alloimmune response. HLA-B51 cross-reactive CMV 
B35/IPS T cells were able to lyse HLA-B51+ PTECs and HUVECs with efficiency comparable to 
PHA-blasts and EBV-LCLs. Similar to HLA-B58+ EBV-LCLs and PHA blasts, HLA-B58/B57 cross-
reactive CMV B35/IPS T cells were incapable of lysing HLA-B58+ and HLA-B57+ PTECs. HLA-B58+ 
HUVECS were not available for testing, but no cytotoxicity was observed against HLA-B57+ 
HUVECs. Furthermore, HLA-B38 cross-reactive FLU A2/GIL T cells efficiently lysed HLA-B38+ 
PHA-blasts, EBV-LCLs, HUVECs and PTECs, although the latter to a lesser extent. VZV A2/ALW 
cross-reactive T cells showed consistent limited cytotoxicity towards HLA-B55+ PHA blasts, EBV-
LCLs, PTECs, and HUVECs. Finally, FLU A2/GIL T-cell clones generated from the HLA-A2+B38+ 
individual again showed no recognition of HLA-B38+ targets (Figure 4B). Cytotoxicity results of 
the T-cell clones that were able to lyse target cells expressing the cross-reactive HLA antigen 
are summarized in Table 3.
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Figure 4. Allo-HLA cross-reactive virus-specific CD8+ memory T cells from different individuals are 
cytotoxic to allogeneic targets. Cytotoxicity was observed to (A) PHA blasts and EBV-LCLs, and (B) PTECs 
and HUVECs expressing the cross-reactive allo-HLA molecules. Non-cross-reactive T cells (including T cells 
from individuals expressing the cross-reactive HLA) were not cytotoxic to allogeneic targets. Plots are 
representative examples, all experiments were performed in triplicate and at different effector:target 
(E:T) ratios (30:1; 10:1; 1:1; 0.1:1); E:T ratio 30:1 is shown. Error bars represent standard deviation. CMV B35/
IPS, cytomegalovirus pp65(123-131) HLA-B*35:01/IPSINVHHY; EBV-LCL, Epstein–Barr virus transformed 
lymphoblastoid cell line; FLU A2/GIL, influenza IMP(58-66) HLA-A*02:01/GILGFVFTL; HUVEC, human umbilical 
vein endothelial cell; PHA, phytohemagglutinin; PTEC, proximal tubular epithelial cell; VZV A2/ALW, varicella 
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DISCUSSION
Because public cross-reactivity hinges on strict TCR preservation in multiple individuals, it is 
allegedly uncommon. Nevertheless, using a small cohort and a restricted set of viral tetramers, 
we were able to identify three novel public allo-HLA cross-reactivities of virus-specific memory 
T cells. All TCRs of HLA-B51- and HLA-B58/57-cross-reactive CMV B35/IPS T cells shared 
strong public features (187) and only minor amino acid differences within their CDR3 loops 
differentiated between HLA-B51 and HLA-B58/B57 allorecognition. TCR clonotypes recognizing 
HLA-B51, HLA-B58/B57, and the combination were detected alongside each other in different 
individuals. FLU A2/GIL cross-reactivity against HLA-B38 was observed in almost all (18 of 
20) tetramer-positive individuals, and TCR usage was identical to an abundant public FLU A2/
GIL TCR clonotype described in literature (12, 195). Although public TCR usage has not been 
described for VZV A2/ALW-specific T cells, CD8+ T-cell responses against the VZV A2/ALW epitope 
are shared by the majority of HLA-A2+ individuals (196) and HLA-B55 cross-reactivity of VZV A2/
ALW-specific T cells with corresponding TCR Vβ usage has in fact been identified previously in 
yet another individual (43). The nearly identical TCR usage in three unrelated individuals again 
firmly points toward the involvement of a public TCR.
FLU A2/GIL and CMV B35/IPS T cells sorted from HLA-A2+B38+ and HLA-B35+B51+ individuals, 
respectively, did not recognize HLA-B38 and HLA-B51 alloantigens, which is likely the result 
of thymic TCR selection to avoid autoimmunity. This confirms the observation in HLA-
B8+B*44:02+ heterozygous individuals, which select oligoclonal EBV B8/FLR TCRs that are 
completely disparate from the public HLA-B*44:02-cross-reactive TCR (197, 198). Furthermore, 
even individuals heterozygous for HLA-B*08:01 and HLA-B*44:03 (which highly resembles 
HLA-B*44:02 but is not functionally cross-reactive) select EBV B8/FLR TCRs that are highly 
distinct from the public HLA-B*44:02-cross-reactive TCR (199). In contrast, we did not find such 
cautious TCR selection. First, unlike HLA-B*44:03 skewing of the EBV B8/FLR TCR repertoire, 
self-expression of HLA-B51 did not abrogate HLA-B58 cross-reactivity of CMV B35/IPS cross-
reactive T cells in a heterozygous HLA-B35+B51+ individual. Moreover, FLU A2/GIL and CMV B35/
IPS TCRs from HLA-A2+B38+ and HLA-B35+B51+ individuals, respectively, were nearly identical to 
the public cross-reactive TCRs, and only small amino acid insertions within both CDR3 regions 
(CMV B35/IPS) and even within the CDR3α region alone (FLU A2/GIL) were able to abrogate 
cross-reactivity. Plausibly, this exceptionally conserved TCR usage illustrates the superiority 
of these TCR clonotypes in generating antiviral immune responses.
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The mechanisms by which the newly identified public TCRs cross-react to allo-HLA remain 
unknown, however, because HLA-B35 is structurally highly similar to HLA-B51 and HLA-B58/
B57, and HLA-B35 and HLA-B51 present a similar peptide repertoire (200, 201), the CMV-B35/
IPS cross-reactivity against HLA-B51 and HLA-B58/B57 may be explained by structural mimicry. 
Structural mimicry between an allo- and viral epitope is the most described mechanism of 
TCR cross-reactivity and underlies EBV B8/FLR cross-reactivity against HLA-B*44:02 as well 
as HLA-B*35:01 (44, 135). Both FLU A2/GIL and VZV A2/ALW public cross-reactivities were 
directed against allo-HLA antigens with only little similarity to the cognate HLA antigen. 
Although this does not exclude structural mimicry (after all HLA-B*08:01 and HLA-B*44:02 
show substantial polymorphism and divergent peptide expression), the finding that FLU A2/
GIL cross-reactivity appears to depend on CDR3a usage, whereas TCR docking to the cognate 
viral epitope depends primarily on binding of the Vβ chain (9, 202), could indicate a different 
mechanism for allorecognition and points toward an altered TCR docking mode, but this should 
be investigated further.
The strong functional difference in HLA-B51 versus HLA-B58/B57 allorecognition by CMV B35/
IPS T-cell clones is remarkable. A possible explanation may be different TCR affinities for these 
alloantigens. The small amino acid differences in the α1 domain between HLA-B51 and HLA-B58/
B57 for example, may affect TCR binding (203), especially because these involve the “generic” 
MHC class I restriction elements on positions 65, 66, and 69 (190). These restriction elements are 
conserved for HLA-B35 and HLA-B51. In addition, variations in peptide presentation between 
HLA-B51 and HLA-B58/B57 could affect TCR avidity and lead to suboptimal or alternative TCR 
signaling and T-cell activation in response to HLA-B58/B57 (204, 205). However, for conclusive 
statements on the mechanisms behind TCR cross-reactivity, the (allo)peptides presented in the 
cross-reactive HLA should be identified and crystal structures need to be assembled, which 
was beyond the scope of this research.
We recently identified FLU A2/GIL cross-reactivity to donor HLA-B38 in an HLA-A2+ renal 
transplant patient (38), emphasizing that (public) cross-reactivities can indeed present 
in a clinical setting. As one of the key endeavors in transplantation research is to predict 
alloreactivity, public cross-reactivity of virus-specific TCRs could provide a useful tool. However, 
potential predictive value will differ by public cross-reactivity.
The prevalence of the public cross-reactive TCR clonotypes, and thus the percentage of 
patients that harbor these TCRs, greatly affects prediction. The here-described FLU A2/GIL 
public cross-reactivity against HLA-B38 is highly abundant, with 90% of FLU A2/GIL tetramer-
6
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positive individuals expressing the public HLA-B38 cross-reactive TCR. In fact, this public 
TCR is considered the most abundant human TCR clonotype (9). This high prevalence is 
facilitated by the facts that HLA-A2 is the most common HLA allele worldwide, that infection 
with the influenza virus occurs in virtually all individuals, and that the CD8+ T-cell response 
to influenza is dominated by T cells that recognize the HLA-A2/GIL epitope. The CMV B35/IPS 
HLA-B51 and HLA-B58/B57 cross-reactive TCR clonotypes were found in 23% of CMV B35/IPS 
tetramer-positive individuals. Although HLA-B35 is less predominant than HLA-A2, CMV affects 
approximately 40-100% of the world population and is one of the most prevailing infections 
after transplantation. The prevalence of the HLA-B55 cross-reactive VZV A2/ALW TCR cross-
reactivity remains to be established, because the low precursor frequency of VZV A2/ALW-
tetramer+ T cells in the peripheral blood hampers its accurate detection. Yet, VZV also affects 
nearly all individuals, the majority of HLA-A2+ individuals show CD8+ T-cell responses against the 
VZV A2/ALW epitope (196), and the identification of highly identical TCRs in different unrelated 
individuals suggests it is indeed common.
Furthermore, functionality differs by cross-reactivity. CMV B35/IPS cross-reactivity against 
HLA-B51 and HLA-B58/B57 were both characterized by proliferation and IFNγ production, but 
only HLA-B51 cross-reactivity induced cytotoxicity. FLU A2/GIL T cells were able to proliferate, 
produce IFNγ, and exert cytotoxicity toward HLA-B38+ targets, whereas VZV A2/ALW-specific T 
cells expressed limited to no cytotoxicity but were able to proliferate and produce IFNγ upon 
allorecognition. Nevertheless, it is still unclear which functional characteristics of cross-reactive 
T cells in vitro affect clinical outcome: where cytotoxic responses may harm the allograft 
directly, cytokine production could harm the allograft indirectly by inducing an inflammatory 
environment (113). In addition, one should keep in mind that functionality may differ in response 
to different cell types (tissue specificity), as shown for the public EBV-B8/FLR cross-reactivity to 
allo-HLA-B*44:02 (87). When the cross-reactive allopeptide has a restricted tissue distribution, 
(public) TCR cross-reactivity may be restricted to specific organs, whereas if it is expressed 
in multiple cell types, it could have broader implications for organ transplantation. In our 
experiments, there were no indications for tissue-specificity of CMV B35/IPS cross-reactivity 
against HLA-B51 or VZV A2/ALW cross-reactivity against HLA-B55. HLA-B38 cross-reactive FLU 
A2/GIL T cells, however, appeared less potent in lysing PTECs compared with HUVECs, EBV-LCLs, 
and PHA blasts, suggesting there may be a certain degree of tissue specificity.
Furthermore, precursor frequencies should be determined because they could affect clinical 
outcome. Unlike low precursor frequencies, high precursor frequencies of alloreactive memory 
T cells are associated with impaired tolerance induction and contribution to graft rejection 
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and graft-versus-host disease (61, 84, 109, 206, 207); therefore, cross-reactive T-cell precursor 
frequencies strongly determine alloreactivity predictive value and should be determined per 
individual. Of note, precursor frequencies of virus-specific T cells have been shown to be subject 
to some fundamental principles that apply to most individuals and that could aid in initial risk 
estimation. FLU-specific memory T cells, for example, compose a small proportion of the T-cell 
repertoire, plausibly due to clearance of the virus after infection. CMV-specific memory T cells, 
in contrast, make up a substantial part of the CD8+ T-cell repertoire (208), likely because CMV is 
(like EBV) a herpes virus that latently persists after infection. In addition, they have been shown 
to dominate T-cell repopulation following lymphodepletion (209) and are even suggested to 
promote solid organ rejection (42). Despite VZV also being a persistent virus, the precursor 
frequency of VZV A2/ALW-specific memory T cells is low: perhaps due to VZV “hiding” from 
the immune system in nerve cells. Nevertheless, the precursor frequency of HLA-B55 cross-
reactive VZV A2/ALW T cells could increase as a result of routine vaccination against VZV in 
transplantation recipients. Indeed, one of the HLA-B55 cross-reactive VZV A2/ALW T-cell clones 
studied in this paper (Clone 12) was derived from a transplant recipient that was vaccinated 
against VZV (193). In addition, adoptive transfer of enriched virus-specific T cells may introduce 
cross-reactive virus-specific T cells at high precursor frequencies.
In conclusion, we were able to identify three novel public cross-reactivities of virus-specific 
memory T cells in a small cohort of individuals, while subjected to a restricted number of 
known dominant viral epitopes and tetramers. It is therefore expected that this is only the tip 
of the iceberg - and public cross-reactivity of virus-specific T cells is much more common than 
anticipated. Increasing the knowledge concerning public cross-reactivities could benefit the 
prediction of anti-donor reactivity, enable monitoring of potentially harmful alloresponses, 
and ultimately support clinical decision making.
6
126
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Public cross-reactivity of virus-induced T cells
Table 3. Cytotoxic potential of virus-specific memory CD8+ T-cell clones with public TCR usage able to lyse 
allogeneic cells expressing cross-reactive HLA antigensa,b
Donor Clone Allo-HLA PHA-blast EBV-LCL PTEC HUVEC
CMV B35/IPS 1 7C8 B51 92 (±2.1)1 83 (±17.7)1 104 98 (±9.2)1
6E5(1) B51 49 44 (±7.1)1 n.d. 76
3 8F4 B51 97 73 (±15.4)1 87 91 (±15.6)1
FLU A2/GIL 1 1A5 B38 43 53 n.d. 58
1F4 B38 47 63 34 56 (±0.7)1
1C4 B38 48 65 (±2.1)1 67 n.d.
3 1B5 B38 5 33 16 n.d.
4 3C2 B38 54 63 (±14.1)1 n.d. 54
VZV A2/ALW 5 Clone 12 B55 24(±2.9)1 21 (±9.1)1 16 0
6 1C12 B55 14(±6.1)1 11 (±0.7)1 11 13 (±8.7)1
CMV B35/IPS, cytomegalovirus pp65(123-131) HLA-B*35:01/IPSINVHHY; EBV-LCL, Epstein–Barr virus 
transformed lymphoblastoid cell line; FLU A2/GIL, influenza IMP(58-66) HLA-A*02:01/GILGFVFTL; HUVEC, 
human umbilical vein endothelial cell; PHA, phytohemagglutinin;
PTEC, proximal tubular epithelial cell; VZV A2/ALW, varicella zoster virus IE62(593-601) HLA-A*02:01/
ALWALPHAA. n.d. = not determined.
aNumbers represent the allo-HLA response as a percentage of the anti-virus response
bAll experiments were performed in triplicate and at different effector: target (E:T) ratios (30:1, 10:1, 1:1, 
0.1:1) of which E:T ratio 30:1 is shown
1Means of two independent experiments with standard deviation
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SUPPLEMENTARY MATERIAL
Data S1
Data S1 can be found at: https://tinyurl.com/yyx8ygj4
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Data S2.
Figure 1 HLA typing
R1 (= Donor #1 
Table 2)
A*02:01 A*11:01 B*35:01 B*40:01 C*03:04 C*04:01 DRB1*15:01 DRB1*11:01 
DQB1*06:02 DQB1*03:01
R2 (= Donor #3 
Table 2)
A*02:01 A*24:02/24:09N/24:11N+ B*08:01/08:05/08:08N+ B*35:01/35:07/35:11+ 
C*03:04/03:05/03:08+ C*04:01/04:09N/04:05+ DRB1*03:01 DRB1*13:02 
DRB3*01:01 DRB3*03:01 DQB1*02:01 DQB1*06:04 DQA1*01:02 DQA1*05:01/05:03 
DPB1*04:01 DPB1*10:01
R3 (= Donor #7 
Table 2)
A2 A3 B51(5) B7 Cw2 Cw7 DR15 DR13 DQ6 DQ1
R4 A2 A24(9) B35 B58(17) Cw3 DR2 DR13 DR6 DR51 DR52 DQ6 DQ1
R5
A*03:01 A*31:01 B*35:01 B*51:01 C*04:01/04:09N/04:05 C*15 DRB1*01:01 
DRB1*09 DRB4*01:03 DQB1*03:03 DQB1*05:01 DPB1*04:02
R6 (= Donor #4 
Table 2)
A*03:01/03:03N/03:04+ A*24:02/24:05/24:09N+ B*35:01/35:07/35:11+ 
B*51:01/51:03/51:09+ C*07:02/07:03/07:10+ C*14:02/14:07N DRB1*04:07 
DRB1*15:01 DRB4*01:03 DRB5*01:01, DQB1*03:01 DQB1*06:02
R7 (= Donor #6 
Table 2)
A*02:01 A*26:01 B*38:01 B*55:01 C*01:02 C*12:03 DRB1*13:01 DRB1*14:54 
DQB1*05:03
S1 A2 A3 B51(5) B7 Cw2 DR15(2)(51) DR11(5)(52) DQ6(1) DQ7(3)
S2 A11 A31(19) B58(17) B18 Cw7 DR11(5)(52) DR8 DQ7(3) DQ4(3)
S3 A3 A31(19) B60(40) Cw10 Cw3 DR4(53) DR11(5)(52) DQ7 DQ3
S4 A1 A24(9) B8 B38(16) DR4 DR14(6) DQ5(1) DQ8(3)
S5
A*24:02 A*26:01 B*38:01 B*35:03 C*12:03 DRB1*13:01 DRB1*14:54 DQB1*05:03 
DQB1*06:03
S6
A*03:01 A*26:01 B*07:02 B*40:01 C*03:04 C*07:02 DRB1*15 DRB1*04:04 
DQB1*06:02 DQB1*03:02
S7
A*03 A*24 B*15:01/15:33/15:34+ B*55:01/55:02/55:05+ C*03 DRB1*04 
DRB1*13:01/13:02/13:06+ DRB3*03 DRB4 DQB1*03:02/03:07/03:08 
DQB1*06:04/06:08/06:17
S8
A24(9) A30(19) B13 B55(22) Cw9 Cw3 Cw6 DR11 DR5 DR13 DR6 DR52 DQ6 DQ1 DQ7 
DQ3
S9
A24(9) A11 B35 B60 (40) Cw10 Cw3 Cw4 DR15 DR2 DR4 DR51 DR53 DQ6 DQ1 DQ7 
DQ3
S10 A24(9) A68(28) B51(5) B45(12) DR13 DR6 DR10 DR52 DQ5 DQ6 DQ1
S11 A*0301 A*2402 B*0702 B*58:01 Cw*0701 DRB1*01 DRB1*1301
S12
A*01:01 A*02:01 B*08:01 C*07:01/07:06/07:07 DRB1*03:01/03:04/03:05+ 
DRB3*01:01 DQB1*02:01/02:02/02:04 DQA1*05:01/05:03 DPB1*01:01 DPB1*04:02
S13
A*02:01 A*03:01 B*07:02 B*51:01 C*02:02 C*07:02 DRB1*11:01 DRB1*15:01 
DRB3*02:02 DRB5*01:01
S14
A*02:01 A*26:01 B*38:01 B*55:01 C*01:02 C*12:03 DRB1*13:01 DRB1*14:54 
DQB1*05:03
S15 A2 B38(16) B72(70) Cw2 DR3 DR13(6) DQ1
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Data S2. Continued
Table 2 HLA typing
Donor 1
A*02:01 A*11:01 B*35:01 B*40:01 C*03:04 C*04:01 DRB1*15:01 DRB1*11:01 
DQB1*06:02 DQB1*03:01
Donor 2 A1 A11 B8 B35 Bw6 Cw4 Cw7 DRB1*0103 DRB1*0301 DQ5 DQ2
Donor 3 A*0201 A*2402 B*0801 B*3501 Cw*0304 Cw*0401 DRB1*0301 DRB1*1302
Donor 4
A3 A24(9) B51(5) B35 C*0702 C*14:02 DRB1*04:07 DRB1*15:01 DRB4*01:03 
DRB5*01:01 DQB1*03:01 DQB1*06:02
Donor 5 A*02 A*03 B*07 B*35 C*04 C*07 DRB1*01 DRB1*08 DQB1*04:02 DQB1*05:01
Donor 6
A*02:01 A*03:01 B*37:01 B*38:01 C*06:02 C*12:03 DRB1*03:01 DRB1*13:01 
DQB1*02:01 DQB1*06:03
Donor 7 A2 A3 B51(5) B7 Cw2 Cw7 DR15 DR13 DQ6 DQ1
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ABSTRACT
Virus-specific T cells can recognize allogeneic HLA (allo-HLA) through cross-reactivity of their 
T-cell receptor (TCR). In a transplantation setting, such allo-HLA cross-reactivity may contribute 
to harmful immune responses towards the allograft, provided that the cross-reactive T cells 
get sufficiently activated upon recognition of the allo-HLA. An important determinant of T-cell 
activation is TCR avidity, which to date, has remained largely unexplored for allo-HLA-cross-
reactive virus-specific T cells. For this purpose, cold target inhibition assays were performed 
using allo-HLA-cross-reactive virus-specific memory CD8+ T-cell clones as responders, and 
syngeneic cells loaded with viral peptide and allogeneic cells as hot (radioactively-labeled) and 
cold (non-radioactively-labeled) targets. CD8 dependency of the T-cell responses was assessed 
using interferon γ (IFNγ) enzyme-linked immunosorbent assay (ELISA) in the presence and 
absence of CD8-blocking antibodies. At high viral-peptide loading concentrations, T-cell clones 
consistently demonstrated lower avidity for allogeneic versus viral epitopes, but at suboptimal 
concentrations the opposite was observed. In line, anti-viral reactivity was CD8 independent 
at high, but not at suboptimal viral-peptide-loading concentrations. The avidity of allo-HLA-
cross-reactive virus-specific memory CD8+ T cells is therefore highly dependent on epitope 
expression, and as a consequence, can be both higher and lower for allogeneic versus viral 
targets under different (patho)physiological conditions.
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INTRODUCTION
In humans, the estimated T-cell receptor (TCR) repertoire after positive and negative selection 
in the thymus covers around 108 unique TCR clonotypes (210). If these would only reflect single 
specificities, the TCR repertoire would be far too restricted to cope with the broad array of 
mutating pathogens encountered throughout life. T cells therefore have the intrinsic ability 
to cross-react to multiple viral epitopes, a phenomenon known as heterologous immunity. In 
recent years, it became clear that virus-specific T cells not only have the ability to cross-react 
to multiple viral peptides, but also to allogeneic HLA (allo-HLA) molecules. Such cross-reactivity 
is very common and occurs within all individuals (43). Heterologous immune responses of 
virus-specific T cells that are directed against allo-HLA molecules could pose a threat to both 
hematopoietic and solid organ transplantation. Indeed, animal models have shown that virus-
specific T cells can actively hamper tolerance induction and mediate allograft rejection (35). 
Recently, we reported the first ex vivo analysis of virus-specific T cells possessing cross-reactivity 
to donor peptide:HLA antigens in renal allograft recipients. In 13 of 25 transplant recipients, 
cross-reactivity to donor antigen was demonstrated within T-cell populations specific for viral 
epitopes (142). Remarkably, the presence of donor cross-reactive T cells in the circulation of 
these transplant patients was not associated with inferior outcomes relative to patients who 
lacked these cells. However, to determine the clinical consequences of virus-specific T cells 
with cross-reactivity to allo-HLA, further and more extensive (prospective) clinical studies are 
necessary.
The potential of allo-HLA cross-reactive T cells to harm an allograft depends on their effector 
function, which in turn hinges on TCR avidity: the cumulative strength of all non-covalent 
binding interactions between a T cell and its target cell. Indeed, high avidity donor-reactive 
cytotoxic T cells have been associated with acute rejection of cardiac allografts (211, 212). Avidity 
is largely defined by the interaction between a TCR and its peptide-MHC (pMHC) ligand (TCR 
affinity), but additional cell surface molecule interactions (e.g. TCR dimerization), co-receptor 
binding and cell adhesion molecules also play an important role. Indeed, TCR affinity and avidity 
are unmistakably correlated with TCR signal strength and T-cell activation (213-215).
Variation in T-cell ligation has been shown to induce differences in downstream signaling 
pathways, mainly by altered phosphorylation downstream of the TCR (216, 217). Phosphorylation 
of immunoreceptor tyrosine-based activation motifs (ITAMs) plays a crucial role in determining 
“T-cell fate” by promoting different TCR signaling pathways (218). TCR ligation of a T cell with 
high avidity for its ligand is more likely to induce a full-blown T-cell response compared to 
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TCR ligation of a T cell with low avidity for its ligand, resulting in more pronounced or even 
qualitatively different effector functions (219, 220). Accordingly, TCRs generally bind with higher 
affinity to agonistic peptides compared to partial agonists or antagonists (221). As a result of 
thymic selection, the peripheral TCR repertoire expresses low to moderate avidity for self-HLA, 
thereby avoiding T-cell activation and autoimmunity. Since allo-HLA is not expressed in the 
thymus, allo-HLA cross-reactivity is not restricted by positive and negative thymic selection. 
Therefore, TCR avidity for allo-HLA could in theory have a much broader spectrum compared 
to self-HLA.
TCR affinity and avidity can be addressed by several techniques: for example, competitive 
tetramer-staining can be used to estimate the hierarchy of TCR avidity for nominal and allogeneic 
epitopes (44, 222) while techniques such as surface plasmon resonance (SPR) (223), Förster 
resonance energy transfer (FRET) (224) and the mechanical micropipette adhesion frequency 
assay (225) can address technical kinetics such as half-life and association / dissociation rates 
of the TCR-pMHC complex. Yet, a downside of these assays is that they require comprehensive 
knowledge of the recognized epitope(s), which in case of allo-HLA cross-reactive T cells not 
only requires identification of the allo-HLA, but also the allopeptide. The latter is laborious and 
time-consuming and has only been done for two human TCRs with the same viral specificity 
(44, 192). As a consequence, much is still unknown about TCR affinity and avidity of virus-
specific cross-reactive T cells. Here, we aimed to characterize the relative avidity of human 
cross-reactive virus-specific CD8+ memory T cells for nominal and allogeneic epitopes by using 
different techniques.
MATERIALS AND METHODS
Collection of responder and target cells
Peripheral blood mononuclear cells (PBMCs) of healthy individuals were obtained after 
informed consent in accordance with the Declaration of Helsinki. Phytohaemagglutinin (PHA) 
blasts were generated by incubating PBMCs for 7 days in RPMI 1640 medium (Gibco, Carlsbad, 
CA) supplemented with penicillin/streptomycin, glutamine, 15% human serum (HS), and PHA 
(4 μg/mL; Murex Biotech Ltd, Dartford, UK).
Epstein-Barr Virus transformed lymphoblastoid cell lines (EBV-LCLs) were generated by 
incubating PBMCs for 1.5 hours at 37°C with supernatant of the EBV-producing marmoset cell 
line B95.8, and subsequently cultured in Iscove’s Modified Dulbecco’s Medium (IMDM; Lonza, 
Basel, Switzerland) supplemented with pen/strep, glutamine and 10% fetal calf serum (FCS).
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Human umbilical vein endothelial cells (HUVECs) were cultured in M199 medium (Gibco) 
supplemented with 10% FCS, sodium pyruvate (Gibco), penicillin/streptomycin (Gibco) and 
β-mercaptoethanol (0.05M; Sigma Aldrich, St. Louis, MO), and were used at passages P1-4.
HLA typing was performed by sequence-specific oligonucleotide (SSO) and sequence-specific 
primer (SSP) genotyping at the European Federation of Immunogenetics (EFI)-accredited 
national reference laboratory for histocompatibility testing at the Leiden University Medical 
Center, Department of Immunohematology and Blood Transfusion, the Netherlands.
Generation of virus-specific CD8+ T-cell lines and clones
Virus-specific CD8+ memory T-cell lines and clones were generated by fluorescence-activated cell 
sorting (FACS Aria; BD) as previously described (118). PBMCs were stained with phycoerythrin 
(PE)-labeled viral tetramers CMV pp65(123-131) HLA-B*35:01/IPSINVHHY (CMV B35/IPS), FLU 
MP(58–66) HLA-A*02:01/GILGFVFTL (FLU A2/GIL), VZV IE62(593-601) A*02:01/ALWALPHAA (VZV 
A2/ALW), and EBV EBNA3A(325-333) B*08:01/FLRGRAYGL (EBV B8/FLR) (Protein facility of the 
Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, 
the Netherlands) and fluorescein isothiocyanate (FITC)-labeled monoclonal antibodies (mAb) 
against CD4, CD19, CD45-RA, CD14, CD40, CD16 and CD56 (BD Pharmingen, San Diego, CA). 
The FITC channel (FL1) was used as a dump channel.
Cold-target inhibition
Cold target inhibition assays were performed to define TCR avidity for syngeneic HLA + viral 
peptide versus allo-HLA + endogenous (allo)peptide. Hereto, the 51Chromium release assay 
(CRA) (226) was altered by including not only hot (radioactively-labeled) but also cold (non-
radioactively-labeled) targets in different cold / hot target ratios (1:1; 2.5:1; 10:1; 20:1). EBV-
LCLs and HUVECs were used as target cells. Both syngeneic HLA + viral peptide and allogeneic 
HLA + (allo)peptide target cells were employed as hot and cold targets, and different peptide-
loading concentrations were used (ranging between 0.01ng/ml to 1000ng/ml). All conditions 
(disregarding validation) were performed in triplicate at effector:target (E:T) ratio 1:1.
CD8-blocking assays
CD8 blocking was assessed in both IFNγ ELISA and 51Chromium release assay. Virus-specific 
CD8+ T-cell clones (5 x 103) were incubated with or without CD8-blocking antibody FK18 (7.7μg/
ml; 1 hour 37°C) as described previously (227). For IFNγ ELISA, T-cell clones were co-cultured 
for 24 hours with EBV-LCLs (5 x 104) expressing either self-HLA, self-HLA + viral peptide, or 
allo-HLA molecules (triplicate wells; 24 hours at 37°C). Culture medium consisted of IMDM 
(Lonza) supplemented with penicillin/streptomycin, glutamine, 5% FCS (Lonza), 5% HS, and 
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IL-2 (10 U/mL). After 24 hours, IFNγ production was assessed in a standard enzyme-linked 
immunosorbent assay (ELISA; U-CyTech, Utrecht, The Netherlands) according to protocol. 
Different peptide-loading concentrations were used (ranging between 0.01ng/ml to 1000ng/ml). 
For 51Chromium release assay, the experiments were performed with EBV-LCLs and PHA blasts 
as previously described (226). All conditions were performed in triplicate at effector:target (E:T) 
ratio 1:10 (ELISA) and 1:1 (CRA) respectively.
RESULTS
Lysis of allogeneic cells by cross-reactive virus-specific T cells can be inhibited 
by competition with syngeneic cells expressing the viral epitope
To assess the difference in TCR avidity of cross-reactive T cells for viral and allogeneic epitopes, 
cold target inhibition assays were performed (Figure 1). T cells expressing the following 
(public) cross-reactivities were used: CMV B35/IPS T cells cross-reacting to allo-HLA-B*51:01/
B*57:01/B*58:01; FLU A2/GIL T cells cross-reacting to allo-HLA-B*38:01; VZV A2/ALW T cells 
cross-reacting to HLA-B*55:01; and EBV B8/FLR T cells cross-reacting to allo-HLA-B*44:02 (and 
the allopeptide EEYLQAFTY) (44, 140) (Figure 2).
First, the conditions of the assay were evaluated. The optimal effector:target (E:T) ratio was 
determined to prevent misinterpretation due to excess of responder and/or target cells. Hereto, 
the same target cells were used as hot and cold targets (both viral and allogeneic origin). 
Employing Epstein-Barr Virus-immortalized lymphoblastoid cell lines (EBV-LCLs) as target 
cells, only E:T ratio 1:1 met the expected inhibition corresponding to the cold:hot (C:H) target 
ratios. This optimal ratio was observed for all viral specificities and confirmed with human 
umbilical vein endothelial cells (HUVECs) as alternative targets (Figure 3A). Furthermore, steric 
hindrance was determined using non-cross-reactive virus-specific T-cells and a-specific cold 
target inhibition at increasing C:H target ratios. At E:T ratio 1:1, steric hindrance was observed 
from C:H target ratios of 10:1 onwards (Figure 3B).
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Figure 1. Principle of the cold target inhibition assay. The cold target inhibition assay (right pane) is based 
on the 51Chromium-release assay (left pane) that measures lysis of radioactively-labeled target cells (“hot 
targets”) by cytotoxic T cells (“responders”), however in addition introduces unlabeled target cells (“cold 
targets”) to the system. This addition stimulates competition between hot and cold target lysis based on TCR 
avidity. A reduction in released 51Chromium illustrates inhibition of hot target cell lysis by cold target cells. 
When TCR avidity is higher for the hot target, no or limited inhibition of hot target cell lysis is observed at 
cold:hot target (C:H) ratio 1:1 (left bar, right graph), when TCR avidity is equal for both hot and cold targets 
a two-fold reduction is observed at C:H ratio 1:1 (middle bar, right graph), and when TCR avidity is higher 
for the cold target strong inhibition of hot target cell lysis is observed at C:H ratio 1:1 (right bar, right graph). 
The C:H ratio in combination with the degree of inhibition indicates whether TCR avidity is higher for the 
hot or the cold target.
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Figure 2. Schematic overview of the virus-specific TCR cross-reactivities used in this study. The cross-
reactive allopeptides of the CMV, FLU and VZV cross-reactivities are still to be determined (indicated by “?”).
Next, the assay was performed with different allo-HLA cross-reactive virus-specific memory 
CD8+ T-cell clones (effectors) versus allogeneic EBV-LCLs and HUVECs (targets). Viral-peptide-
loaded autologous cold targets were able to inhibit lysis of allogeneic hot targets, whereas 
allogeneic cold targets were not able to inhibit lysis of viral-peptide-loaded autologous hot 
targets. This was consistently observed regardless of viral specificity and target cell type. 
Moreover, it also held when both viral peptide and allopeptide were employed in the assay: 
EBV B8/FLR-specific T cells preferentially lysed HLA-B*08:01 EBV-LCLs loaded with viral peptide 
(FLRGRAYGL) over HLA-B*44:02 EBV-LCLs loaded with equal concentrations of the cross-reactive 
allopeptide (EEYLQAFTY) (Figure 4).
The alloresponse of cross-reactive virus-specific memory CD8+ T cells is co-
receptor dependent
In general, high-affinity TCRs do not require CD8 co-receptor binding for activation, whereas 
low-affinity TCRs do (228). For all viral specificities, CD8 co-receptor blocking on the T-cell 
surface hampered IFNγ production against allogeneic targets, but not against the viral targets 
(Figure 5A). CD8 co-receptor binding also hampered cytotoxicity towards allogeneic cells, but 
not towards syngeneic cells expressing the viral peptide (Figure 5B).
141















































































































































































































































































































































































































TCR avidity of allo-HLA cross-reactive T cells
143
Heterologous immunity in organ transplantation
Figure 4. Cold target inhibition assays consistently showed higher TCR avidity for the viral epitope 
compared to the alloepitope, regardless of viral specificity of the T-cell clones and the target cell 
type (EBV-LCL or HUVEC). Left panels: CRAs with different E:T ratios (30:1; 10:1; 1:1; 0.1:1). Right panels: 
CTIs with E:T ratio 1:1 and different C:H ratios (1:1; 2.5:1; 10:1; 20:1). Red: hot targets. Blue: cold targets. 
Error bars represent the standard deviation (S.D.) of triplicate wells. Peptide concentrations: 1000 ng/ml.
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Figure 5. The effect of CD8 co-receptor binding on viral versus alloreactivity. A) CD8 blocking by the 
CD8-blocking antibody FK18 hampered IFNγ production in response to the alloepitope, but not the viral 
epitope. The HLA-B*44:02 alloresponse of EBV B8/FLR cross-reactive T cells was hampered by CD8 blocking 
even with addition of the allopeptide (EEY). B) CD8 blocking by the CD8-blocking antibody FK18 hampers 
cytotoxicity in response to the alloepitope, but not the viral epitope. Both EBV-LCLs (upper panels) and PHA 
blasts (lower panels) confirmed the findings. Error bars represent the standard deviation (S.D.) of triplicate 
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Variation in peptide expression affects TCR avidity for viral and alloepitopes
Considering that TCR avidity is directly related to epitope expression (214), the expression of 
the specific HLA-peptide complex is a crucial determinant of TCR avidity. As proof of principle, 
cold target inhibitions were performed using the same target cells expressing syngeneic HLA 
loaded with different concentrations of viral peptide. Indeed, T-cell reactivity and TCR avidity 
were positively correlated with viral peptide expression (Figure 6A). Thereupon, cold target 
inhibition assays with allogeneic targets were conducted using different viral-peptide-loading 
concentrations. At high levels of viral-peptide loading, TCR avidity was consistently higher 
for the viral epitope compared to the alloepitope, as observed in Figure 4. Yet, at suboptimal 
viral-peptide-loading levels TCR avidity appeared to be stronger for the alloepitope (Figure 
6B). CD8-blocking experiments with peptide titration confirmed these findings: in contrast to 
optimal concentrations, suboptimal viral-peptide-loading concentrations required CD8 for IFNγ 
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Figure 6. Cold target inhibition depends on epitope expression. A) Optimal and suboptimal viral 
peptide loading concentrations were determined in IFNγ ELISAs (left panel) and cytotoxicity for optimal 
and suboptimal viral peptide loading concentrations in chromium-release assays (middle panels). Cold 
target inhibitions showed that target cells with suboptimal epitope expression were unable to hamper lysis 
of target cells with optimal epitope expression (right panels). B) TCR avidity is higher for the viral epitope 
compared to alloepitope, but only at optimal viral epitope expression. C) Suboptimal levels of viral peptide 
expression require CD8 co-receptor binding for IFNγ production (upper panels) and cytotoxicity (lower 
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DISCUSSION
The aim of the present study was to assess the differential avidity of cross-reactive virus-specific 
T cells for viral peptides presented by self-HLA molecules versus the cross-reactive allogeneic 
HLA molecule. The TCR cross-reactivities used in this study represent examples of the vast 
amount of allo-HLA cross-reactive virus-specific T cells that can be present in the human body 
(43). We selected for public cross-reactivities, and therefore the results of this study apply to 
multiple individuals (44, 229).
Cold target inhibition assays showed that at high levels of viral-peptide loading, TCR avidity of all 
cross-reactive virus-specific T-cell clones was consistently higher for the viral epitope compared 
to the allogeneic epitope. However, whether the high concentrations of viral peptide used in 
these in vitro studies are representative for the in vivo situation remains to be established. 
Interestingly, at suboptimal levels of viral peptide loading, TCR avidity shifted its preference 
to allogeneic epitopes instead. Indeed, peptide-MHC (pMHC) density is known to be a strong 
regulator of T-cell activation (214, 230), and whereas high peptide-MHC levels are able to 
compensate for low-affinity TCRs in the induction of T-cell proliferation (231), T-cell activation 
does not occur when epitope expression is insufficient (232). Important to keep in mind is that 
the physiological expression of viral and allopeptides in vivo remains elusive and is difficult to 
investigate, even when the hurdle of identifying the allopeptide is overcome. Furthermore, viral 
peptide expression differs during latency and active infection, and TCR avidity could thereby 
transiently change upon episodes of viral (re)activation. Likewise, depending on the origin of 
the allopeptide, alloepitope expression may also alter over time with TCR avidity following 
its lead. EBV- and CMV-peptide expression have been investigated on EBV-LCLs under latent 
infection for a selected number of HLA molecules, but these did not include the HLA molecules 
used as targets in the present study (233). However, in our experiments latent viral peptide 
expression of EBV-LCLs was too low to induce any EBV B8/FLR T-cell responses in vitro, and we 
were unable to detect cytokine production and/or lysis without the external addition of viral 
FLR peptide as far as up to 100 ng/ml (data not shown).
In addition, we compared TCR avidity under optimal levels of both viral and allopeptide 
expression. Hereto, the known human cross-reactive allopeptide EEYLQAFTY (EEY) was used. 
Target loading with optimal levels of both the allopeptide and the viral peptide continued to 
show that TCR avidity was higher for the HLA-B*08:01/FLR viral epitope compared to the HLA-
B*44:02/EEY alloepitope (Figure 4). These results appear to agree with literature, as tetramer 
149
Heterologous immunity in organ transplantation
competition and SPR studies have shown that TCR affinity is 15 times higher for the HLA-
B*08:01/FLR viral epitope compared to the HLA-B*44:02/EEY alloepitope (44).
To further substantiate the findings, the avidity of the clones was also assessed by blocking 
the CD8 co-receptor on the T-cell surface, as CD8 co-receptor binding to MHC is an important 
determinant of TCR avidity. It enhances antigen sensitivity, is involved in early T-cell activation 
by stabilizing the TCR-pMHC complex and by mediating phosphorylation of the intracellular 
domain of the TCR/CD3z complex, and is furthermore involved in the formation of TCR-pMHC 
microdomain structures at the cell surface (234-236). Accordingly, TCR affinity is negatively 
correlated to CD8 co-receptor dependency: low TCR affinity requires CD8 co-receptor signaling 
for T-cell activation whereas high TCR affinity generally does not (237). Interestingly, regulation 
of CD8 expression has been shown to alter TCR specificity (236) and even to facilitate T-cell 
cross-reactivity (238). In agreement with the cold target inhibition assays, CD8 blocking did not 
hamper anti-virus reactivity when viral peptide expression was optimal, but did when it was 
suboptimal, whereas the alloresponse was consistently hampered by CD8 blocking also under 
optimal allopeptide (EEY) loading conditions (Figure 5).
The present experiments show that cold target inhibition and CD8-blocking assays are useful 
tools to estimate allo-HLA TCR avidity of cross-reactive virus-specific T cells for which the 
allopeptide is unknown. Even when the allopeptide has been identified, TCR avidity assays 
are a useful addition to TCR affinity assays, as they take into account all non-covalent binding 
interactions and cluster formations at the cell surface membrane instead of TCR/pMHC 
interactions alone. While TCR affinity remains static, TCR avidity can change over time: for 
example, activation-induced membrane changes can enhance TCR avidity upon T-cell activation 
(239), an event that would go unnoticed in assays that measure TCR affinity alone. Furthermore, 
the assays employ live cells, which permits a natural state of antigen presentation. This includes 
spatio-temporal interactions between the TCR and its ligand and natural variation in HLA and 
(allo)peptide expression under physiological circumstances. For example, epitope expression 
can differ per cell type as a result of tissue-specificity, which can be addressed by employing 
different tissue cell types. In addition, epitope expression can be affected by inflammation: 
under non-inflammatory conditions HLA expression is reasonably constant and epitope 
expression is primarily determined by the level of (allo)peptide presentation, yet it is enhanced 
under inflammatory conditions (e.g. during acute rejection), which could boost TCR avidity for 
the (allo)epitope. By incubating the target cells with cytokines, the impact of inflammation on 
HLA expression can roughly be simulated, which will be subject of future studies.
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Of note, TCR affinity assays that use soluble pMHC and tetramers can underestimate TCR affinity 
compared to membrane-bound assays (204, 224, 240), indicating that the cell membrane is 
important even for TCR-pMHC affinity studies. TCR affinity and avidity studies can complement 
each other and generate insights into TCR-ligand interactions beyond their own boundaries. In 
addition, the cold target inhibition and CD8-blocking assays allow for in vitro T-cell activation 
and determination of functional characteristics such as cytokine production and cytotoxicity.
In conclusion, without prior knowledge of the allopeptide we were able to compare the avidity 
of allo-HLA cross-reactive virus-specific T cells for both their viral and alloepitopes. Our 
observations show that the relative TCR avidity for these targets is variable depending on 
epitope expression, and that depending on the circumstances, the avidity of allo-HLA cross-
reactive virus-specific T cells may be higher for its alloepitope compared to its viral epitopes 
- an issue that has been long debated. The clinical consequences of these in vitro observations 
are still to be established.
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Viral infections are an important health issue for transplant recipients. In healthy individuals, 
viral infections can be controlled by virus-specific T cells, but in immunosuppressed transplant 
recipients the response to viral infection is less efficient. As recently outlined by D’Orsogna 
et al, infectious pathogens can affect alloreactivity at all levels of the immune system (241). 
Therefore, common viruses that do not pose a significant health risk to non-immunosuppressed 
individuals, can become major threats to the health of transplant recipients and can severely 
affect transplantation outcome (242). Especially cytomegalovirus (CMV), a common virus 
with a prevalence of around 70% in the general population, is of great concern in kidney 
transplantation (243-246).
Current immunosuppressive drugs are not specific: they not only hamper anti-donor immune 
responses but also anti-viral immune responses. Ideally, these drugs should specifically target 
the immune response to the donor and only to a minor extent the anti-viral immune responses. 
For this purpose, the differences between these immune responses need to be investigated. 
One way to make this distinction is by looking at their composition: in theory, the anti-viral 
immune repertoire largely consists of memory cells that are primed by previous viral infections, 
whereas the donor-specific immune repertoire consists of naïve cells that are yet to be primed 
upon transplantation. Consequently, this implies that immunosuppressive drugs directed at 
the naïve T-cell compartment (such as co-stimulatory inhibitors) prevent the priming of naïve 
donor-reactive T cells, while they render anti-virus T cells with a memory phenotype unaffected. 
Thereby the host is protected from anti-donor immunity and life-threatening viral infections.
However, recent clinical trials in which calcineurin inhibitor-based immunosuppression against 
the memory repertoire was tapered or withdrawn, repeatedly reported impaired tolerance 
and acute graft rejection (75, 139, 247-249), which may (partly) be explained by heterologous 
immunity. Some of the virus-specific memory T cells that are so urgently needed for viral 
control also respond (cross-react) to donor HLA in addition to their cognate viral epitope – a 
“mistake” that occurs frequently (43). As a consequence, these virus-specific memory T cells 
can elicit potentially harmful immune responses against the donor allograft. Indeed, studies 
in mice have shown that cross-reactive virus-specific memory T cells can induce solid organ 
rejection (35, 250), but the impact of cross-reactive virus-specific memory T cells on allograft 
survival in humans remains a matter of debate. Clinical studies do not, as yet, show a significant 
impact on transplantation outcome (38, 40, 41). The number of studies and cross-reactivity 
models studied are however too limited to draw any generalizable conclusions. Besides, if the 
cross-reactive T cells are hampered by immunosuppression, they may become a serious issue 
in the future when alternatives are sought to replace or taper immunosuppression. Therefore, 
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it remains important to strive towards understanding the mechanisms and clinical impact of 
virus-specific TCR cross-reactivity. The role of T-cell alloreactivity, and in particular of cross-
reactive virus-specific T cells, in transplantation outcome is discussed in Chapter 2.
There are several ways in which TCR cross-reactivity of virus-specific T cells can be detected 
in an experimental setting, and their potencies and flaws are discussed in Chapter 3 (226). 
Although these methods do enable accurate detection, it is necessary to keep their limitations 
in mind. Importantly, one should be aware that current methods based on cross-reactivity 
detection with viral tetramers rely heavily on known public viral epitopes: and therefore only 
address the tip of the iceberg regarding the scope of all possible cross-reactivities mediated 
by virus-specific T cells.
Regardless of this limitation, we were able to show that infection with a single virus can induce 
many different allo-HLA cross-reactivities (Chapter 4). For example, a large percentage of 
CMV-specific memory CD8+ T cells are cross-reactive with allogeneic HLA, and we identified 
a cross-reactivity of CMV A2/NLV-specific T cells specifically recognizing the complex of allo-
HLA-A*02:05 presenting a peptide derived from allo-HLA-B*50:01. Interestingly, a recent paper 
describes how CMV peptides often mimic human peptides and thereby induce alloreactivity 
(251), and therefore it is not unlikely that HLA-derived peptides could be among those as well.
Furthermore, we found identical allo-HLA cross-reactivity of virus-specific T cells in multiple 
individuals (public cross-reactivity), as described in Chapter 6 (140). Partly because dominant 
TCR usage was considered uncommon, public cross-reactivity was believed to be extremely 
rare, despite the fact that a public allo-HLA response of EBV-directed T cells had already been 
documented. Our studies show that public alloresponses are more common than anticipated, 
which could potentially hold promise for the prediction of alloreactivity in transplant recipients 
and risk estimation for specific donor-recipient combinations. However, with the exception 
of the unlikely event of having a surplus of equally suitable donors, we stress that increased 
knowledge concerning public cross-reactivities should not lead to the discouragement of donor-
recipient combinations. In the current climate of organ scarcity, it is not recommended to 
complicate donor selection or further restrict organ allocation. Rather, the identification of 
public cross-reactivities could provide a tool to monitor patients at risk for generating memory-
like alloreactive T-cell responses, and ultimately to support clinical decision making. Such 
knowledge may for instance affect the composition of immunosuppressive regimens and the 
decision whether or not to taper immunosuppression (252). In addition, insights into public 
cross-reactivity could be used to selectively tailor the composition of pre-transplant vaccines 
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and adoptive anti-viral T-cell grafts (253). Yet, there is still a long way to go to determine whether 
public cross-reactivities could have clinical implications.
First of all, the functional characteristics of the cross-reactive virus-specific T cells should be 
thoroughly analysed. The newly identified public cross-reactive T cells were able to produce 
cytokines, show cytotoxicity towards alloantigen-expressing target cells derived from different 
tissues, and reach similar cytokine and cytotoxicity levels in response to alloantigen as to viral 
antigen in vitro. If they retain these capabilities in vivo, these T cells could contribute to the 
generation of an inflammatory environment in or around the allograft or even directly kill 
donor cells.
Important to keep in mind is that a functional alloreactive T-cell response depends on T-cell 
activation, which is determined by the interaction of the TCR with the alloepitope. Indeed, 
TCR affinity and avidity for the alloepitope play a crucial role in determining whether a T cell 
becomes activated upon allorecognition (214, 231). In Chapter 7, we have shown that TCR 
avidity depends on the expression of the (viral and allo-) peptide (144). In other words: the 
onset of alloreactivity (and whether it is persistent or transient) could depend on alloepitope 
expression. Defining parameters that affect this expression could provide novel insights 
into if and when potentially harmful alloreactive responses may emerge in a transplantation 
setting. For example, if the cross-reactive allopeptide is involved in specific cell processes 
(for instance damage repair or cell division) cross-reactive alloresponses may be transient, 
and if its expression is affected by genetic polymorphisms the immunogenicity of allografts 
could vary between donors. Preliminary experiments in which public cross-reactive CMV B35/
IPS T-cell clones were stimulated by cells of first-degree related individuals indeed suggest 
a genetically determined stimulation capacity. Additional experiments are needed to make 
conclusive statements (FIGURE 1, unpublished data).
Moreover, we showed that, depending on epitope expression, TCR avidity for the alloepitope 
could surpass TCR avidity for the viral epitope - indicating that the alloresponse could have 
similar immune potential as the anti-virus response.
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Figure 1. Family members may share immunogenicity. CMV B35/IPS T-cell clone 8F4, cross-reactive 
against allo-HLA-B*51:01, showed increased IFNγ production in ELISA towards HLA-B*51:01+ members of 
Family 2 (n = 7) compared to HLA-B*51:01+ members of Family 1 (n = 5) and Family 3 (n = 6). Depicted is the 
percentage of the virus-specific response (EBV-LCL B35 + IPS peptide) and experiments were performed 
in triplicate.
Two major determinants of TCR avidity are the interaction between the TCR and pMHC molecule 
(TCR affinity) and CD8 co-receptor binding to the side of the MHC molecule. TCR affinity is 
directly correlated with T-cell activation, however, most T-cell responses are mediated by T 
cells expressing intermediate TCR affinity to prevent overstimulation leading to rapid T-cell 
senescence and that could potentially pose a threat to the host (214). Unfortunately, TCR affinity 
for an alloepitope can only be accurately determined when the allopeptide is known, using 
methods as surface plasmon resonance (SPR) (223). When TCR affinity is sufficiently strong, CD8 
co-receptor binding is not needed to elicit an immune response (237), but when TCR affinity 
is low, CD8 co-receptor binding is needed to strengthen the TCR-pMHC interaction. It thereby 
compensates for the low TCR affinity to ensure full T-cell activation (234, 254). Interestingly, 
CD8 co-receptor binding can also play an important role in allorecognition, and differences in 
CD8 expression on a cross-reactive T cell have been shown to alter its fine-specificity (255). Of 
note, such shaping would only occur for alloreactive T cells that are CD8 dependent. Although 
alloreactive T cells are generally considered to be CD8 dependent, recently alloreactive HCV-
specific T cells have been documented that do not require CD8 binding for allorecognition (256).
CD8 dependency varies between HLA class I molecules, depending on mutations in the a3 
domain (primarily due to a negatively charged loop at residues 223-229) (257). Decreased 
CD8 binding capacity can hamper the recognition of certain allo-HLA antigens and shape 
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the fine specificity of the allorepertoire. All self-HLA molecules (HLA-B*35:01; HLA-A*02:01) 
and cross-reactive allo-HLA molecules (HLA-B*51:01, HLA-B*58:01, HLA-B*57:01; HLA-B*38:01; 
HLA-B*55:01) tested in this thesis were identical in amino acid composition in their CD8 
binding region of the a3 domain (DQTQDTE), indicating that the binding potential of the CD8 
co-receptor was comparable between the different HLA molecules. We evaluated CD8 co-
receptor dependency in functional assays by CD8 blocking and observed that CD8 co-receptor 
dependency was generally stronger for allorecognition compared to viral recognition (Chapter 
7). Although one should keep in mind that other interactions at the cell surface, such as those 
mediated by adhesive molecules, contribute to TCR avidity as well, a potential explanation for 
the difference in CD8 co-receptor dependency may be lower TCR affinity for the alloepitope 
versus the viral epitope (especially since the CD8 binding potential was similar for all HLA 
molecules). For example, the FLU A2/GIL TCR is known to recognize its cognate antigen in an 
CD8-independent manner, plausibly due to its specific pMHC docking mode that results in 
sufficient TCR affinity that diminishes the need for CD8 co-receptor signaling (9, 258). Our TCR 
sequencing data suggest that the CDR3a region, in contrast to cognate docking, is vital for HLA-
B*38:01 allorecognition, hence a potential explanation for the observed CD8 dependency for 
allorecognition could be an alternative TCR docking mode. It is however impossible to make 
any conclusive statements without generating crystal structures of this interaction, which was 
beyond the scope of this thesis.
Interestingly, TCR affinity of the EBV B8/FLR cross-reactivity model is lower for the alloepitope 
versus the viral epitope (44). However, it remains to be investigated whether this can be 
generalized for all virus-specific T cell cross-reactivities. Perhaps more importantly, one should 
keep in mind that partial T-cell activation as a result of low affinity T cell - antigen interaction 
could be detrimental as well (259). Interestingly, a recent study in mice shows that low-affinity 
priming with pathogen antigen induces a different differentiation program in cross-reactive T 
cells compared to high-affinity priming; yet these low-affinity primed T cells are equally potent 
in inducing graft rejection upon exposure to high-affinity alloantigen (260). This holds promise 
for the priming of HIV-cross-reactive allospecific T cells as suggested by Almeida et al (261): in 
Chapter 5, we showed that virus-specific T cells can indeed be induced by allostimulation (143), 
and if priming is independent of TCR affinity, this would suggest that TCR affinity for allo-HLA 
is no limiting factor for generating a potent HIV-reactive T-cell repertoire.
Finally, in the quest to determine the clinical relevance of (public) cross-reactivities, the most 
important element that is missing so far is the identification of the peptide presented by 
the cross-reactive HLA allo-antigen. If the origin of the peptide is known, this can provide 
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information on tissue-specificity, as well as on the (patho)physiological expression of the 
alloepitope. In addition, TCR affinity can be assessed using SPR and functional assays can be 
optimized: for example, knowing the allopeptide would allow for TCR avidity determination 
using the same levels of viral and alloepitope expression. Furthermore, the allopeptide can 
unravel the structural mechanisms behind the TCR cross-reactivities using crystallography. With 
regard to monitoring, tetramers of the allo-HLA and allopeptide could be used to determine 
the frequency of T cells recognizing this complex in the blood of patients, pre-transplant and 
at follow-up. When alloreactivity mediated by these cross-reactivities plays an important role 
in graft rejection, knowing the allopeptide may ultimately even hold therapeutic potential with 
regard to the administration of altered peptide ligands (205). Unfortunately, the identification 
of the allopeptide is a long and complicated process with no universal experimental strategy. 
The only allopeptide that has been described so far is the EEY allopeptide, and its identification 
took several years. It was finally indirectly identified using the baculovirus vector system in 
insect cells that happened to yield a peptide mimic in the human genome (44, 262).
To benefit other cross-reactivity models as well, a more generalizable approach to identify 
allopeptides is therefore needed. A promising strategy for allopeptide identification combines 
functional T-cell assays with chromatography, mass spectrometry, biochemistry and 
crystallography, and is currently under development in the groups of Prof. Anthony Purcell 
and Prof. Jamie Rossjohn at Monash University (Melbourne, Australia) by Dr. Nicole Mifsud 
and Dr. Stephanie Gras, respectively. Using peptide elutions of the allogeneic target cells and 
HPLC fractionation of the resulting peptidome, functional screening of those HPLC fractions can 
reveal one (or more) positive fractions containing the allopeptide(s). Having joined their efforts 
for a year, we gathered preliminary results showing that a positive fraction for the CMV B35/
IPS TCR cross-reactivity against HLA-B*51:01 can indeed be identified in CD69 assays (FIGURE 
2, unpublished data).
Subsequently, the peptides present in the positive HPLC fraction are identified by mass 
spectrometry. A single HPLC fraction still contains hundreds to thousands of peptides - but 
comparing the positive and negative HPLC fractions can already rule out peptides that are 
unlikely to induce cross-reactivity. Furthermore, attempts are made to re-fractionate the 
positive fraction into smaller fractions, despite the requirement of extensive numbers of 
allogeneic cells for elution (>1 x 1010). Another promising path aims to identify a peptide motif 
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Figure 2. HPLC fractionation can be used to identify fractions containing allopeptides. A) A positive 
HPLC fraction (A9) was identified in CD69 assay for the CMV B35/IPS cross-reactivity model against HLA-
B*51:01. B) Verification in additional CD69 assays showed both cross-reactive TCRs (7C8 and 8F4) were able 
to recognize peptides in the A9 faction. X-axis: Responder cells: retrovirally transduced SKW3s expressing 
the cross-reactive CMV B35/IPS TCRs; Stimulator cells: C1Rs and T2s retrovirally transduced with allo-
HLA-B*51:01, of which three conditions HLA-B*51:01+ T2s loaded with HPLC fractions. Y-axis: MFI fold change 
of CD69 expression compared to media alone values.
The peptide motif can be achieved in an unbiased way using a combinatorial peptide ligand 
library (CPL), which covers the entire peptide spectrum divided into subgroups based on a 
single shared amino acid at a fixed position. Screening those subgroups in functional assays (the 
MIP-1b ELISA proves to be most sensitive) reveals an amino acid pattern, i.e. motif, that the TCR 
is most responsive to (238, 263, 264). Using this knowledge, peptides that are unlikely to cross-
react based on the peptide motif can be discarded from the positive HPLC fraction. However, 
a downside of CPL is the requirement of cross-reactive T-cell clones, which are not always 
available, and it has only ever been used to identify cognate peptides rather than allopeptides. 
Currently, experiments are performed at Monash University to evaluate whether the above-
mentioned approaches are suitable to identify allopeptides for different cross-reactivity 
models, including the public CMV B35/IPS and FLU A2/GIL cross-reactivity models described 
in this thesis. If successful, this would yield a generalizable strategy that can be implemented 
for the allopeptide identification of all (public and private) virus-specific TCR cross-reactivities, 
and their clinical relevance for transplantation can finally be resolved.
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Virusinfecties vormen een groot risico voor transplantatiepatiënten. Met name het 
cytomegalovirus (CMV) heeft een significante impact op transplantaatoverleving. Wat minder 
mensen weten, is dat de immuunrespons tegen dit soort virussen ook nadelig kan zijn voor 
de patiënt. Dit komt doordat de afweercellen die getraind zijn om een virus te herkennen, 
een “vergissing” kunnen maken en het donororgaan aan kunnen vallen. Er is echter nog veel 
onduidelijk over de rol van deze cellen in transplantaatafstoting. Kunnen deze cellen ook 
daadwerkelijk een sterke immuunrespons tegen een donororgaan opwekken? Welke factoren 
spelen hierbij een rol? En kunnen we deze immuunresponsen voorspellen? In dit proefschrift 
probeer ik antwoord te geven op deze vragen.
Virus-specifieke T cellen
Het immuunsysteem bestaat uit vele verschillende soorten afweercellen, die elk hun eigen 
kenmerkende eigenschappen hebben en hun eigen rol vervullen. In dit proefschrift is specifiek 
gekeken naar T cellen die gespecialiseerd zijn in de afweer tegen virussen (“virus-specifieke” T 
cellen) en tevens direct een virus-geïnfecteerde cel kunnen aanvallen en doden.
T cellen herkennen specifieke eiwitcomplexen op het celoppervlak, namelijk de combinatie van 
een humaan leukocytenantigeen (HLA) en het peptide dat daarin wordt gepresenteerd. Deze 
combinatie wordt ook wel het peptide-HLA (pHLA) complex genoemd. Het peptide dat in het 
HLA gepresenteerd wordt is een stukje eiwit afkomstig van binnenin de cel en reflecteert als het 
ware wat zich daar afspeelt. Als dit peptide afwijkt van de norm, zoals tijdens een virusinfectie 
of de ontwikkeling van een maligniteit, kan een T cel dit herkennen en wordt hij geactiveerd 
om een afweerreactie op gang te zetten. Nadat de afwijkende cellen zijn opgeruimd, blijven 
in het lichaam “geheugen” T cellen achter die, mocht het ongewenste materiaal zich nogmaals 
aandienen, extra snel en krachtig een aanval kunnen inzetten zodat de gastheer niet (opnieuw) 
ziek wordt.
Heterologe immuniteit
Een T cel herkent een pHLA complex door middel van T-cel receptoren op zijn celoppervlak, die 
zeer specifiek alleen bepaalde peptide-HLA combinaties herkennen. Dit wordt ook wel “T-cel 
specificiteit” genoemd. Wie een oud leerboek openslaat, zal daarin lezen dat een T-cel receptor 
slechts één specificiteit heeft. Vandaag de dag weten we echter dat dit gegeven achterhaald 
is. Een T-cel receptor kan wel degelijk meerdere specificiteiten hebben - hetgeen zelfs een 
groot voordeel heeft, omdat zulke “multispecificiteit” gepaard gaat met een gunstig effect op 
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de overleving van de soort. Immers, als een afweerreactie tegen virus X tevens bescherming 
biedt tegen virus Y, dan geeft dat de gastheer een evolutionair voordeel als hij later in aanraking 
komt met virus Y. Dit fenomeen wordt ook wel “heterologe immuniteit” genoemd. Bij heterologe 
immuniteit tussen virussen herkent een T-cel receptor dus verschillende pHLA complexen; 
waarin lichaamseigen HLA moleculen verschillende peptides presenteren afkomstig van 
verschillende virussen. Het herkennen van verschillende pHLA complexen door dezelfde T-cel 
receptor wordt ook wel “kruisreactiviteit” genoemd.
Heterologe immuniteit in transplantatie
Interessant genoeg komt heterologe immuniteit niet alleen voor bij antivirale immuunresponsen, 
maar ook bij immuunresponsen tegen vreemd (“allogeen”) HLA - bijvoorbeeld met HLA van een 
donor in een transplantatiesetting (“alloreactiviteit”). In dat geval is het mogelijk dat dezelfde 
T-cel receptor niet alleen een pHLA complex met een ander peptide herkent, maar tevens met 
een ander HLA antigeen. Een T cel die aanvankelijk getraind is om een virus te bestrijden kan 
zodoende een “vergissing” maken en een donorcel aanvallen. Doordat zulke virus-specifieke 
T cellen een geheugenfenotype hebben, zou zo’n vergissing dus relatief snelle en sterke anti-
donorreactiviteit tot gevolg kunnen hebben.
Dit proefschrift
Zoals gezegd is er nog veel onduidelijk over de rol van virus-specifieke T cellen die kruisreageren 
met allogeen HLA in transplantaatafstoting. In dit proefschrift probeer ik meer inzicht te 
genereren in de rol van deze cellen in orgaantransplantatie.
In Hoofdstuk 1, de algemene inleiding, wordt achtergrondinformatie gegeven over de 
geschiedenis van de orgaantransplantatie en tevens worden de basisprincipes van het 
immuunsysteem geïntroduceerd.
Hoofdstuk 2 schetst een overzicht van studies die het effect van virus-specifieke T cellen 
die kruisreageren met allogeen HLA in een transplantatiesetting onderzocht hebben. Waar 
in muizen een duidelijk verband kan worden gelegd tussen virus-specifieke T cellen en 
transplantaatafstoting, is dit bij mensen tot op heden nog niet zo eenduidig. Ook blijkt het aantal 
klinische studies dat tot op heden uitgevoerd is, erg beperkt te zijn. Er dient zodoende meer 
kennis vergaard te worden over heterologe immuniteit van virus-specifieke cellen, zodat een 
inschatting gemaakt kan worden of dit fenomeen een risico vormt voor transplantatiepatiënten.
Dit blijkt echter makkelijker gezegd dan gedaan. De huidige experimentele technieken waarmee 




gaan alle gepaard met zowel voor- als nadelen. In Hoofdstuk 3 worden hun mogelijkheden 
en valkuilen besproken. Het is belangrijk te realiseren dat de meeste methoden lang niet alle 
kruisreacties kunnen detecteren, waardoor vele zo onder de radar blijven. Daarnaast kunnen 
vals-positieve resultaten optreden doordat omstander T cellen, die niet zelf met allogeen HLA 
kunnen kruisreageren, geactiveerd raken door het inflammatoire milieu dat gecreëerd wordt 
door toedoen van “echte” kruisreagerende T cellen. Door een kleine aanpassing door te voeren 
in een bestaande experimentele techniek, bleek de detectie van echte kruisreactiviteit tegen 
allogeen HLA sterk verbeterd te kunnen worden.
In Hoofdstuk 4 waren we in staat om aan te tonen dat een infectie met een enkel virus een 
breed assortiment aan kruisreactieve T cellen kan doen ontstaan die zowel virus als allogeen 
herkennen. Op basis van proliferatie-experimenten, waarin virus-specifieke T cellen werden 
blootgesteld aan een verzameling van donorcellen met de meest voorkomende HLA antigenen, 
bleken T cellen die hetzelfde virus herkennen kruisreactief te zijn tegen verscheidene allogene 
HLA antigenen. Zo kan een infectie met een enkel virus ervoor zorgen dat diens gastheer 
een afweerreactie ontwikkelt tegen meerdere donor HLA antigenen, zonder eerder aan die 
antigenen te zijn blootgesteld.
In tegenstelling tot het mogelijk nadelige effect van kruisreactiviteit in een transplantatie-
setting, hebben we in Hoofdstuk 5 aangetoond dat heterologe immuniteit ook positieve 
effecten kan hebben. Door allogene (donor)cellen juist in te zetten om T cellen te stimuleren, 
kunnen goed functionerende antivirale reacties opgewekt worden. Door deze “omweg” te 
nemen zou antivirale immuniteit bevorderd kunnen worden in immuun-gecompromitteerde 
patiënten (denk bijvoorbeeld aan HIV patiënten).
Daarnaast hebben we in Hoofdstuk 6 gevonden dat meerdere ongerelateerde personen 
identieke kruisreacties tegen allogeen HLA kunnen ontwikkelen, zogenaamde “publieke” 
kruisreactiviteit. Dat personen met diverse HLA achtergronden precies dezelfde T-cel receptoren 
tot expressie kunnen brengen is al een klein wonder – wat verklaart waarom men voor lange 
tijd in de veronderstelling was dat publieke kruisreactiviteit extreem zeldzaam is. Echter, het 
feit dat eerder al een publieke kruisreactiviteit tegen allogeen HLA was gedocumenteerd van 
T cellen die het veel voorkomende Epstein-barr virus (EBV) herkennen, toont aan dat publieke 
kruisreactiviteit wellicht toch niet zo zeldzaam is. In dit proefschrift hebben we maar liefst 
drie additionele publieke kruisreacties kunnen identificeren, namelijk van cytomegalovirus-
specifieke T cellen (CMV B35/IPS tegen allogeen HLA-B57/58 en HLA-B51), influenza-specifieke 
T cellen (FLU A2/GIL tegen allogeen HLA-B38) en varizella zoster virus-specifieke T cellen (VZV 
167
Heterologous immunity in organ transplantation
A2/ALW tegen allogeen HLA-B55). Deze bevinding toont aan dat publieke kruisreactiviteit veel 
vaker voorkomt dan aanvankelijk voor mogelijk werd gehouden. Indien de klinische relevantie 
van publieke kruisreacties zorgvuldig bestudeerd wordt, kan deze kennis ingezet worden om 
alloreactiviteit te voorspellen en een risicoanalyse te maken voor transplantaatafstoting bij 
individuele donor-ontvanger combinaties.
Niet alle kruisreactieve T cellen zijn in staat om een volwaardige afweerreactie tegen allogene 
(donor)cellen te verwezenlijken. Een T cel wordt namelijk pas geactiveerd als de interactie 
tussen de T cel en zijn doelwit-cel sterk genoeg is (“T-cel aviditeit”). In Hoofdstuk 7 hebben we 
aangetoond dat alloreactiviteit afhankelijk is van de expressie van het allogene pHLA complex 
(het “allo-epitoop”) op het celoppervlak - en dat de T-cel aviditeit zelfs hoger uit kan vallen voor 
het allo-epitoop dan voor het het virale epitoop (het lichaamseigen HLA dat een virus peptide 
presenteert). Dit laatste suggereert dat een alloreactie een vergelijkbaar immuunpotentieel 
kan hebben als een antivirale reactie. Daarnaast vonden we dat de alloreacties die we in 
dit proefschrift bekeken hebben afhankelijk waren van hulp van een extra receptor op het 
oppervlak van de T cel (de “CD8 co-receptor”), die aan de zijkant van het HLA molecuul bindt 
en zo de interactie tussen de T-cel receptor en het allogene pHLA complex versterkt. De reactie 
van dezelfde kruisreactieve T cellen voor hun virale pHLA complex was niet afhankelijk van deze 
hulp. Of dit ook gegeneraliseerd kan worden voor alle kruisreactieve virus-specifieke T cellen 
moet nog worden onderzocht.
Tenslotte worden de bevindingen van dit proefschrift in Hoofdstuk 8 samengevat en in een 
breder perspectief geplaatst. Met name de queeste om het allogene peptide te vinden dat bij 
een kruisreactie betrokken is (het “allopeptide”) komt uitgebreid aan bod, aangezien kennis 
over de aard van dit peptide onmisbaar is om de klinische relevantie van (al dan niet publieke) 
kruisreactiviteit te bepalen. Tot op heden bestaat er geen universele werkwijze voor de 
identificatie van deze allopeptides. Echter, een veelbelovende nieuwe strategie is momenteel 
in ontwikkeling aan de Monash Universiteit in Melbourne, Australië, welke functionele T-cel 
assays met chromatografie en massaspectrometrie combineert. Als deze aanpak zijn belofte 
waarmaakt, ontstaan vele nieuwe mogelijkheden voor vervolgonderzoek en zouden we eindelijk 
de klinische relevantie van kruisreagerende virus-specifieke T cellen die donor-HLA herkennen 
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ABCD3  ATP-binding cassette sub-family D member 3
Allo-HLA  allogeneic HLA
ATG  anti-thymocyte globulin
CD  cluster of differentiation
CFSE  carboxyfluorescein succinimidyl
CMV  cytomegalovirus
CNI  calcineurin inhibitor
CRA  51Chromium-release assay
CTLA-4  cytotoxic T lymphocyte-associated antigen 4
CU  Cetus unit
DLI  donor lymphocyte infusion
EBV  Epstein-Barr virus
EBV LCL  EBV-transformed lymphoblastoid cell line
EFI  European Federation of Immunogenetics
ELISA  enzyme-linked immunosorbent assay
FACS  fluorescence-activated cell sorting
FCS  fetal calf serum
FITC  fluorescein isothiocyanate
FLU  influenza virus
FRET  Förster resonance energy transfer
GVHD  graft-versus-host disease
GVL  graft-versus-leukemia
GVM  graft-versus-myeloma
HLA  human leukocyte antigen
HS  human serum
HSCT  human stem cell transplantation
HUVEC  human umbilical vein endothelial cell
IFNγ  interferon γ
IL-7  interleukin 7
IMDM  Iscove’s Modified Dulbecco’s Medium
ITAM  immunoreceptor tyrosine-based activation motif
mAb  monoclonal antibody
ME  β-mercaptoethanol
mHAg  minor histocompatibility antigen
MHC  major histocompatibility complex
MLR  mixed lymphocyte reaction
MMF  mycophenolate mofetil
mTOR  mammalian target of rapamycin
NO  nitric oxygen
PBMC  peripheral blood mononuclear cell
191
Heterologous immunity in organ transplantation
PCR  polymerase chain reaction
PE  phycoerythrin
PHA  phytohaemagglutinin
PLT  primed-lymphocyte test
pMHC  peptide-MHC
RPMI  Roswell Park Memorial Institute medium
SOT  solid organ transplantation
SPR  surface plasmon resonance
SSO  sequence-specific oligonucleotide
SSP  sequence-specific primer
TCR  T-cell receptor
TEC  tubular epithelial cell
Th1  type 1 helper T cell
Treg  regulatory T cell
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twijfel de juiste zet.
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we het aan. Dank je wel voor al je goede adviezen, je steun en gezelligheid en dat je mijn 
paranimf wilde zijn.
Gezellig was het ook in de “bieb”: dames, ik vond het een eer dat ik deel van de groep uit mocht 
maken en ontzettend bedankt voor alle goede tips en adviezen. Paula, je zit inmiddels alweer 
heel wat jaartjes in Australië, maar ik zal je hulp nooit vergeten. En het was geweldig om te zien 
hoe je je leven hebt opgebouwd in Perth. Marry, je was een geweldige buurvrouw en ik had 
geen betere kunnen wensen. Els, dank je wel voor al je lieve zorgen; dat glazen oog is me mooi 
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extra goed na een lange werkweek. Anita, ook al deelden we zelden dezelfde geografische 
coördinaten, heb ik genoten van het sparren over ons onderzoek. En uiteraard dank aan alle 
andere PhD studenten; Els, Anna-Sophia, Frederieke, Li Na, Gijs, Jan-Willem, Tetje, Niels, Angela, 
Lisa, Tess... en uiteraard alle anderen.
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voor jullie leuke gezelschap bij de vele congressen. Dave, ik heb een hoop van je geleerd over 
heterologe immuniteit en je kennis heeft me enorm geholpen. Geert, dank je wel voor je 
altijd waterdichte statistiek! Arend, dank voor je adviezen en je triviakennis ten tijde van de 
Claas Quiz. Ilias, dank je wel voor de motiverende werkbesprekingen aan het begin van het 
promotietraject. Moshe, you are a true inspiration, not just as a scientist but also as a human 
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Naast het werk wil ik ook mijn lieve vriend(innet)jes bedanken. Meiden van de Ruysdael, 
lieve Aaf, Ling, Miki, Yannouck, Krista: jullie gezelligheid, positiviteit en waardevolle adviezen 
hebben me er steevast doorheen geholpen. Dank jullie wel voor de mooie tijd! Joke, Frouke, 
Ilse, Odette, José: we zijn samen de reis aangegaan van onbevangen eerstejaarsstudenten naar 
echte “Grote Mensen” en ik had me geen betere reisgenoten voor kunnen stellen. Steef, Su, 
Pau, onze vriendschap gaat door landsgrenzen heen en zal dat altijd blijven doen - op naar de 
volgende 28 jaar! Nina, Joep, Ambi en Renske, hoewel onze jubileum-etentjes soms wat (jaartjes) 
later waren dan gepland, waren ze altijd memorabel.
Pap en mam, er zijn natuurlijk geen woorden voor hoeveel ik jullie zou willen bedanken. Jullie 
zijn er altijd onvoorwaardelijk en dat is onbetaalbaar. Lieve Mariëtte, bedankt voor je steun 
aan je kleine zus.
Lieve Cyril, wat is de wereld leuk met jou. Dank je wel voor je nimmer aflatende steun en je 
geloof in mij.
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